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Mathematics and Statistics 
 
ABSTRACT 
Anthrax Vaccine Adsorbed (AVA) immunization protects against anthrax disease 
by eliciting a neutralizing antibody response. However, antigen-specific antibody 
concentrations are not observed in high quantities until three immunizations have been 
administered over six months. Even then, humoral responses to AVA do not provide 
long-term immunity without an annual booster. 
We followed six healthy volunteers over the five-dose, 18-month AVA schedule 
to characterize the genetics of the immunoglobulin repertoire during the vaccination 
series. Two tiers of data were collected: 1) Immunoglobulin variable region genes 
(IgVRG) from bulk sorted naïve, memory and plasmablast (PB) B cells and 2) single cell 
sorted and sequenced IgVRG from plasmablasts. Samples were collected prior to and one 
and two weeks following each immunization. Our initial analyses indicated that technical 
error, the variation introduced by biological sampling and standard sample preparation, 
resulted in skewed output, and we developed a model to better estimate quantitative 
values from Ig-seq. We also utilized unique molecular identifiers to correct for nucleotide 
errors and PCR over-amplification. 
  ix 
Our analysis of IgVRG following AVA administration reveals that the population 
of peripheral PBs following primary immunization is not distinguishable from the pre-
immune peripheral PB repertoire. These PBs have more somatic mutations than expected 
for newly activated and differentiated naïve B cells, and are unlikely to be vaccine-
elicited. In contrast, PBs observed following the 2nd dose have low mutation frequencies 
that increase upon subsequent vaccination. These clones are more persistent than clones 
first observed following any other immunization, but still make up a very small 
proportion of the overall repertoire. At no time is the clonal repertoire consistently 
dominated by a few clones, and the total and plasmablast repertoires are highly transient, 
even after the elicitation of vaccine-specific antibodies. AVA immunization thus results 
in a polyclonal B cell response which is not dominated by one or a few highly specific, 
strongly-elicited clones. We conclude that primary immunization by AVA is not 
sufficiently immunogenic to elicit vaccine-responsive, class-switched PBs to the 
periphery, nor is complete AVA immunization able to sustain proliferation of individual 
clones, providing insight into why AVA may require regular boosts.  
  
  x 
TABLE OF CONTENTS 
 
DEDICATION ................................................................................................................... iv 
ACKNOWLEDGMENTS .................................................................................................. v 
ABSTRACT ..................................................................................................................... viii 
TABLE OF CONTENTS .................................................................................................... x 
LIST OF TABLES .......................................................................................................... xvii 
LIST OF FIGURES ......................................................................................................... xix 
LIST OF ILLUSTRATIONS .......................................................................................... xxv 
LIST OF ABBREVIATIONS ........................................................................................ xxvi 
CHAPTER ONE: INTRODUCTION ................................................................................. 1 
Anthrax disease ............................................................................................................... 1 
History and epidemiology ........................................................................................... 1 
Transmission ............................................................................................................... 2 
Clinical manifestations................................................................................................ 3 
Anthrax pathogenesis .................................................................................................. 4 
Vaccine and treatment................................................................................................. 5 
Vaccines .......................................................................................................................... 7 
Historical development ............................................................................................... 7 
Immunological mechanism of vaccination ................................................................. 9 
Challenges in vaccine improvement and development ............................................. 15 
  xi 
Immunoglobulin Biology .............................................................................................. 16 
Antibodies ................................................................................................................. 16 
Functions ................................................................................................................... 18 
B cell and BCR development .................................................................................... 20 
Immunoglobulin repertoire diversification ............................................................... 22 
Affinity maturation ................................................................................................... 26 
Response Kinetics ..................................................................................................... 28 
Immunoglobulin repertoire sequencing ........................................................................ 30 
Rationale and special considerations for immunoglobulin sequencing (Ig-seq) ...... 30 
Common approaches ................................................................................................. 30 
Library preparation ................................................................................................... 32 
Next-generation sequencing...................................................................................... 34 
Current challenges with methods .............................................................................. 35 
Scientific proposal and hypothesis................................................................................ 37 
Part I. Immunoglobulin repertoire sequencing ......................................................... 37 
Part II. The immunoglobulin repertoire response to Anthrax Vaccine Adsorbed 
(AVA) immunization ................................................................................................ 38 
CHAPTER TWO: MATERIALS AND METHODS ....................................................... 40 
Anthrax Vaccine Adsorbed ........................................................................................... 40 
Vaccine formulation.................................................................................................. 40 
Study design .............................................................................................................. 40 
Immunization and sample collection ........................................................................ 42 
  xii 
Blood processing ....................................................................................................... 42 
ELISA ....................................................................................................................... 42 
HEp-2 anti-nuclear antigen (ANA) staining ............................................................. 45 
Flow cytometry ......................................................................................................... 46 
Library preparation ................................................................................................... 53 
Sequencing ................................................................................................................ 59 
Production of recombinant human antibodies .......................................................... 59 
Surface plasmon resonance ....................................................................................... 61 
Protein microarray .................................................................................................... 63 
Statistical analyses .................................................................................................... 65 
Technical error study .................................................................................................... 65 
Sample collection ...................................................................................................... 65 
Blood processing ....................................................................................................... 65 
Library preparation and sequencing.......................................................................... 66 
Statistical analyses .................................................................................................... 66 
Computational sample processing ................................................................................ 66 
Sequence processing pipeline ................................................................................... 66 
Immunoglobulin analysis .......................................................................................... 67 
Model pipeline .......................................................................................................... 70 
Buffers and reagents ..................................................................................................... 71 
Cell media for PBMC processing (RPMI-10) .......................................................... 71 
FACS buffer .............................................................................................................. 71 
  xiii 
Sequencing primers ................................................................................................... 71 
LB agar for antibody synthesis transformation ......................................................... 71 
Sample loading buffer for antibody synthesis (SDS-PAGE) .................................... 72 
Electrophoresis running buffer for antibody synthesis (SDS-PAGE) ...................... 72 
Blocking buffer for Protoarray®............................................................................... 72 
Washing buffer for Protoarray® ............................................................................... 72 
Supplemental Material .................................................................................................. 73 
Primer sequences ...................................................................................................... 73 
CHAPTER THREE: TECHNICAL ERROR DURING IMMUNOGLOBULIN 
REPERTOIRE PROCESSING CAUSES VARIATION IN QUANTITATIVE AND 
QUALITATIVE OUTPUT ............................................................................................... 77 
Rationale ....................................................................................................................... 77 
Results ........................................................................................................................... 81 
3.1 Unique molecular identifiers correct nucleotide errors from sequencing. .......... 81 
3.2 Standard library preparation introduces significant technical variation to 
biological sample output. .......................................................................................... 88 
3.3 Technical errors are not resolved by unique molecular identifier tagging. ........ 97 
3.4 Both biological and technical replicates are valuable for overcoming random 
error. ........................................................................................................................ 104 
3.5 UID-tags decrease the proportion of Ig-Seq that is immunoglobulin. .............. 107 
3.6 Observed raw reads are from a bimodal distributions. ..................................... 112 
  xiv 
3.7 UID-tagged data can be used to develop a regression model to estimate read 
counts from non-UID-tagged Ig-seq. ...................................................................... 117 
3.8 Evaluation of model prediction. ........................................................................ 122 
Discussion ................................................................................................................... 126 
Supplemental Material ................................................................................................ 135 
CHAPTER FOUR: HIGH THROUGHPUT IMMUNOGLOBULIN REPERTOIRE 
SEQUENCING FOLLOWING ANTHRAX VACCINE ADSORBED IMMUNIZATION 
REVEALS POTENTIAL CLONAL CORRELATES OF THE VACCINE RESPONSE
......................................................................................................................................... 154 
Rationale ..................................................................................................................... 154 
Results ......................................................................................................................... 157 
4.1 Memory B cells and plasmablasts do not increase until following 3rd and 4th 
immunizations. ........................................................................................................ 157 
4.2 There is no observable change in repertoire IgVRG mutation frequencies 
following AVA immunization. ............................................................................... 159 
4.3 IgVRG CDR3 lengths do not change following any AVA administration. ..... 166 
4.4 Clones do not proliferate or persist following AVA immunization. ................ 168 
4.5 B cell subset-specific IgVRG reveals dynamic clonal lineages and delayed 
elicitation of potential vaccine response correlates. ............................................... 173 
4.6 Gene usage does not suggest robust purifying interclonal selection. ............... 180 
4.7 A closer inspection of individual clones. .......................................................... 184 
Discussion ................................................................................................................... 190 
  xv 
Supplemental Material ................................................................................................ 194 
CHAPTER FIVE: ANTHRAX VACCINE ADSORBED IMMUNIZATION ELICITS 
HIGHLY TRANSIENT, VACCINE-RESPONSIVE PLASMABLAST CLONES 
FOLLOWING SECONDARY PRIMING DOSE .......................................................... 206 
Rationale ..................................................................................................................... 206 
Results ......................................................................................................................... 209 
5.1 Anti-PA serum antibody and increased IgG+ peripheral blood plasmablasts are 
observed following secondary immunization and increase until after the fourth. .. 209 
5.2 There is a population of persistent, non-immunization responsive clones in the B 
cell repertoire. ......................................................................................................... 214 
5.3 Clonal responses are highly transient and do not move towards homogeneity 
following immunization. ......................................................................................... 218 
5.4 Plasmablasts observed following the primary dose are similar to the pre-immune 
repertoire, while those following secondary immunization are naïve-derived. ...... 222 
5.5 The dynamics of the responding clones exhibits two distinct patterns of growth 
and succession. ........................................................................................................ 229 
5.6 Preexisting memory clones decline over time, do not diversify, and do not bind 
PA. Naïve-derived clones grow and diversify. ....................................................... 232 
5.7 The naïve-derived response is driven by IgG1+ plasmablasts. ......................... 237 
5.8 Gene segment usage is dynamic. ...................................................................... 240 
Discussion ................................................................................................................... 244 
Supplemental Material ................................................................................................ 249 
  xvi 
CHAPTER SIX: CONCLUDING REMARKS .............................................................. 264 
Overview ..................................................................................................................... 264 
Summary of Major Findings ....................................................................................... 264 
Significance................................................................................................................. 267 
Future Directions ........................................................................................................ 270 
Study Limitations ........................................................................................................ 272 
APPENDIX ..................................................................................................................... 274 
A POPULATION OF STEADY STATE PLASMABLASTS IN HEALTHY 
INDIVIDUALS ENCODE AUTOREACTIVE IMMUNOGLOBULIN. ...................... 274 
Rationale ..................................................................................................................... 274 
7.1 Preexisting memory, but not naïve-derived antibodies bind human autoantigens.
................................................................................................................................. 275 
7.2 Autoantigens against observed antibodies are not genetically similar to anthrax 
vaccine components. ............................................................................................... 277 
7.3 Serum does not contain detectable autoreactivity before or after AVA 
immunization. ......................................................................................................... 278 
Discussion ............................................................................................................... 281 
Supplemental Material ................................................................................................ 284 
BIBLIOGRAPHY ........................................................................................................... 292 
CURRICULUM VITAE ................................................................................................. 316 
 
  
  xvii 
LIST OF TABLES 
Table 2.1. Tagged antibodies for fluorescence-activated cell sorting (FACS) to isolate B 
cell subsets. ............................................................................................................... 49 
Table S2.1. Primers for cDNA synthesis .......................................................................... 73 
Table S2.2. Primers for amplification PCR (PCR 1) ........................................................ 73 
Table S2.3. Primers for Illumina MiSEQ adaptor PCR (PCR2)....................................... 73 
Table S2.4. Primers for Illumina MiSEQ sequencing ...................................................... 76 
Table 3.1. Analysis of variance (ANOVA) and post hoc tests to determine factor 
contribution to variance. ........................................................................................... 96 
Table 3.2. ANOVA and post hoc tests to determine contribution to variance in UID 
consensus Ig-seq. .................................................................................................... 103 
Table 3.3. Error estimation for biological and technical replicates. ............................... 106 
Table S3.1. Fligner-Killeen Test of Homogeneity of Variances for raw Ig-seq. ............ 139 
Table S3.2. Summary of unique and shared clonal observations in biological and 
technical replicates. ................................................................................................. 140 
Table S3.3. UID consensus Ig-seq data exploration. ...................................................... 144 
Table S3.4. Total raw reads and immunoglobulin output for all sequencing runs. ........ 146 
Table S4.1. UID-consensus sequence counts per subject and visit. ............................... 199 
Table 5.1. Kolmogorov-Smirnov tests to compare baseline to post-AVA immunization 
clone mutation frequencies. .................................................................................... 228 
Table 5.2. Selected naïve- but not preMPBs have measurable affinity for PA. ............. 236 
Table S5.1. Total counts for Atreca, Inc. single-cell plasmablast FACS. ...................... 250 
  xviii 
Table S5.2. Descriptive statistics of mutation frequencies of IGH at first clonal 
observation following AVA immunization. ........................................................... 257 
Table S5.3. Pairwise Kolmogorov-Smirnov tests between all time points before and 
following AVA immunization.. .............................................................................. 260 
Table 7.1. Protein microarray assessment of autoantigen binding to candidate antibodies.
................................................................................................................................. 276 
Table S7.1. Autoantigen hits against plasmablast IgVRG. ............................................. 287 
Table S7.2. BLASTP comparison of AVA components to autoantigen hits. ................. 290 
 
  
  xix 
LIST OF FIGURES 
Figure 2.1. Representative example of single cell plasmablast FACS. ............................ 50 
Figure 2.2. Representative example of bulk FACS for naïve, memory and plasmablast B 
cells. .......................................................................................................................... 51 
Figure 3.1. Unique molecular identified (UID)-tagged clonal phylograms reveal technical 
error. .......................................................................................................................... 85 
Figure 3.2. A UID-tagged clone with an insertion erroneously added during sample 
processing. ................................................................................................................ 87 
Figure 3.3. Observed clonal overlap between non-UID-consensus sequences from 
biological and technical replicates. ........................................................................... 93 
Figure 3.4. The proportion of total observed clones per sample which are unique to that 
sample. ...................................................................................................................... 94 
Figure 3.5. Comparison of proportion unique clones and counts in raw versus consensus-
called immunoglobulin sequencing (Ig-seq). ............................................................ 99 
Figure 3.6. Clonal overlap of UID-tagged consensus sequences from biological and 
technical replicates. ................................................................................................. 101 
Figure 3.7. Immunoglobulin-specific output from UID-tagged and untagged high 
throughput sequencing. ........................................................................................... 109 
Figure 3.8. Rarefaction assessment to estimate immunoglobulin repertoire coverage... 111 
Figure 3.9. Distribution of the number of sequences per UID-tag from AVA vaccinated 
individuals. .............................................................................................................. 114 
Figure 3.10. The distribution of total, non-consensus sequences per clone. .................. 115 
  xx 
Figure 3.11. The relationship between clone and UID counts is non-linear................... 116 
Figure 3.12. Random forest classification identifies two classes within UID-tagged data.
................................................................................................................................. 119 
Figure 3.13. Random forest regression model of UID-tagged data for UID estimation. 121 
Figure 3.14. Random forest regression model estimates of raw-UID ratio. ................... 125 
Figure S3.1. Example Phred quality score analyses for raw, 2x300bp MiSeq runs. ...... 135 
Figure S3.2. Quality score analysis for joined reads passing quality filtering. .............. 137 
Figure S3.3. Q-Q plot of unique proportions of clones observed from raw Ig-seq. ....... 138 
Figure S3.4. Interactions between pairwise steps during Ig-seq library preparation and 
sequencing............................................................................................................... 141 
Figure S3.5. UID consensus Ig-seq data exploration. ..................................................... 143 
Figure S3.6. Rarefaction assessment to estimate immunoglobulin coverage per library 
preparation method. ................................................................................................ 148 
Figure S3.7. Modeled and real data distributions to determine initial values for random 
forest classification. ................................................................................................ 150 
Figure S3.8. Correlation analyses for class predictors. ................................................... 151 
Figure S3.9. Random forest regression prediction with classification. .......................... 153 
Figure 4.1. B cell counts of total peripheral blood mononuclear cells (PBMC) before and 
after Anthrax Vaccine Adsorbed (AVA) immunization. ........................................ 158 
Figure 4.2. Mutation frequencies of memory and plasmablast immunoglobulin variable 
region genes (IgVRG) over time. ............................................................................ 161 
Figure 4.3. Cumulative substitution frequencies before and after AVA immunization. 162 
  xxi 
Figure 4.4. Distribution of mutation frequency in the earliest observed differentiated B 
cells by clone........................................................................................................... 164 
Figure 4.5. Density distribution of clone CDR3 lengths by week. ................................. 167 
Figure 4.6. Mean clone size prior to and following AVA immunization. ...................... 170 
Figure 4.7. The distribution of clone sizes before and one-week following AVA 
immunizations. ........................................................................................................ 171 
Figure 4.8. The immunoglobulin repertoire is highly diverse and transient before and 
after AVA immunization. ....................................................................................... 172 
 176 
Figure 4.9. B cell subsets within clones in total high throughput Ig-seq. ....................... 176 
Figure 4.10. Plasmablasts, then memory B cells increase in the IgVRG repertoire 
following AVA immunization. ............................................................................... 177 
Figure 4.11. Isotype composition of IgVRG before and after AVA immunization. ...... 178 
Figure 4.12. IgM+ and IgG+ Protective Antigen (PA)-specific serum reactivity by week.
................................................................................................................................. 179 
Figure 4.13. IGHV and IGHJ gene segment usage of bulk IgVRG through AVA 
vaccination. ............................................................................................................. 183 
Figure 4.14. Clonograms of random and candidate clones of the AVA response. ......... 187 
Figure 4.15. IgVRG entropy of random versus vaccine-responding candidates clones. 189 
Figure S4.1. Proportion of naïve, memory and plasmablast B cells of total B cells isolated 
during bulk FACS sorting. ...................................................................................... 194 
  xxii 
Figure S4.2. Cumulative substitution frequencies before and after AVA immunization.
................................................................................................................................. 196 
Figure S4.3. Clone size distribution from UID-consensus Ig-seq by week. ................... 197 
Figure S4.4. The distribution of clone size (proportion of all observed clones) by week.
................................................................................................................................. 198 
Figure S4.5. B cell subsets within clones in total HTS Ig-seq by subject. ..................... 200 
Figure S4.6. Isotype composition of IgVRG before and after AVA immunization. ...... 202 
Figure S4.7. IGHV gene segment usage of bulk IgVRG through AVA vaccination, by 
subject. .................................................................................................................... 204 
Figure S4.8. IGHJ gene segment usage of bulk IgVRG through AVA vaccination, by 
subject. .................................................................................................................... 205 
Figure 5.1. Total IgG+, IgM+ and IgA+ Protective Antigen (PA)-specific serum reactivity 
expressed as equivalent concentrations of anti-PA monoclonal antibody by week 
following AVA vaccination. ................................................................................... 212 
Figure 5.2. Plasmablast dynamics prior to and following AVA immunizations. ........... 213 
Figure 5.3. B cell subset usage within clones in high throughput sequencing inclusive 
Atreca immunoglobulin sequencing (Ig-seq).......................................................... 216 
Figure 5.4. Clones are highly transient following AVA immunization. ......................... 219 
Figure 5.5. Interclonal diversity is variable, but reaches a minimum following the third 
AVA immunization. ................................................................................................ 220 
Figure 5.6. Clone size invariably peaks at first observation throughout AVA 
immunization. ......................................................................................................... 221 
  xxiii 
Figure 5.7. Observed mutation dynamics in IgG+ plasmablasts following AVA 
immunization. ......................................................................................................... 224 
Figure 5.8. Cumulative nucleotide substitution by week and subject following AVA 
immunization. ......................................................................................................... 225 
Figure 5.9. Intraclonal nucleotide diversity following AVA immunization. .................. 226 
Figure 5.10. Distribution of mutation frequency in the earliest observed heavy chain 
members following AVA immunization. ............................................................... 227 
Figure 5.11. Distinctive patterns of clonal evolution suggest two population sources 
following AVA immunization. ............................................................................... 231 
Figure 5.12. Persistent clones have distinct patterns of somatic hypermutation following 
AVA immunization. ................................................................................................ 234 
Figure 5.13. Phylogram describing clone 2202. ............................................................. 235 
Figure 5.14. The proportion of IgG subclass observed by week following AVA 
immunization. ......................................................................................................... 238 
Figure 5.15. IgG subclass mutation frequencies following AVA immunization. .......... 239 
Figure 5.16. IGHV and IGHJ gene segment usage in plasmablasts following AVA 
immunization. ......................................................................................................... 243 
Figure S5.1. Variance of plasmablast proportion of B cells between subjects following 
AVA immunization. ................................................................................................ 249 
Figure S5.2. B cell subset usage within clones in HTS inclusive Atreca Ig-seq by subject.
................................................................................................................................. 251 
Figure S5.3. Cumulative light chain nucleotide substitution by week and subject. ....... 253 
  xxiv 
Figure S5.4. Distribution of mutation frequency in the earliest observed light chain 
members following AVA immunization. ............................................................... 255 
Figure S5.5. Plasmablast persistence and mutation frequencies reveal two classes of 
clones. ..................................................................................................................... 261 
Figure S5.6. Representative examples of surface plasmon resonance (SPR) sensorgrams 
measuring antigen-binding fragments..................................................................... 262 
Figure S5.7. Rarefaction analysis of single cell sorted, plasmablast Ig-seq. .................. 263 
Figure 7.1. HEp-2 anti-nuclear antigen staining of serum before and after primary AVA 
immunization. ......................................................................................................... 279 
Figure 7.2. Quantification of HEp-2 anti-nuclear antigen staining of plasma before and 
after primary AVA immunization. .......................................................................... 280 
Figure S7.1. Autoreactivity array for preexisting memory-derived plasmablasts. ......... 285 
Figure S7.2. Autoreactivity array for naïve-derived plasmablasts. ................................ 286 
 
  
  xxv 
LIST OF ILLUSTRATIONS 
Illustration 1.1. T cell-dependent B cell responses to protein-based vaccination. ............ 10 
Illustration 2.1. Anthrax Vaccine Adsorbed (AVA) vaccination and blood draw study 
schedule..................................................................................................................... 41 
Illustration 2.2. Anthrax Vaccine Adsorbed vaccination blood sample processing and use 
overview. ................................................................................................................... 44 
Illustration 2.3. Schematic of bulk B cell immunoglobulin library preparation. .............. 57 
Illustration 2.4. 5’ Switching Mechanism at 5’ End of RNA Template (SMARTer) RACE 
strategy for high throughput immunoglobulin sequencing (Ig-seq). ........................ 58 
Illustration 2.5. Schematic of Ig-seq bioinformatics processing....................................... 69 
Illustration 3.1. Schematic of replicate study sample processing. .................................... 91 
Illustration 5.1. Schematic of plasmablast-focused Anthrax Vaccine Adsorbed (AVA) 
experimental design ................................................................................................ 211 
  
  xxvi 
LIST OF ABBREVIATIONS 
ADCC ........................................................ Antibody-dependent cell-mediated cytotoxicity 
AID ......................................................................... Activation-induced cytidine deaminase 
Alum ................................................................................................... Aluminum hydroxide 
ANA ......................................................................................................Anti-nuclear antigen 
ANOVA ................................................................................................ Analysis of variance 
APC .................................................................................................. Antigen-presenting cell 
ASC .................................................................................................. Antibody secreting cell 
AVA ........................................................................................... Anthrax Vaccine Adsorbed 
AVP........................................................................................ Anthrax Vaccine Precipitated 
B. anthracis .............................................................................................. Bacillus anthracis 
BCR................................................................................................................ B cell receptor 
BLAST® ...................................................................... Basic Local Alignment Search Tool 
bp.............................................................................................................................Base pair 
BSA ................................................................................................... Bovine serum albumin 
BU ............................................................................................................ Boston University 
C ................................................................................................................. Constant domain 
cAMP ............................................................................... Cyclic adenosine monophosphate 
CD .................................................................................................. Cluster of differentiation 
cDNA .................................................................................................. complementary DNA 
CDR ........................................................................... Complementarity determining region 
CFR ............................................................................................................ Case fatality rate 
  xxvii 
CH .......................................................................................... Heavy chain constant domain 
CI............................................................................................................ Confidence interval 
CMG2 ............................................................................ Capillary morphogenesis protein 2 
CO2 .................................................................................................................................................................... Carbon dioxide 
CTCF.................................................................................. Corrected total cell fluorescence 
D ....................................................................................................... Diversity gene segment 
DC .................................................................................................................... Dendritic cell 
Df ........................................................................................................... Degrees of freedom 
D-MEM  ...................................................................... Dulbecco’s Modified Eagle Medium  
DMSO .....................................................................................................Dimethyl sulfoxide 
DNA .................................................................................................. Deoxyribonucleic acid 
dNTP ......................................................................................................... Deoxynucleotides 
dT .............................................................................................................. Deoxy-thymidine 
DTT .................................................................................................................. Dithiothreitol 
e.g. ...................................................................................................................exempli gratia 
EA1 .................................................................................................... Extractable Antigen 1 
EDC........................................................ 1-Ethyl-3-(3-dimethylaminopropyl)-carbodiimide 
EDTA ................................................................................. Ethylenediaminetetraacetic acid 
EF .................................................................................................................... Edema Factor 
ELISA ...................................................................... Enzyme-linked immunosorbent assays 
Ex/em .............................................................................................. Excitation and emission 
FACS.............................................................................. Fluorescence-activated cell sorting 
  xxviii 
FBS ......................................................................................................... Fetal bovine serum  
Fc...................................................................................................... Fragment crystallizable 
FcR ..................................................................................... Fragment crystallizable receptor 
FDA...................................................................................... Food and Drug Administration 
FDC .................................................................................................. Follicular dendritic cell 
FITC ............................................................................................ Fluorescein isothiocyanate 
FR ............................................................................................................. Framework region 
g.................................................................................................................................... Gram 
GC ................................................................................................................ Germinal center 
GFP ..............................................................................................Green Fluorescent Protein  
GI ................................................................................................................. Gastrointestinal 
HCL......................................................................................................... Hydrogen chloride 
HEPES ................................................ 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
HIV .................................................................................... Human immunodeficiency virus 
HRP .................................................................................................. Horseradish peroxidase 
HTS .......................................................................................... High-throughput sequencing 
Ig ................................................................................................................. Immunoglobulin 
IgH ......................................................................................... Immunoglobulin heavy chain 
Ig-seq........................................................................................ Immunoglobulin sequencing 
IgVRG ....................................................................... Immunoglobulin variable region gene 
Igκ .................................................................................. Immunoglobulin kappa light chain 
Igλ ................................................................................ Immunoglobulin lambda light chain 
  xxix 
IRB ............................................................................................... Institutional review board 
IUPAC................................................. International Union of Pure and Applied Chemistry 
J ........................................................................................................... Joining gene segment 
KD ........................................................................................................ Dissociation constant 
kDA ...................................................................................................................... Kilodalton 
KS ...................................................................................................... Kolmogorov-Smirnov 
LF ..................................................................................................................... Lethal Factor 
LLPC ................................................................................................. Long lived plasma cell 
M .............................................................................................................................. Memory 
Mab ..................................................................................................... Monoclonal antibody 
MAPKK ................................................................ Mitogen-activated protein kinase kinase 
Mb ........................................................................................................................ Megabases 
mg ......................................................................................................................... Milligram  
MHC ............................................................................. Major Histocompatibility Complex 
mL ........................................................................................................................... Milliliter  
mM .........................................................................................................................Millimole 
mRNA ......................................................................................................... Messenger RNA 
N nucleotide ................................................................................. Non-templated nucleotide 
N ................................................................................................................................... Naïve 
NaCl ............................................................................................................ Sodium chloride 
NaOH ....................................................................................................... Sodium hydroxide 
ng........................................................................................................................... Nanogram 
  xxx 
NGS...........................................................................................Next-generation sequencing 
NHS................................................................................................... N-hydroxysuccinimide 
NIAID ................................................. National Institute of Allergy and Infectious Disease   
NIH .......................................................................................... National Institutes of Health  
nM ......................................................................................................................... Nanomole 
nt .......................................................................................................................... Nucleotide 
P ......................................................................................................................... Plasmablast 
PA ........................................................................................................... Protective Antigen 
PB ....................................................................................................................... Plasmablast 
PBMC ........................................................................... Peripheral blood mononuclear cells 
PBS .............................................................................................. Phosphate buffered saline  
PBST ..................................................................................... Phosphate buffer saline tween 
PCA ........................................................................................ Principal component analysis 
PCR ............................................................................................. Polymerase chain reaction  
PE ..........................................................................................................................Paired end 
PI ................................................................................................................ Propidium iodide 
P-nucleotide ..................................................................................... Palindromic nucleotide 
Pol ....................................................................................................................... Polymerase 
PRR ........................................................................................... Pattern recognition receptor 
psi ..................................................................................................... Pounds per square inch 
p-value........................................................................................................ Probability value 
Q ....................................................................................................................... Quality score 
  xxxi 
qPCR ....................................................................... Quantitative polymerase chain reaction  
RACE ........................................................................... Rapid Amplification of cDNA Ends 
RAG1/2 .............................................................................. Recombination Activating Gene 
RCF ............................................................................................... Relative centrifugal force 
RLM ...................................................................................................... Robust linear model 
RMSE ............................................................................................... Root mean square error 
RNA ............................................................................................................Ribonucleic acid 
RNA-seq .................................................................................................... RNA sequencing 
rPA .................................................................................... Recombinant Protective Antigen 
RPM ................................................................................................. Revolutions per minute 
RPMI ................................................................... Roswell Park Memorial Institute medium 
RS ........................................................................................................Recombination signal 
RT ....................................................................................................... Reverse transcriptase 
RU ................................................................................................................... Response unit 
SAP .................................................................................................... Surface Array Protein 
SDI .............................................................................................. Simpson’s Diversity Index 
SDS-PAGE ............................. Sodium dodecyl sulfate polyacrylamide gel electrophoresis 
Seq.......................................................................................................................... Sequence 
SEQC .................................................................... Sequencing Quality Control Consortium 
SHM ................................................................................................. Somatic hypermutation 
SMART ................................................ Switching Mechanism at 5’ End of RNA Template 
SPR ............................................................................................ Surface plasmon resonance 
  xxxii 
TdT ........................................................................... Terminal deoxynucleotidyl transferase 
TEM8 ..................................................................................... Tumor endothelium marker-8 
TH ......................................................................................................... T helper lymphocyte 
TLR ........................................................................................................... Toll-like receptor 
U ..................................................................................................................................... Unit 
UCA ....................................................................................... Unmutated common ancestor 
UID .......................................................................................... Unique Molecular Identifier 
UP .............................................................................................................. Universal primer 
V ........................................................................................................ Variable gene segment 
Yo ........................................................................................................................... Years old 
µg .........................................................................................................................Microgram 
µl ........................................................................................................................... Microliter  
µm ....................................................................................................................... Micrometer  
µM ........................................................................................................................ Micromole 
 
 
  
1 
CHAPTER ONE: INTRODUCTION 
Anthrax disease 
History and epidemiology 
Anthrax disease is an acute bacterial infection caused by Bacillus anthracis (B. 
anthracis) that primarily affects livestock, but is transmissible to humans and can result 
in hypoxia and death. Anthrax is an ancient disease, with records of anthrax-like 
symptoms from Greek antiquity, and has a robust history described in many regions. The 
bacteria was identified in 1850 by Pierre Rayer and Casimir Davaine, and further 
clarified in 1855 by Aloys Pollender who connected the “stick-shaped corpuscles” in 
blood from diseased sheep to Anthrax disease 1798 (Pollender, 1855; Théodoridès, 
1966). Robert Koch famously isolated B. anthracis and used it to infect mice to 
recapitulate disease in the inaugural demonstration of Koch’s postulates (Koch, 1881). 
Koch was also the first to demonstrate B. anthracis’ sporulating activity, which allows 
the bacteria to survive harsh conditions. Louis Pasteur also performed significant 
scientific work with B. anthracis, developing the first live-attenuated vaccine using an 
oxidized form of the bacteria. He demonstrated his vaccine’s efficacy in a famous 
inoculation and challenge infection of livestock (Sternbach, 2003). 
B. anthracis is a soil dwelling, endospore-forming, obligate pathogen that is 
globally distributed. Max Sterne developed an efficacious live spore vaccine for use in 
animals in 1937, which has since been widely used, leading to a global decrease in 
human infections. However, outbreaks are still relatively common around the world, with 
around 2,000 annual cases (Turnbull, 2008). Modern outbreaks involving human 
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infections tend to be located in central Asia and Africa, though sporadic cases do occur 
elsewhere including in the United States. One notable Russian outbreak in 2016 has been 
postulated to be from a reindeer carcass from 1968 that was exposed by melting 
permafrost during a heatwave, highlighting the underappreciated relationship between 
climate and infectious disease (ProMED-mail). 
Transmission 
Anthrax infection can be acquired by humans by three primary routes of 
transmission, 1. Cutaneous, 2. Ingestion/oral, and 3. Inhalation. Around 95% of infections 
are cutaneous, whereby B. anthracis is introduced through skin lesions. These infections 
are typically occupational, and affect workers who handle livestock or susceptible 
materials such as hides. The infectious dose for humans is estimated to be from the 
thousands to tens of thousands of spores, thus the disease is considered functionally non-
contagious between humans. 
In general, treatment of cutaneous infections is highly successful, with <1% case 
fatality rate (CFR). Without treatment, CFR of up to 40% have been historically 
recorded. Recently, intravenous drug use with B. anthracis contaminated material has led 
to outbreaks of more extreme “cutaneous” infections with CFR above 30% (Grunow et 
al., 2012). Ingestion or orally acquired infection is rare, but is most commonly due to 
ingestion of meat from infected animals. With treatment, case fatality rates are 40% 
(Beatty et al., 2003). Inhalation anthrax is very rare and occurs when aerosolized spores 
are inhaled, but it is of special concern as an agent of bioterrorism, as occurred in the 
United States in 2001. Inhalational anthrax has a relatively high CFR (45%) even with 
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aggressive treatment, and is highly fatal (85-90% CFR) without treatment (Jernigan et al., 
2001; Barakat et al., 2002; Turnbull, 2008). 
Clinical manifestations 
 The pathology of anthrax is dependent on the route of infection. In cutaneous 
infection, painless, black ulcers will develop within 5-7 days of exposure. This may be 
accompanied by fever, headache and malaise. Cutaneous anthrax is most dangerous when 
lesions form on the upper body near the neck or chest. In more extreme cases, edema 
from the lesion, toxemia, hypotension, a change in mental status and the inability to eat or 
drink may also arise. (Inglesby et al., 2002; Jernigan et al., 2002; Turnbull, 2008). Oral 
anthrax has a shorter incubation period, 3-7 days, and a wide spectrum of symptoms, 
likely based on infectious dose and co-morbidities (Doganay et al., 1987; Doganay and 
Metan, 2009). Initial symptoms are non-specific, including fever, headache, nausea, 
vomiting, and mild diarrhea, but can quickly become more extreme. Ulcerative lesions 
may form within the oral cavity or gastrointestinal tract. GI lesions may lead to 
hemorrhage, ascites and shock, and oral cavity lesions may lead to extensive neck 
swelling, toxemia and acute respiratory distress (Sirisanthana et al., 1984; Doganay et al., 
1986; Sirisanthana et al., 1988; Inglesby et al., 2002). Inhalational anthrax is very rare 
and clinical manifestations are not clearly defined. Based on the 2001 incidents of 
anthrax bioterrorism, where spores were sent by mail and infected a number of postal 
workers and recipients, this transmission type has an estimated incubation period of 4-6 
days and initially presents with non-specific symptoms including chills, malaise, cough, 
nausea and confusion with invariant abnormal chest X-rays (Jernigan et al., 2001; 
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Inglesby et al., 2002). These are followed by more severe symptoms that may rapidly 
lead to death including dyspnea, cyanosis, disorientation and coma (Plotkin et al., 1960; 
Turnbull, 2008). Sepsis and septic shock may occur following lymphatic dissemination of 
the bacteria from a primary lesion through any form of transmission (Dutz et al., 1970; 
Nalin et al., 1977; Bhat et al., 1985; Sirisanthana and Brown, 2002; Kanafani et al., 
2003). Anthrax meningitis a serious, often fatal outcome of all forms of anthrax, and is 
characterized by head and neck pain, high-grade fever, vomiting and changes in mental 
state. Meningeal inflammation and edema lead to a serious increase in cerebrospinal fluid 
pressure (Sejvar et al., 2005; Turnbull, 2008; Hendricks et al., 2014). 
Anthrax pathogenesis 
 Anthrax disease is primarily caused by two important virulence factors: 1. Poly-γ-
D-glutamic acid (PGA) capsule and 2. Tripartite anthrax toxin secreted by B. anthracis, 
which is composed of Protective Antigen (PA), Lethal Factor (LF), and Edema Factor 
(EF). On entry into a susceptible host, B. anthracis spores are transported by phagocytes 
into the lymphatic system and germinate to produce toxins (Ross, 1957). Vegetative cells 
are protected from macrophage phagocytosis by the anionic PGA capsule (Makino et al., 
1989; Makino et al., 2002). Anthrax toxin is assembled on target cells after PA first binds 
an anthrax toxin receptor, which are highly expressed and ubiquitous. Two known 
receptors are TEM8 and CMG2 (Bradley et al., 2001; Scobie et al., 2003; Sternbach, 
2003; Moayeri and Leppla, 2004; Turnbull, 2008). PA may then be cleaved by furin 
family proteases and oligomerize to form a PA heptamer which is capable of binding LF 
and/or EF. Lethal toxin is PA and LF, and Edema toxin is PA and EF. Following clathrin-
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mediated endocytosis of the toxin, endosome acidification causes the PA heptamer to 
form a channel through which LF and EF may enter the cytosol (Petosa et al., 1997). EF 
is a calmodulin-dependent adenylate cyclase that rapidly increases cAMP, causing edema 
and disrupting cellular signaling pathways (Drum et al., 2002; Moayeri and Leppla, 
2004). LF is a zinc-dependent endoprotease that inactivates MAPKK, leading to cellular 
apoptosis, particularly in macrophages, and ultimately causes hypotension, shock and 
death (Friedlander, 1986; Hanna, 1999; Pannifer et al., 2001). 
Vaccine and treatment 
Anthrax disease was one of the earliest targets of immunization, and its first 
vaccine was developed by Louis Pasteur in the infancy of vaccination for agricultural use. 
Routine vaccination of livestock has been common since the Sterne vaccine was 
introduced in the 1930s, though global coverage rates vary. The first anthrax 
immunization intended for human use was a live-attenuated, unencapsulated spore 
vaccine licensed in the Soviet Union in 1953 (Turnbull, 1991a; Shlyakhov et al., 1997; 
Turnbull, 2000; Turnbull, 2008; Turnbull, 2010). The United Kingdom (UK) and United 
States independently developed and tested vaccines using the culture supernatants of 
attenuated B. anthracis strains during the 1950s, which are still the basis of the currently 
licensed vaccines in these countries (Brachman et al., 1962; Turnbull, 2010). The only 
FDA licensed vaccine against anthrax disease is Anthrax Vaccine Adsorbed (AVA, trade 
name: BioThrax®, Emergent Biosolutions), which was approved in 1972 and is currently 
administered in five doses at 0, 4, 6, 12 and 18 months with annual boosters . AVA uses 
the unencapsulated V770-NP1-R strain of B. anthracis to harvest its secreted proteins, 
  
6 
primarily PA, as antigenic vaccine components (2008). While the complete components 
of AVA are not public knowledge, Emergent Biosolutions has published that it is 
partially comprised of the non-cleaved form of PA, aluminum hydroxide in sodium 
chloride for adjuvant, benzethonium chloride and formaldehyde as preservatives. The 
primary consumer of AVA is the US military, where it is administered to those who are 
deployed to areas under biological threat. 
The mechanism of AVA action is not well understood, but it is likely to be 
mediated by the elicitation of neutralizing antibodies against PA. Anti-PA antibodies are 
a primary correlate of AVA-mediated protection in rabbit and macaque models and also 
have neutralizing functions against in vitro cytotoxicity (Ivins et al., 1998; Pitt et al., 
2001; Reuveny et al., 2001). A variety of anti-PA antibodies have been isolated and 
characterized from both humans and animal models. Antibody-mediated neutralization 
can occur via antibody binding to a multiple sites on PA that inhibit its pathogenic 
function. PA domain IV is a primary neutralization target that inhibits receptor binding 
and antibodies that target this domain can provide protection against anthrax infection in 
guinea pigs (Little et al., 1997). Other binding sites can block furin cleavage, 
oligomerization, LF and EF binding and pore formation, though it is not clear if 
antibodies against these sites provide in vivo protection (Rivera et al., 2006; Froude et al., 
2011; Smith et al., 2012). 
 All forms of anthrax may be specifically treated with antibiotics and antitoxin. 
There are two FDA-approved antitoxins, which are comprised of antibodies against PA. 
These bind and neutralize secreted PA in a passive manner which does not extend to 
  
7 
immunological memory, while antimicrobials target the bacteria itself. Post-exposure 
prophylactic (PEP) oral antibiotics may be used, and AVA is also indicated for PEP 
administration. (Hendricks et al., 2014; 2015; 2016a). Pleural fluid drainage is positively 
correlated with survival, and is postulated to remove toxins and lower mechanical lung 
pressure (Holty et al., 2006). As with many infectious diseases, early diagnosis and 
treatment are important for survival (Hendricks et al., 2014).  
Vaccines 
Historical development 
 The development of modern immunization, beginning with Edward Jenner’s work 
on smallpox vaccination in 1798, has enormously contributed to improving global public 
health. Jenner’s approach to vaccine development was based on his observation that dairy 
maids who routinely contracted the milder Vaccinia-caused cowpox were not affected by 
smallpox. During this time, variolation was in regular use, whereby dried material from 
pustules of smallpox infected persons were rubbed onto superficially scratched skin. 
When effective, this produced a mild form of smallpox in the variolated person and 
offered protection from future smallpox infection. However, this also carried a risk of 
lethal infection. Jenner postulated that cowpox might offer the same protection with a 
lower risk, as cowpox caused a naturally milder disease in humans. Instead of rubbing 
scab material, he inoculated subjects with it, then challenged them using standard 
variolation. Instead of developing mild smallpox, they did not develop disease (Jenner, 
1798). While enormous technical advances have occurred in vaccinology, Jenner’s 
approach is integral to our most important and celebrated vaccines. 
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Vaccine development began with direct inoculation with attenuated forms of the 
pathogen of interest, and this has remained an important part of modern immunization. 
Louis Pasteur developed a number of vaccines for livestock and humans by using oxygen 
and heat exposure as well as chemicals to attenuate the pathogen to balance its virulence 
and immunogenicity. In 1927, Albert Calmette and Camille Guérin improved on 
attenuation methodology by performing serial passage of Mycobacterium bovis, bovine 
tuberculosis, in media. Serial passage alters selective pressure as the pathogen adapts to 
the environment, aiding in the identification of immunogenic mutants with low virulence. 
Max Theiler successfully adopted this idea by attenuating pathogens in vivo. Theiler 
passaged yellow fever virus through chicken embryos and mice to allow the virus to 
adapt to the host until a strain emerged that was safe and protective in humans (Plotkin, 
2014). Soon thereafter, tissue culture techniques were improved and in vitro passage 
proved similarly successful in the attenuation of a variety of pathogens (Enders et al., 
1949).  
Vaccine approaches have also been modified as knowledge of microbiology and 
immunology have grown. In the late 19th century, it was found that carefully killed or 
inactivated pathogens could elicit protection, which laid the foundation for important 
inactivated vaccines such as typhoid, cholera and modern rabies vaccine. Similarly, it 
was during the early 20th century that knowledge of secreted toxins by Corynebacterium 
diphtheria and Clostridium tetani was used to make formalin-inactivated toxin-based 
vaccines, a precursor to the subunit vaccine (Leroux-Roels, 2010; Plotkin, 2014). By the 
mid-20th century, tremendous work was done by Jonas Salk, Albert Sabine, Maurice 
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Hilleman and others to develop vaccines against many of the worst and most burdensome 
infectious diseases. A number of vaccine strategies are currently used and being 
developed, including live-attenuated, inactivated, toxoid, subunit, conjugate, 
glycoconjugate, DNA and recombinant vector vaccines. Vaccines are estimated to 
prevent over 3 million deaths annually. Today, polio, measles, mumps, rubella, tetanus 
and rabies are some of our most important and efficacious vaccines, significantly 
reducing global health burdens (O'Hagan and Fox, 2015). 
Immunological mechanism of vaccination 
 The historical development of vaccination has been a remarkable demonstration 
in the power of empirical science. Even through much of the 20th century, little was 
known about the immunological mechanisms underlying the efficacy of vaccination 
(Pulendran and Ahmed, 2011). An ideal vaccination will impart long term, active 
immunity against a pathogen or toxin, which stands in contrast to the temporary, passive 
immunity imparted by pre-formed antibodies. The primary effectors of vaccine efficacy 
are B cell-secreted antibodies (humoral immunity), though cytotoxic CD8+ T 
lymphocytes may also be elicited (cellular immunity), particularly by live attenuated 
vaccines. These effector cells are activated and maintained by CD4+ T helper (TH) 
lymphocytes. (Siegrist, 2008).  
The immune response induced by non-live, protein based vaccines such as AVA 
is mediated through T cell-dependent antibody responses and is shown in a simplified 
diagram (Illustration 1.1). Antigen presenting cells (APCs), often dendritic cells (DCs), 
presenting antigenic peptides migrate to local draining lymph nodes and encounter naïve  
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Illustration 1.1. T cell-dependent B cell responses to protein-based vaccination. 
Antigen presenting cells (APC) such as dendritic cells (DC) phagocytize and process 
antigenic proteins introduced by vaccination and migrate to local secondary lymphoid 
tissues where they encounter circulating, antigen-specific, naïve B and T helper cells. 
Upon APC stimulation, cognate B and T cells migrate to the edge of their respective B 
cell and T cell zones and provide additional activation signals on major 
histocompatibility complex and co-receptor binding. Early responses to novel antigens 
(3-4 days) are primarily from extrafollicular proliferation and differentiation into IgM+ 
and IgG+, short lived plasmablasts. Activated B cells may also enter the B cell follicle 
and, upon receiving additional stimulation signals from follicular dendritic cells (FDC) 
and T follicular helper cells (TFH), undergo rapid proliferation and somatic 
hypermutation, establishing the dark zone of a germinal center. Germinal center B cells 
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may then cycle in and out of the dark zone, where they compete for FDC and TFH 
interactions and may undergo apoptosis or class switch recombination. During this 
cycling, B cells may differentiate and exit into the periphery as short lived antibody 
secreting plasmablasts, memory B cells or long lived plasmacytes (LLPC). Memory B 
cells and LLPC migrate to survival niches in bone marrow, and LLPC continue to secrete 
antibody throughout their life. The B cell types highlighted in red were studied in this 
dissertation.  
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CD4+ TH cells. On successful peptide presentation by APCs to antigen-specific T cell 
receptors (TCR), cognate B cells may then be involved in an early, extrafollicular 
response, or a later follicular response. In the former, within the first few days of 
immunization with a novel antigen, B cell receptors (BCR) that can bind the antigen with 
some affinity, a measurement of antibody-epitope binding strength, will increase CCR7 
expression on the cell surface (Reif et al., 2002; Pereira et al., 2010). This functions as a 
chemokine receptor for CCL19 and CCL21, which are expressed by fibroblastic reticular 
cells in the T cell zone of secondary lymphoid tissue (Pereira et al., 2010). Following 
migration to this region, B cells may then encounter cognate, activated T helper cells and 
differentiate into short lived plasmablasts which secrete low affinity antibody. Activated 
B cells may also undergo a form of functional diversification known as class switch 
recombination which results in the loss of immunoglobulin constant region IgM 
expression in lieu of IgG, IgA or IgE expression (Siegrist, 2008).  
A second wave of the vaccine response is the development of germinal centers 
leading to affinity matured antibodies and memory. Follicular dendritic cells (FDCs) 
reside in the B cell follicle and produce CXCL13, which attracts antigen-specific, 
activated CXCR5-expressing B and T cells. FDCs are able to capture and retain antigen 
for long periods, which affords circulating lymphocytes time to encounter their cognate 
antigen (Wang et al., 2011). On receiving additional activation signals by both FDC 
antigen presentation and T follicular helper cells (TFH), an antigen-specific B cell may 
rapidly proliferate and develop a germinal center where its progeny undergo mutation, 
discussed in more detail in the section titled “Affinity maturation.” These progeny B cells 
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are thought to compete for additional FDC and TFH binding and survival signals, resulting 
in selection of B cells with immunoglobulin with high antigen affinity (Siegrist, 2008; 
Kranich and Krautler, 2016). During the germinal center reaction, B cells may also 
undergo class switching and differentiation into antibody-secreting plasmablasts and 
longer lived memory B cells and plasmacytes. Antigen-experienced B and T cells can 
both go on to survive in long term memory niches for more rapid adaptive responses 
upon future exposure.  
B cell-secreted antibodies are the primary correlate of protection in most current 
vaccines (Plotkin, 2010). However, vaccines are also capable of eliciting T cell, or cell-
mediated immunity, with varying intensity. CD8+ T cells are cytotoxic and target infected 
host cells (intracellular pathogens). CD4+ TH cells are an essential part of nearly all 
vaccine mechanisms, and can be skewed to TH1 or TH2-type response. APCs present 
antigen peptides to TCRs via the major histocompatibility complex (MHC). MHC class I 
is recognized by CD8+ T cells, and MHC class II is recognized by CD4+ T cells. The TH1 
response targets intracellular pathogens by producing IFNγ and TNFα which support 
macrophage activation and CD8+ T cell differentiation. TH2 responses target extracellular 
antigens by producing IL-4, IL-5 and IL-13 (Stetson et al., 2004; Siegrist, 2008). Both 
CD4+ TH cells can provide B cell help. T cells also produce cytokines that skew class 
switch outcomes. IL-21 skews towards IgG1, IgG3 and IgA1 class switch in humans. 
Similarly, IL-10 skews to IgG1 and IgG3; IL-4 and IL-13 to IgG4 and IgE; and TGFβ to 
IgA (den Haan et al., 2014). CD4+ T cells can also persist as memory T cells, however 
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this outcome is correlated to priming antigen loads that are generally not met by non-live 
vaccines (Wherry et al., 1999; Siegrist, 2008).  
 As knowledge of immunology has grown, it has become apparent that natural 
infection by different pathogens elicits different molecular responses, and that the 
recapitulation of these responses may play a role in successful vaccination. For instance, 
to begin an immune response against infection, innate immune cells first recognize a 
foreign antigen. Pattern recognition receptors (PRRs) such as toll-like receptors (TLRs) 
recognize molecular motifs found on foreign, but not self, antigens, and transduce 
inflammatory signals. Different PRRs lead to different qualities of the response. This 
knowledge may then be applied to help understand some vaccine mechanisms and to 
design adjuvants that might specifically elicit responses similar to natural infection when 
appropriate. The strain of yellow fever used in the vaccine, YF-17D, has been shown to 
synergistically stimulate four TLRs, and is known to elicit a mixed TH1 and TH2-type 
response, leading to lifelong memory (Napolitani et al., 2005; Querec et al., 2006). In this 
case, the vaccine immunogenicity is provided by the endogenous adjuvant activity of the 
virus itself. While some live-attenuated vaccines may effectively utilize PRRs, only a few 
licensed adjuvants are thought to signal through them and adjuvant-mediated vaccination 
tends to lead to shorter-term memory (Pulendran and Ahmed, 2011). While live-
attenuated vaccines are able to elicit a productive immune response with pathogen alone, 
some acellular vaccines cannot. Thus, exogenous adjuvants, immunology’s “dirty little 
secret,” have been used to enhance antigen immunogenicity by activating an immune 
response in lieu of complete infectious particles.  
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Aluminum salt, or alum, is one of the most common adjuvants, and is used in 
AVA. Alum use in vaccination results in strong antibody production, but its mechanism 
of action is not yet understood. There is some evidence that alum retains antigen at the 
site of inoculation and improves persistence, and it also promotes maturation of 
monocytes into dendritic cells, an important APC (Gavin et al., 2006; Oleszycka and 
Lavelle, 2014). Other exogenous adjuvant mechanisms differ, as do the intensity and 
characteristics of their functional use.  Adjuvant development is particularly challenging 
as immunogenicity must be balanced against toxicity, and current formulations do not 
result in excellent long term memory as with smallpox and yellow fever vaccines 
(Pulendran and Ahmed, 2011; Mosaheb et al., 2017).  
Challenges in vaccine improvement and development 
While vaccines have been in successful use for decades, there are outstanding 
challenges in the field. These broadly include, 1. The development of novel vaccines 
against pathogens that evade or complicate typical approaches (e.g. HIV, malaria, dengue 
virus), 2. Rapid development and manufacture of vaccines against new and re-emerging 
diseases of epidemic concern (e.g. coronaviruses, zika virus) 3. The improvement of 
routine vaccinations to improve stability, vaccination method and long term protection 
(e.g. varicella, MMR), and 4. Efficacy and safety concerns for the very young and 
elderly, and immunocompromised individuals (e.g. influenza) (Leroux-Roels, 2010; 
Mortellaro and Ricciardi-Castagnoli, 2011; Kumru et al., 2014). 
Increased knowledge of the mechanisms underlying specific natural infections 
and vaccines may do a great deal to move the field forward into more focused, rational 
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vaccine design. The primary protective outcome for most vaccines is the development of 
a high affinity antibody response, and these antibody responses have historically been 
evaluated through empirical studies, observing the functional binding and neutralizing 
ability of existing antibodies in vitro and in vivo using animal models. This is problematic 
as in vitro assays do not always accurately predict in vivo function, and animal models 
are imperfect representations of human disease. One outcome of this empirical approach 
to vaccine design is that even the most efficacious vaccines do not confer immunity to all 
who are vaccinated and it is not easily understood why this is the case. This emphasizes 
that there are underlying biological influences of vaccine efficacy in diverse populations. 
(McElhaney et al., 2013). Another challenge is in the evaluation of vaccination during 
development. A better understanding of shared correlates or protection or non-protection 
might speed progress as vaccines are evaluated, and lead to more efficient design 
strategies (Plotkin, 2008; Hagan et al., 2015).  
Immunoglobulin Biology 
Antibodies 
A monomeric antibody molecule comprises four polypeptide chains: two identical 
heavy chains and two identical light chains, and exhibits symmetry under a 180 degree 
rotation about one axis. Secreted IgG is ~150kDa, where each heavy chain is ~50kDa and 
each light chain is ~25kDa. The molecule has three functional domains: two identical 
antigen binding domains, and a single domain Fc (“fraction crystallizing”) that binds to 
receptors on phagocytes and to other effector molecules of innate immunity (Janeway et 
al., 2005). The antigen binding domain can be found in an enormous number of specific 
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forms within any given individual, and each has a unique antigenic specificity. The 
antibody repertoire—the collection of all such binding specificities within an individual 
organism, collectively provides protection against an essentially unlimited universe of 
antigens. 
The structure of the IgVRG is characterized as being composed of relatively 
invariant framework regions (FR1-4), and intervening hypervariable loops known as 
complementarity determining regions (CDR1-3). Invariant cysteine residues are found 
within FR1 and at the 3’ end of FR3 and form a disulfide bond that stabilizes the β-sheet 
structure of the FRs (Edelman, 1973). CDR3, which begins at the second invariant 
cysteine, terminates at an invariant tryptophan in the heavy chain, or an invariant 
phenylalanine in the light chain. The total IgVRG is approximately 129 amino acids in 
length (Lefranc, 2003). 
There exist five isotypes of immunoglobulins which each have different structures 
and functions. Isotypes are determined by the expression of the immunoglobulin constant 
region gene, which are comprised of 3-4 domains (CH1-4). All isotypes have a disulfide 
or noncovalent bond in CH1 which secures the light chain, as well as a variable number 
of disulfide bonds that connect the two heavy chains. Some flexibility is conferred by the 
junction region between the V and C domains, particularly in isotypes with a hinge 
region. All naïve mature B cells first express IgM and IgD isotypes. IgD functions are not 
yet known, but the molecule is expressed only on antigen-naïve B cells. Upon antigen 
stimulation, immunoglobulins may undergo class switch recombination by excising the 
IgM constant region genes to allow IgG, IgA or IgE expression. IgG is the most common 
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serum antibody (85%), followed by IgA (7-15%), IgM (5%), IgD (0.3%) and IgE 
(0.02%) (Manz et al., 2005). 
Functions 
Antibodies control infection by neutralization, opsonization, antibody-dependent 
cell-mediated cytotoxicity (ADCC) and activation of the complement system. Antigen-
specificity conferred by the variable region binding site is the primary mechanism of 
neutralization, of which all isotypes are capable. However, opsonization, ADCC and 
complement require the constant region genes of the Fc. Naïve B cells express IgM and 
IgD BCRs, and early responding plasmablasts largely secrete IgM antibodies which 
generally have low antigen affinity but high avidity. Avidity is a measurement of the 
overall strength of interactions between epitope(s) and multivalent antibodies. Secreted 
IgM can multimerize in pentamers and, less commonly, hexamers, and is a strong 
complement activator. 
Early extrafollicular, activated B cell antibodies may be class switched, from IgM 
to IgG or, less commonly, IgA and IgE. Later, more effective plasmablasts typically 
secrete monomeric IgG, which is the dominant effector isotype in humoral immunity 
(Janeway et al., 2005; Vidarsson et al., 2014). IgG is the primary mediator of ADCC, 
neutralization, acts as an opsonin and activates complement. IgA exists in monomeric and 
dimeric forms, is primarily located in the mucosa and is also the primary antibody in 
breastmilk. Thus, its functions are distinct from IgM and IgG, and it is a weak opsonin 
and complement activator, instead acting primarily to neutralize. IgA can still signal 
through FcαR on neutrophils, monocytes, eosinophils, and some monocytes and dendritic 
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cells, leading to phagocytosis, cytokine secretion and ADCC (Woof and Russell, 2011). 
IgE strongly binds FcεR on mast cells, basophils and eosinophils. On parasite-based 
antigen recognition, IgE triggers cellular degranulation to kill the parasite. However, this 
mechanism can be triggered inappropriately on the development of non-pathogenic 
antigen recognition, resulting in allergy (von Bubnoff et al., 2003; Janeway et al., 2005). 
In addition to the variation in isotypes, there are multiple subclasses of IgG and 
IgA which also alter antibody functionality. In humans, IgG has four subclasses, ordered 
by their relative abundance (IgG1-4). IgG1 and IgG3 have stronger complement 
activating and Fc receptor-binding properties than IgG2 and IgG4 (Bindon et al., 1988; 
Bruhns et al., 2009). Soluble protein antigens and membrane proteins elicit the most 
common subclass, IgG1, and, to a lesser extent, IgG3 and IgG4 (Ferrante et al., 1990). 
IgG responses against bacterial capsular polysaccharides are strongly IgG2 skewed (Siber 
et al., 1980; Barrett and Ayoub, 1986), though IgG1 is important in the capsular response 
to Haemophilus influenza type b natural infection (Ferrante et al., 1990). Glycoconjugate 
vaccines have also been observed to elicit IgG1 and IgG3 responses (Vidarsson et al., 
1998). Antiviral responses first elicit IgG3 antibodies, which have strong pro-
inflammatory properties, then shift to IgG1 antibodies (Ferrante et al., 1990; Vidarsson et 
al., 2014). In an infectious setting, the rarest subclass, IgG4, may be elicited by parasites 
such as helminths (Ottesen et al., 1985; Adjobimey and Hoerauf, 2010). IgG4 may also 
be elicited upon repeated antigen exposure without infection, and is thus associated with 
allergens (Aalberse et al., 1983; Aalberse et al., 2009), which may also elicit IgG1 
antibodies (Vidarsson et al., 2014). IgA also has two subclasses. Monomeric IgA1 is 
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generally located in serum and is a weak ADCC activator. IgA2 exists in mucosal 
secretions as a dimer and is structurally protected from proteolysis to withstand the 
harsher environment. IgA2’s primary function is immune exclusion by neutralization and 
agglutination of ingested and inhaled antigens (Janeway et al., 2005; Woof and Kerr, 
2006). The presence of specific immunoglobulin isotypes and subclasses in the repertoire 
and against specific antigens are useful in understanding responses to infection and 
disease. 
B cell and BCR development 
B cells, like T cells and all other white blood cells, originate from multipotent 
hematopoietic stem cells in the bone marrow (Somasundaram et al., 2015). In the initial 
stages of development before release from the bone marrow, the B cell precursor 
rearranges its heavy chain variable region gene (IGH). There are no mechanisms 
enforcing a condition of frame-consistency through the junctions: two of every three 
recombinations will be out of frame and therefore non-productive. In this case, 
rearrangement is initiated on the corresponding locus on the other chromosome. If the 
rearrangement is productive and makes an intact protein, rearrangement on the other 
allele is blocked. This phenomenon is known as allelic exclusion and ensures that most B 
cells express a single antibody specificity. If neither allele is rearranged productively, the 
cell undergoes apoptosis (ten Boekel et al., 1995; Meffre and Nussenzweig, 2002; 
Naradikian et al., 2014). 
After productive heavy-chain recombination, explained in more detail in the 
section “Immunoglobulin repertoire diversification,” the B cell enters the pre-B cell 
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stage, where the rearranged heavy chain is temporarily paired with a surrogate light chain 
and expressed at the cell surface as the pre-B-cell receptor. Signals transduced through 
this pre-BCR activate light-chain rearrangement, starting with the kappa light chain genes 
(IGκ) and proceeding to lambda light chain genes (IGλ) if no productive kappa 
rearrangements occur (Naradikian et al., 2014). After productive heavy and light chain 
rearrangements have occurred, the mature BCR is expressed on the surface of the cell, 
which progresses to the immature B cell stage.  
Because each BCR arises from a stochastic process, the antigen to which it binds, 
if any, is not known in advance. Positive selection may occur to ensure that the BCR is 
not completely inert. In order to be non-pathogenic, the BCR must not have high affinity 
for self-antigens. At the immature stage, while still in the bone-marrow, B cells that 
transduce strong signals on exposure to self-antigens through their BCRs are deleted, 
made non-responsive (anergic), or rescued by receptor editing (Gay et al., 1993; 
Wardemann et al., 2003; Gaudin et al., 2004). After exit from the bone marrow, most 
transitional B cells will die within a few days. Those that survive complete their 
maturation into naïve B cells and circulate the lymphatic system, through lymphoid 
follicles within the spleen and lymph nodes (referred to as the secondary lymphoid 
tissues—bone marrow is primary). Newly emigrant B cells are restricted by a final 
peripheral tolerance checkpoint before becoming fully mature naïve B cells. Naïve 
peripheral B cells have a half-life of 3-8 weeks in the absence of antigenic stimulation 
(Fu and Chaplin, 1999; Rolink et al., 2002). 
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Thus, in addition to strict genetic limitations, developing immature B cells are 
bound by functional requirements for proper structure and against autoantigen 
recognition despite the intrinsic stochasticity required for broad antigen recognition 
within the immunoglobulin repertoire. It is estimated that up to 75% of nascent human 
bone marrow cells have at least transient autoreactivity, and 80-90% of B cells are 
deleted in the bone marrow of mice before reaching maturity due to these checkpoints. 
Despite these barriers, ~20% of antibody from human mature naïve B cells displays 
measurable autoreactivity in healthy adults (Wardemann et al., 2003; Tiller et al., 2007). 
It is possible to develop antibodies with known pathologies in animal models that lack 
specific checkpoints which would otherwise preclude them. 
Immunoglobulin repertoire diversification 
It is integral for humoral protection that there is a wide functional breadth of 
IgVRGs to match the near limitless number of potential foreign antigens. Adult humans 
are estimated to have on the order of 1010-1011 peripheral B cells, and known mechanisms 
of antibody diversity have been estimated to be capable of producing >1014 unique 
immunoglobulins. Current estimates of total B cell diversity by capture-recapture 
methods estimate individual diversity of unique paratopes, the antigen binding region, to 
be 3.5 x 1010 in naïve IgM+ B cells, the most common subset. If each unique B cell had a 
specifically encoded, unique IgVRG, the immunoglobulin locus alone would be larger 
than the entirety of the human genome (Glanville et al., 2009; Georgiou et al., 2014; 
Yaari and Kleinstein, 2015). Thus, the introduction of diversity to the immunoglobulin 
repertoire is multivariate, and may include additional unknown processes. 
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The diversity of antigen-binding domains is first established through an unusual 
system of intra-individual genetic recombination. Each heavy chain gene is constructed 
from the recombination of one each of variable (IGHV), diversity (IGHD), and joining 
(IGHJ) genes. In humans, these germline genes are arrayed along a single locus with 46-
54 IGHV genes (there is copy number polymorphism among individuals) followed by 23 
IGHD genes, and then by 6 IGHJ genes. D gene duplication is also possible, contributing 
to the overall gene diversity of the heavy chain (Larimore et al., 2012). The light chain 
genes come in two types on two distinct genomic loci, kappa and lambda and are 
recombined using two components rather than three (variable and joining). The stochastic 
selection of these germline genes constitutes antibody combinatorial diversity. There is 
also substantial allelic diversity among individuals at the immunoglobulin loci (Lefranc, 
2003; Munshaw and Kepler, 2010).  
Allelic diversity poses a few special challenges in immunoglobulin repertoire 
research. First, the total allelic diversity in a population or species is difficult to capture in 
genetic databases. This is particularly true in animals with less individual sequencing 
data. For instance, while several thousands of sequenced human immunoglobulins have 
contributed to 273 alleles among 53 IGHV genes, just ten sequenced macaque genomes 
have resulted in 215 alleles IGHV alleles, indicating the population is likely to have 
many more as yet unidentified variants. Second, standard alignment methods against a 
library of known genes are not sufficient to differentiate between alleles that may have as 
few as 1 base pair (bp) difference (Ramesh, 2017). New methods are currently in 
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development to mitigate these challenges by performing intra-individual gene and allele 
library building, which is expected to improve correct gene inference.  
In addition to combinatorial and allelic diversity, IgVRG exhibits junctional 
diversity. The enzymatic complex consisting of the recombination activating genes 
RAG1 and RAG2 binds to a recombination signal (RS) adjacent to each of the V, D and J 
genes, bringing the genes into close proximity. Proper ordering of the genes is enforced 
by the so-called 12/23 rule. There are two different types of RS, one with a 12-nucleotide 
spacer and one with a 23-base spacer. Synapsis occurs only between heterogeneous pairs. 
The recombinase nicks the DNA at the starts of each RS resulting in a DNA hairpin on 
each gene which is then cleaved stochastically by the Artemis complex, resulting in 
variable recombination points. Because of the hairpin structure, this cleavage may occur 
beyond the end of the coding region into the non-coding strand resulting in the 
appearance of p- (palindromic) nucleotides. Terminal deoxynucleotidyl transferase (TdT) 
may then add several n- (non-templated) nucleotides, which are yet another source of 
stochasticity. The strands then pair in complementary regions and unpaired nucleotides 
are removed and filled in to form the final junction region (Schatz and Ji, 2011; Nishana 
and Raghavan, 2012; Naradikian et al., 2014). The site of RAG-mediated cleavage and n-
nucleotides together supply the junctional diversity of the antibody repertoire. This highly 
stochastic process is limited by genetic requirements for proper translational processivity 
and may result in non-functional BCRs that are either edited during development or result 
in cell anergy or deletion.  
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The junction regions are another source of diversity that are difficult to call and 
annotate during analysis. First, due to the variability of the recombination site, the most 
likely base pair ends of each gene segment must be differentiated from the first p- or n- 
nucleotide, or from the first base pair of the subsequent gene segment. This is 
problematic as 1. The junction regions are encompassed by the CDR3, a hypervariable 
region that is especially mutable, 2. Random n-nucleotides may incidentally be the same 
as the gene segment or an allele thereof and 3. For IGH, the diversity gene segment can 
be very small, as short as a few base pairs, making it infeasible to assign to a specific 
gene for additional base pair or p-nucleotide information. 
Much translational and pharmaceutical research has focused on the CDR3 given 
its demonstrable effect on antigen affinity and high threshold for mutation. This has 
resulted in immunoglobulin sequencing (Ig-seq) reagent and method development that is 
often focused on this relatively small part of the IgVRG (15.5 ± 3.2 amino acids) (Shi et 
al., 2014). While this approach is appropriate for a number of applications, particularly in 
the development of high affinity monoclonal antibodies, it does not gather sufficient 
genetic information for the inference of accurate models for mutational and clonal 
analysis. Specifically, it includes only the 3’-end of the V gene and 5’-end of the J gene 
while fulling covering the very small and dynamic D gene and junctional regions. With 
such little information from the additional FR and CDRs, alleles and even gene segments 
cannot always be called with high probability, leading to downstream challenges when 
inferring which B cells are related by a common unmutated B cell ancestor. 
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In summary, before B cells mature and exit the bone marrow into the periphery, 
they have undergone robust immunoglobulin/BCR diversification. This is achieved 
through allelic diversity within populations and species, combinatorial diversity by V(D)J 
gene selection, and junctional diversity through the recombination mechanism that 
introduces random recombination points and p- and n-nucleotides.  
Affinity maturation 
Immunizations work by introducing controlled doses of foreign antigen to induce 
protective immune responses, including affinity maturation, to establish antigen-specific 
memory. Once a B cell has been activated, it divides several times; its progeny may 
differentiate into different cell types, including plasmablasts. The key to this system is 
that secreted antibody is encoded by the same IgVRG that encodes the BCR and thus 
retains the same antigen specificity. Other progeny differentiate into follicular germinal 
center cells and undergo affinity maturation, eventually becoming the memory cells and 
long-lived plasmacytes (LLPC) that provide protection against subsequent encounters 
with the pathogen from which the antigen was derived. All B cell progeny that are 
produced from a shared mature naïve B cell progenitor are in a biological clonal lineage, 
called a clone. 
Germinal centers (GC) can be observed as early as four days after primary 
immunization and typically reach maximum size within a few days. These transient 
anatomical structures consist of the dark zone, containing rapidly dividing B cells, 
centroblasts, and the light zone, containing specialized antigen presenting cells known as 
follicular dendritic cells (FDC), T follicular helper (TFH) cells, and non-dividing B cells 
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called centrocytes. In general, individual GCs are thought to be expanded from a single 
founder B cell. However, recent research has revealed that at least some GCs are likely to 
be comprised of multiple founder or migratory B cell progenitors (Tas et al., 2016). 
B cells that receive sufficient FDC and TFH signal competitively differentiate into 
centroblasts. Centroblasts undergo somatic hypermutation (SHM) of their IgVRG, 
accumulating point mutations at a rate of 10-4-10-3 mutations per nucleotide per cell 
division, orders of magnitude higher than is observed in typical genome replication 
(Tanaka et al., 2010; Victora and Nussenzweig, 2012; De Silva and Klein, 2015). The 
enzyme activation-induced cytidine deaminase (AID) is responsible for the initial lesions 
in the DNA which are followed by error-prone repair by the enzyme polymerase eta 
(polη). SHM is also preferentially targeted to certain nucleotide motifs known as 
hotspots. Though the mechanism and number of these sites is not yet fully understood, at 
least one motif has been shown to influence polƞ, while another specifically attracts AID. 
Many known hotspots are located in the CDRs, which at least partially explains the 
higher mutation frequency in these regions (Li et al., 2004; Tanaka et al., 2010; Zhao et 
al., 2013). In addition to point mutations, insertions and deletions (indels) and 
duplications are common during SHM, particularly in the CDR3. Centroblasts eventually 
differentiate into centrocytes and migrate to the light zone, where they interact with FDC 
and TFH cells and receive signals to survive, divide, or differentiate. Some surviving cells 
leave the GC as memory B cells, while others return to the dark zone and undergo further 
rounds of proliferation and mutation. At this stage, B cells may also undergo class switch 
recombination (Victora and Nussenzweig, 2012; De Silva and Klein, 2015).  
  
28 
Finally, recent research has revealed a novel source of immunoglobulin 
diversification through inter-chromosomal transposition of non-Ig gene segments into the 
hypervariable region. This natural phenomenon was observed in two malaria-infected 
individuals, where a 100 amino acid collagen-binding protein domain was introduced in 
the IgVRG. Instead of critically disabling this immunoglobulin, it gained mutations such 
that the gene segment’s collagen-binding function was lost while gaining affinity for 
malaria-infected red blood cells (Tan et al., 2016).  It is unlikely that this mechanism is 
widespread in healthy repertoires, but the prospect of even further plasticity in the 
immunoglobulin repertoire is intriguing. 
During affinity maturation, tremendous intra-clonal diversification is produced by 
somatic hypermutation and class switch recombination. The extraordinary diversity 
introduced at this stage leads to many challenges in appropriate statistical analysis of 
repertoire sequencing data. Prior methods to assign immunoglobulin sequences into 
clones include assignment based on IGHV and IGHJ genes alone, CDR3 length and 
composition, and estimated somatic mutation cutoffs. These methods are insufficient to 
capture the diversity that defines this subset of lymphocytes, and may overestimate 
repertoire uniformity while missing important selection steps during affinity maturation. 
Response Kinetics 
The earliest peripheral B cell response to novel antigen exposure is typically 
observed in 4-5 days, when short lived plasmablasts can differentiate and exit the lymph 
node. These are terminally differentiated antibody secreting cells (ASCs), and tend to 
secrete IgM with relatively low antigen affinity. The primary effectors of humoral 
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immunity are antibody secreted by affinity matured plasmablasts. These antibodies tend 
to be IgG, and are observed in the periphery 7 or more days after primary exposure, or 3-
4 days upon subsequent exposure(s) (Janeway et al., 2005). While plasmablasts cannot 
reenter the GC or survive for long term memory, they are quickly differentiated from 
proliferating memory B cell populations. Some memory B cells are capable of reentering 
germinal centers to undergo additional proliferation, affinity maturation and 
differentiation, further enhancing affinity maturation potential (Mcheyzer-Williams et al., 
2015; Seifert et al., 2015). 
Circulating mature B cell subsets can be grouped into naïve, plasmablast, LLPC 
and memory B cells. In peripheral blood mononuclear cells, 5-20% is comprised of B 
cells. While new B cells are produced throughout one’s life, there are characteristic 
changes in the repertoire. The majority of peripheral B cells consistently express a naïve 
phenotype, but 0-20% express a memory phenotype, increasing with age. Plasmablasts 
make up 0-5% and remain steady with increasing age (Morbach et al., 2010). LLPC 
primarily reside in splenic and bone marrow survival niches that provide appropriate 
survival signals and only rarely circulate. Long lived memory B cells also persist in these 
survival niches but are commonly found in circulation (Manz et al., 1997; Cancro, 2010). 
Even in a sequestered state, these cells are capable of constant antibody secretion (Slifka 
and Ahmed, 1998; Yu et al., 2008). Most impressively, long lived antibody memory is 
capable of lasting a lifetime, up to 89 years in one subject over 100 years old (Yu et al., 
2008). 
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Immunoglobulin repertoire sequencing 
Rationale and special considerations for immunoglobulin sequencing (Ig-seq) 
Ig-seq utilizes next-generation sequencing (NGS) platforms to generate 
immunoglobulin sequence libraries in an effort to capture total repertoire coverage within 
individual subjects. This is a difficult goal from both a wet lab and analysis perspective. 
Immunoglobulin libraries are particularly difficult to prepare for NGS due to repetitive 
motifs, variable length and high mutation frequency. Appropriate primer design and 
length exclusion remain difficult to surmount. Most importantly for method design, 
reagents and analysis tools, it is not generally appropriate to begin library preparation by 
DNA or RNA fragmentation, as used in most NGS protocols. While most pipelines are 
designed for random, 50-150bp fragments, the genetic similarities, high mutation 
frequency and junction regions make it impossible to align and join fragmented IgVRG 
from standard libraries with high confidence. Due to these challenges, accurate 
sequencing requires long read lengths and low error rates. NGS is more limited than 
Sanger sequencing in both regards, but has been steadily improving, and outperforms 
Sanger in the depth of data it can provide and cost per base (Liu et al., 2012). 
Common approaches 
Ig-seq encompasses a highly diverse target population and molecule, and NGS 
strategies must be carefully selected based on the question being posed. The B 
cell/sample source must first be considered. Bone marrow B cells will include non-
productive and developing Ig rearrangements. B cells found in blood will be primarily 
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naïve, but increase in plasmablasts following infection or immunization and are easier to 
obtain from human subjects. The vast majority of B cells will be found in secondary 
lymphoid tissues and at mucosal surfaces. Lymph nodes near sites of recent 
immunization are likely to contain activated centroblasts and centrocytes. In human Ig-
seq, the most common and convenient sample origin is blood. Blood is generally 
processed by Ficoll gradient to isolate peripheral blood mononuclear cells (PBMC), 
comprised of lymphocytes and monocytes. B cells may be enriched for using 
immunomagnetic selection or fluorescence-activated cell sorting (FACS). Complete 
PBMC or B cell-enriched samples may then be used for mRNA or genomic DNA 
isolation. 
There are three genetic sources for Ig-seq: 1) Germline Ig DNA from non-B cell 
sources, 2) Rearranged Ig DNA from B cells and 3) Ig mRNA from B cells. When 
constructing a genomic immunoglobulin loci, germline DNA is the appropriate target. 
While this region lacks the junctional diversity of rearranged Ig, it is very repetitive and 
thus also requires long read lengths to build appropriate scaffolds. Rearranged DNA and 
mRNA from immature and mature B cells may both be used to build IgVRG libraries 
describing expressed immunoglobulin. Rearranged Ig DNA includes IgVRG introns, 
which are spliced out of Ig mRNA, and may be obtained using standard capture methods 
and is more stable for long term sample storage. Theoretically, DNA should lead to more 
accurate quantitative output, as it will not be biased by increased gene expression in 
different B cell subsets, but this has not been observed using current methods (Langerak 
and van Dongen, 2012; Bashford-Rogers et al., 2014). This strategy will also capture Ig 
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made non-functional by allelic exclusion. Ig mRNA is robustly produced in antibody 
secreting cells, which are important effectors in disease and immunization, but still 
captures subsets with lower gene expression. This sensitivity to expression also skews 
raw count output, as a single plasmablast can produce up to 100-fold more copies of Ig 
mRNA than a naïve B cell. One comparative study found that mRNA is a more 
appropriate tool for functional studies of the IgVRG repertoire, likely due to 
overrepresentation of non-functional IgVRG (Bashford-Rogers et al., 2014; Georgiou et 
al., 2014). Ig-seq using mRNA has been further developed for quantitation by the use of 
Unique Molecular Identifier (UID) tags during cDNA synthesis (Shiroguchi et al., 2012; 
Islam et al., 2014). 
Library preparation 
Ig-seq library preparation generally follows a standard pipeline with variations 
depending on the question. After appropriate B cell sources are determined, samples are 
enriched for B cells or specific B cell subsets. An emerging variation here is the use of 
high throughput single cell sorting or emulsion of B cells after which cells are 
individually tagged and amplified before pooling (Busse et al., 2013; DeKosky et al., 
2013; Weinstein et al., 2013). While this may lower overall cell throughput, it retains 
information about biological heavy and light chain pairs through sequencing. At this step 
it may also be useful to separate antigen-binding from non-antigen binding B cells by 
FACS. These populations may then be given unique multiplexing barcodes to 
differentiate IgVRGs. Previously, non-antigen binding B cells were often discarded in 
order to maximize functional data. Current NGS output are now robust enough for 
  
33 
sufficient coverage of IgVRG within samples, and can supply useful data to understand 
both the repertoire context and generation of antigen-binding Ig via affinity maturation 
(Bashford-Rogers et al., 2014).  
Following B cell enrichment or isolation, genomic DNA or mRNA are isolated by 
cell lysis and standard reagents, and mRNA is reverse transcribed to cDNA. It is 
becoming common in Ig-seq to normalize data by adding UIDs at this step, which are n-
nucleotide regions in primers. To increase IgVRG from the total genetic pool, primary 
polymerase chain reaction (PCR) amplification is performed using two basic strategies.  
1) Multiplex primers which consist of forward V gene or leader region primers and 
reverse J or CH gene primers. This method is efficient at capturing Ig and primers are 
easily tagged with UIDs. 2) 5’ RACE (Rapid Amplification of cDNA Ends) adds a 
known template switch primer to the 5’ end of mRNA during cDNA synthesis by 
template-switching reverse transcriptase. After this, a shorter secondary PCR is 
performed to add platform-specific adaptors to each molecule for annealing to the 
sequencing surface. Due to the high read output on NGS platforms, most library 
preparations involve multiplexing, where known primer barcode sequences (usually 
~10nt) are incorporated in the adaptor primers to identify sample subsets. Multiple 
IgVRG targets may be selected, including targeted CDR3, total IgVRG and variable, 
incomplete lengths within the IgVRG, and the PCR strategy will depend on this choice. 
Though CDR3 information is useful for specific applications, as previously discussed, 
CDR3 targeted capture is insufficient for Ig repertoire sequencing and shows major 
biases (Bashford-Rogers et al., 2014). 
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In most cases, samples can be pooled at this step. Length-based PCR product 
selection is necessary for library cleanup, and may be performed by gel excision/selection 
or with optimized reagent ratios using magnetic bead selection. Unlike pre-fragmented 
RNA-seq, the length of PCR products in Ig-seq will be variable within libraries due to 
their different gene segments and junction regions. IgVRG will range from ~350-500bp 
depending on the chosen methods, and can vary within libraries ±100bp. While targeted 
sequencing requirements are met by most NGS platforms, full length variable regions 
require platforms that can sequence >300bp fragments. After library size selection and 
cleanup, samples are quantified by qPCR or otherwise, then appropriately multiplexed for 
sequencing.  
Next-generation sequencing 
NGS describes a number of sequencing methods that are not dependent on Sanger 
sequencing methods. In general, NGS involves the binding of sample DNA molecules to 
a solid surface followed by cluster amplification to increase the independent molecule 
readout signal (fluorescence, light, pH). Massive parallel sequencing is conducted by 
covering the surface in a specific nucleotide and making a call for that base if there is a 
resulting chemical or physical signal indicating an incorporation event. The nucleotide 
solution is washed off and the process is repeated, resulting in a large number of 
sequencing reads for analysis. This process is termed “sequencing by synthesis.” The 
most dominant platforms for NGS and Ig-seq are currently the Illumina-based HiSeq and 
MiSeq sequencers. Similar platforms include the Roche 454 GS series and Ion Torrent 
PGM. Other NGS approaches include nanopore-based (MinION, Oxford Nanopore 
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Technologies), sequencing by ligation (SOLiD, Life Technologies, Grand Island, NY) 
and single molecule real time sequencing (PacBio RS, Pacific Biosciences). 
454 GS pyrosequencing was a dominant platform in early Ig-seq due, in part, to 
its long average read lengths (500 or 700bp, 450-700 Mb). The relatively low depth and 
1-2% error rate are problematic for questions that require near-complete repertoire 
coverage, but the excellent read length distributions make the 454 GS one of the most 
reliable platforms for full length IgVRG sequencing (Metzker, 2010). Unfortunately 454 
no longer produces GS sequencers and the technology will soon be impractical. Instead, 
the dominant Ig-seq platform is currently the Illumina MiSeq. This sequencer has a 300-
cycle paired-end kit (13.2-15Gb) which ostensibly covers the full IgVRG. The Illumina 
user base is large, and there are a number of tools that have been developed for 
sophisticated data processing and analysis. Due to the low complexity of Ig-seq libraries, 
it is recommended that libraries to be sequenced on Illumina machines are spiked with 
10-50% PhiX, depending on the diversity of the sample origin (Jiang et al., 2015). 
Current challenges with methods 
The Sequencing Quality Control Consortium (SEQC) was established to address 
the continuing concerns of reproducibility and variation in RNA-sequencing research 
(RNA-seq) (Marioni et al., 2008; 't Hoen et al., 2013; Kratz and Carninci, 2014; Su et al., 
2014). RNA-seq is the investigation of genetic transcripts using NGS-based approaches 
for sequencing, mapping and quantification. Immunoglobulin repertoire sequencing is a 
variant of RNA-seq, and immunoglobulin genes are largely not specifically considered in 
methods development for RNA-seq. However, the enormous diversity within and 
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between Ig mRNA exemplifies and magnifies challenges associated with RNA-seq. Our 
systematic assessment of Ig repertoire variation will inform both the labs conducting this 
research, and will also have broader implications to a “worst case”-type scenario for 
RNA-seq quantitation. 
Major challenges remain in the optimization of Ig-seq library preparation and 
sequencing. Regarding primary PCR amplification, it has been shown that multiplex Ig 
primers may have biased annealing and result in skewed PCR amplification (He et al., 
2014; Lu et al., 2014b; Khan et al., 2016). Similarly, mispriming of primers to closely 
related alleles may introduce indistinguishable technical mutations in both total library 
and single cell sorted PCR. 5’ RACE was proposed as a way to eliminate primer bias as 
the only forward primer used is that of the new, shared 5’ end. In conjunction with a CH 
reverse primer, this eliminates the bias introduced by multiple primers. However this 
method requires the transcription of the long 5’ untranslated region which lowers reverse 
transcription efficiency and makes the total molecule length difficult to sequence on the 
most common platforms. It also has been reported that libraries using this method have 
poor Ig capture rates, leading to many incomplete and non-Ig reads per run, and this 
inefficiency may be enhanced by UIDs, limiting the advantages of NGS (Tang et al., 
2013; Best et al., 2015). UIDs appear to be particularly important as recent studies have 
shown that stochastic events during library preparation of both RNA-seq and Ig-seq can 
result in skewed gene-specific sequence counts (Bashford-Rogers et al., 2014; Islam et 
al., 2014; Su et al., 2014). 
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IgVRG sequencing itself has proven challenging due to the field’s preference for 
high quality short reads over long reads. The Illumina 300bp paired-end chemistry has 
not yet proven to be as high quality over the full read length as the 50 and 100bp 
chemistries, and characteristically drops precipitously in quality score early in read 2 
(Kozich et al., 2013; Duke et al., 2015; Schirmer et al., 2015). This is problematic for Ig-
seq because 1) the total sequence length can be up to 500bp with the primer additions and 
untranslated regions, 2) the consistently low quality regions are at the end of each read, 
where they are computationally aligned and joined in reverse complement and 3) the area 
of read overlap used for joining is also in the most variable, mutated region. That is, it is 
essentially impossible to join and make a confident base call where there is a conflict 
between two low quality reads, and library information cannot be reliably used to fill in 
the gaps. Similarly, the sequencing by synthesis platforms share a flaw in accurate base 
calling in homopolymer and long repeat regions, both of which are possible in IgVRG. 
The observed error rate for the Illumina MiSeq is 0.8%, or an expected ~2.8nt errors in a 
350nt IgVRG sequence. Single molecule sequencers do not have increased error rates at 
specific patterns, but do have much higher rates of random error, making Ig-seq a 
challenge (Quail et al., 2012; Jain et al., 2015). 
Scientific proposal and hypothesis 
Part I. Immunoglobulin repertoire sequencing 
As modern biomedical science moves toward larger dataset collection and 
analysis, a key challenge will be maintaining the scientific tenet of reproducibility. This 
is already an issue of concern and discussion among researchers, publishers, policy 
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makers and other stakeholders. RNA-seq and transcriptomics have quickly become an 
important method of understanding gene regulation and disease, but the rapid data 
accumulation has not been consistently met by statistical scrutiny (Marioni et al., 2008; 't 
Hoen et al., 2013; Kratz and Carninci, 2014; Su et al., 2014). These studies, unlike 
genomic sequencing for references or presence/absence of a genetic marker, rely on 
accurate quantitative values of the sequencing output for comparison of RNA expression 
against functional or phenotypic differences.  
Ig-seq, a specialized form of RNA-seq, requires special attention for the 
development of accurate quantitative methods. Immunoglobulin is a challenging region 
to capture and sequence, and the biological underpinnings of B cells and clonal selection 
make the population naturally highly variable, extremely diverse and occasionally prone 
to bursts of homogeneity that are difficult to distinguish from technical duplication. We 
hypothesize that the biological and technical variation introduced during standard sample 
collection and processing for high throughput Ig-seq quantitatively skews and biases raw 
sequence output, and that these quantitative biases may be mitigated by model-based 
count estimation from collected data. This proposal will be addressed in Chapter Three. 
Part II. The immunoglobulin repertoire response to Anthrax Vaccine Adsorbed (AVA) 
immunization 
 With the potential limitations of Ig-seq in mind, we asked if and how the 
immunoglobulin repertoire changes in response to prime-boost immunization. Empirical 
evaluation of antibodies following many efficacious immunizations show that vaccine 
antigen-specific antibodies are an important correlate of protection, and that these 
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antibodies can gain affinity over multiple doses of a vaccine. The immunological 
mechanisms of this process are well studied but still not fully clarified. 
We asked if the genetics of immunoglobulin, a primary component of humoral 
immunity, could give us insight into the origins and evolution of the clonal populations 
responding to vaccination. Here, we know that antigen-specific antibodies are being 
produced, but we do not know if or how a clonal signature may correlate to that response. 
We take three approaches to study the immunoglobulin response to AVA, a homologous 
prime-boost vaccine, which act to narrow the focus of our capture and analysis. First, we 
attempt to capture the total repertoire at a given time point by performing high throughput 
sorting and sequencing of B cell subsets before and after AVA immunization. Here, we 
use the highest throughput methods available to us to capture as many immunoglobulin 
transcripts as possible. Second, we narrow our focus to a more quantitatively accurate 
method that reduces technical error. Third, we perform single cell sorting of the primary 
effector cell of this response, plasmablasts, for proportionally accurate analyses. 
Together, we hypothesize that observable immunoglobulin dynamics before and after 
immunization can reveal clonal markers of the efficacious elicitation of vaccine-induced 
humoral immunity. This proposal will be addressed in Chapters 4 and 5. 
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CHAPTER TWO: MATERIALS AND METHODS 
Anthrax Vaccine Adsorbed 
Vaccine formulation 
AVA, or BioThrax® (Emergent BioSolutions, Gaithersburg, MD), is the cell-free 
filtrate of avirulent B. anthracis cultures (Vollum strain, V770-NP1-R) with aluminum 
hydroxide (Alhydrogel®) adjuvant, 0.0025% benzethonium chloride and 0.0037% 
formaldehyde (2008). BioThrax® is the only FDA approved vaccine against Anthrax 
disease, though other formulations are available in the UK and Russia. The primary 
immunogen in AVA is Protective Antigen (PA), the primary protein component of 
Anthrax toxin. Lethal Factor (LF) and Edema Factor (EF) make up non-dominant 
immunogenic components (Taft and Weiss, 2008). The exact composition of the vaccine 
is not public knowledge, but the UK formulation, Anthrax Vaccine Precipitated (AVP), is 
likely to be similar and is primarily composed of PA with small concentrations of EF and 
LF. In addition, AVP includes other B. anthracis proteins such as EA1 and SAP (Whiting 
et al., 2004).  
Study design 
Six healthy, adult volunteers were enrolled at Duke University under an IRB-
approved protocol. Four subjects were administered a standard 5-dose Anthrax Vaccine 
Adsorbed (BioThrax®) course, at weeks 1 and 4, and months 6, 12 and 18. Two subjects 
dropped out after the third immunization due to relocation. A schematic of the subject 
visits is given in Illustration 2.1.  
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Illustration 2.1. Anthrax Vaccine Adsorbed (AVA) vaccination and blood draw 
study schedule. 
Six healthy volunteers within age ranges from 25-50 years old (yo) were administered 
AVA vaccine as per manufacturer directions, intramuscularly at 0, 1, 6, 12 and 18 
months. 50mL blood was collected on the day of each vaccination, as well as 1 and 2 
weeks after. Two subjects dropped out for non-study related reasons prior to the 4th 
vaccination. 
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Immunization and sample collection  
AVA was administered intramuscularly as per manufacturer instructions. For all 
immunizations, 50mL of blood was collected on the day of, and one and two weeks post-
immunization at the Duke Vaccine Research Center. For each subject, the first three 
administrations used AVA lot #FAV366A, the fourth #FAV374A, and the fifth 
#FAV428A. A schematic of the overall use of these samples is given in Illustration 2.2. 
Blood processing  
Whole blood samples were processed to collect peripheral blood mononuclear 
cells and sera using standard techniques at Duke University. PBMC were stored in 90% 
FBS/10% DMSO at -180°C, and further processing was performed by Atreca, Inc. 
(Redwood City, CA) and in Dr. Kepler’s lab at Boston University. Sera was stored at -
80°C and processed at Boston University.  
ELISA 
Enzyme-linked immunosorbent assays (ELISA) were performed in triplicate on serially 
diluted sera and quantified based on standards prepared from a known anti-PA 
monoclonal antibody (Abcam, Cambridge, MA; BAP-0105), or relative OD values for 
IgM antibodies. 96-well ELISA plates (ThermoFisher Scientific, 15041) were coated 
with 1µg/mL recombinant Protective Antigen in PBS (rPA, BEI Resources, Manassas, 
VA; NR-3780; PBS, ThermoFisher Scientific, AM9625) and incubated overnight at 4°C. 
The plate was washed 3x with 100µl 0.1% PBST and wells were blocked with 100µl 
Pierce Clear Milk blocking buffer per well (Life Technologies, 37587) for 2 hours at 
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room temperature on shaker. Plates were washed 3x with 100µl 0.1% PBST. Serum was 
thawed at room temperature, gently mixed and diluted at least 1:2 in PBS. 100µl PBS-
diluted sera, controls and standards were added in triplicate and incubated for 1 hour at 
room temperature on shaker. Samples were gently pipetted out and washed 3x with 100µl 
0.1% PBST. Goat anti-human IgG, IgM or total Ig (IgA, IgG, IgM), peroxidase labeled 
secondary antibody (SeraCare, Milford, MA; IgG: 5220-0279; total Ig: 5220-0331; 
Sigma, St. Louis, MO; IgM: A6907-1ML) was diluted at 1:1000 in PBS, added 100µl per 
well and incubated 1 hour at room temperature on shaker, followed by 3x washes with 
100µl 0.1% PBST. 100µl ABTS® ELISA HRP Substrate (SeraCare, 5120-0032) per well 
was added and allowed to react for 5-30 minutes per plate, until the spectrophotometric 
reading was ~1.8 for the most concentrated sample. 100µl ABTS Peroxidase Stop 
Solution (SeraCare, 5150-0017) was added and plates were measured on a SpectraMax® 
M Series Microplate Reader (Molecular Devices, Sunnyvale, CA) at wavelength of 
405nm. 
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Illustration 2.2. Anthrax Vaccine Adsorbed vaccination blood sample processing 
and use overview. 
Blood samples were processed to perform immunoglobulin deep sequencing, single cell 
plasmablast full length IgVRG sequencing, antibody synthesis and functional assays, and 
serum assays. The flowchart illustrates the pipeline used to process samples for this 
dissertation. 
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HEp-2 anti-nuclear antigen (ANA) staining 
HEp-2 ANA (MBL, Woburn, MA; ANK-120) staining was performed using 
manufacturer protocol. Briefly, serum was diluted either 1:20 or 1:40 in supplied IFA 
diluent followed by PBS. Slides were held at room temperature for >5 minutes, and 30µl 
sample or undiluted, supplied positive and negative controls added in duplicate wells. 
Slides were incubated at room temperature in a moist chamber for 30 minutes and gently 
rinsed with PBS first with a wash bottle then submerged for 5 minutes. Slides were gently 
dried around edges and 50µl secondary conjugate added per well (anti-IgM, IgA, IgG, 
supplied in kit) Slides were incubated at room temperature in a dark, moist chamber for 
30 minutes and washed as before protected from light. Coverslips were added and slides 
read on an Axiovert 200 M inverted microscope with a FITC (470ex/515em) reflector at 
10x. 
Images were collected using an HD Hamamatsu ORCA-ER-1394 digital camera 
and AxioVision software (v4.8.2.0). For micrographs with visible signal, normalized 
quantification was performed by calculating the mean corrected total cell fluorescence 
(CTCF) per image using ImageJ (Rasband, 2012; McCloy et al., 2014). For each 
micrograph, 20 cells were selected for individual measurement of total cytoplasm and 
nucleus pixel value and area. Five areas with no visible cells were selected for 
background correction. CTCF = Integrated density – (Area of selected cell x Mean 
fluorescence of background readings). 
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Flow cytometry 
Single-cell sorting 
IgG VRG sequences were obtained from cells enriched from cryopreserved 
PBMCs by staining and gating for CD20-CD19+CD38hiCD27+CD3-CD14-IgA-IgM- cells 
at Atreca, Inc (Representative example, Figure 2.1). Propidium iodide (PI) was used for 
selection of live cells.   
Bulk sorting 
Cryopreserved PBMCs were thawed in a 37°C water bath, and 1mL cold RPMI-
10 added dropwise to cells. Cells were transferred dropwise to a 15mL conical held on 
ice. 11mL cold RPMI-10 was added slowly to the cells, and centrifuged at 1000RPM for 
10 minutes at room temperature. Supernatant was aspirated, and the pellet re-suspended 
in 1mL RPMI-10 supplemented with 1:10,000 benzonase nuclease (Millipore, Billerica, 
MA; 70746). Samples were then counted by diluting a small amount at 1:50 in erythrosin 
B (Sigma, 15905-32-5) and adding 10µl to a hemacytometer. Dilutions were changed as 
needed to obtain ~6-20 cells per grid square. Five squares were counted for live cell 
presence and sample cell count was estimated as 
 𝐶 =
10,000𝑑𝑥
𝑠
 
where d is the dilution factor, x is the measured cell count, s the number of counted 
squares, and C is the cells per mL sample. 106 cells were aliquoted per experiment to a 
separate tube as a no-stain control. Samples were then centrifuged 1500RPM for 5 
minutes at room temperature and supernatant aspirated. 100µl 0.4% Zombie NIR Dye 
(BioLegend, San Diego, CA; 423106) in PBS was added per 106 cells, or PBS alone for 
the no-stain control, and incubated in the dark, on ice for 30 minutes. 5ml fluorescence-
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activated cell sorting (FACS) buffer was added to sample tubes then centrifuged 
1500RPM for 5 minutes at room temperature and supernatant aspirated. 250µl antibody 
cocktails or FACS buffer were added to samples as in Table 2.1 and incubated in the 
dark, on ice for 30 minutes. Single-stain UltraOne compensation beads (ThermoFisher 
Scientific, 01-2222-41) were prepared monthly for machine gating and compensation 
calibration at 1µl stain per drop beads, and incubated 30 minutes with the cell samples. 
Antibodies used for fluorescence-activated cell sorting were for extracellular anti-human 
markers: Zombie NIR™ Fixable Viability dye, CD45 (FITC), CD19 (BV655), CD20 
(PE-Cy7), CD38 (BV421), CD27 (APC), IgD (BV510), CD14, CD16 and CD3 (AF700) 
(BioLegend, Table 2.1). Samples were then centrifuged 1500RPM for 5 minutes at room 
temperature, supernatant aspirated and re-suspending in ~500µl FACS buffer. Samples 
were held on ice in the dark and sorted within three hours.  
Sorting was performed on a FACSAriaII SORP (BD Biosciences, San Jose, CA) 
with the Boston University Flow Cytometry Core. All antibodies were optimized by 
fluorescence-minus-one assays for fluorochrome selection and titered for dilution. All 
samples were gated for size, granularity and living status, and were sorted into 250µl pre-
chilled, heat inactivated, sterile, filtered 100% FBS. Naïve B cells were gated as CD45+, 
CD3/14/16-, CD19+, CD20+, CD27-, CD38-, IgD+. Memory B cells were gated as CD45+, 
CD3/14/16-, CD19+, CD20+, CD27+. Plasmablasts were gated as CD45+, CD3/14/16-, 
CD19+, CD20-, CD27+, IgD-, CD38++ (Representative example, Figure 2.2). Flow 
cytometry data was analyzed using FlowJo (Treestar, Ashland, OR). Sorted cells were 
held on ice, transferred to 1.5ml screw top tubes and centrifuged 2100RPM for 7 minutes. 
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Supernatant was carefully removed and the pellet re-suspended in 600µl cold RNAzolRT 
(MRC, Cincinnati, OH; RN190). 
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Table 2.1. Tagged antibodies for fluorescence-activated cell sorting (FACS) to 
isolate B cell subsets. 
FACS staining solutions for isolated peripheral blood mononuclear cells were prepared 
using the following reagents and dilutions: 
Target 
Fluorescence 
conjugate 
Species Source Dilution 
CD3 Alexa 700 Mouse BioLegend (300324) 1:50 
IgD BV510 Mouse BioLegend (348220) 1:50 
CD138 PE Mouse BioLegend (352306) 1:50 
CD45 FITC Mouse BioLegend (304006) 1:100 
CD38 BV421 Mouse BioLegend (303526) 1:100 
CD14 Alexa 700 Mouse BioLegend (325614) 1:100 
CD16 Alexa 700 Mouse BioLegend (302026) 1:100 
CD19 BV650 Mouse BioLegend (302238) 1:250 
CD20 PE-Cy7 Mouse BioLegend (302312) 1:250 
IgM PerCP-Cy5.5 Mouse BioLegend (314512) 1:500 
CD27 APC Mouse BioLegend (356409) 1:500 
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Figure 2.1. Representative example of single cell plasmablast FACS. 
FACS gating strategy used by Atreca, Inc. to isolate plasmablasts for subject 1. PBs were 
sorted as live, CD19+CD20-CD27+CD38hiCD3-CD14-IgA-IgM-. V refers to the visit, 
corresponding to weeks 0, 1, 5, 27, 53 and 79. 100,000 total events are shown per sample.   
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Figure 2.2. Representative example of bulk FACS for naïve, memory and 
plasmablast B cells. 
  
52 
FACS gating strategy used at Boston University to isolate B cell subsets for subject 1. 
Peripheral blood mononuclear cells were stained using standard methods as described in 
“Materials and Methods: Flow cytometry.” 100,000 total events captured by the 
FACSAriaII for one sample are shown. Naïve B cells: CD45+, CD3/14/16-, CD19+, 
CD20+, CD27-, CD38-, IgD+. Memory B cells: CD45+, CD3/14/16-, CD19+, CD20+, 
CD27+. Plasmablasts: CD45+, CD3/14/16-, CD19+, CD20-, CD27+, IgD-, CD38++.   
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Library preparation 
 Single cell library preparation was performed by Atreca, Inc. using proprietary 
Immune Repertoire Capture™ technology. Natively paired, heavy and light chain 
sequences were recovered from single cells as previously described (Lu et al., 2014a; Tan 
et al., 2014). In brief: Generation of barcoded cDNA, PCR amplification, and Roche 454 
sequencing of IgG were performed as described in previously (Tan et al., 2014), with the 
following modifications: biotinylated Oligo (dT) and RT maxima H- (Fisher Scientific 
Company) were used for reverse transcription, cDNA was extracted using Streptavidin 
C1 beads (Life Technologies), and DNA concentrations were determined using qPCR 
(KAPA SYBR® FAST qPCR Kit for Titanium, KAPA Biosystems, Wilmington, MA). 
The library preparation protocol for high-throughput, bulk cell sequencing was 
adapted from Dr. Daniel Douek (Francica et al., 2015). A schematic of this protocol is 
given in Illustration 2.3. All primers used at Boston University are listed in Supplemental 
Material. 
0.4x volume sterile water added to sorted samples in RNAzolRT with vigorous 
shaking, and incubated at room temperature for 10 minutes. Samples were centrifuged at 
16,000RCF for 15 minutes, and ~85% of the supernatant volume transferred to a fresh 
tube with 1µl glycogen (Life Technologies, 10814-010) and 1x volume isopropanol 
(Sigma, 190764). Tubes were vortexed to mix, incubated 10 minutes at room temperature 
and centrifuged 14,800RPM for 15 minutes. Supernatant was carefully pipetted out, 
leaving 50-80µl volume and a small pellet. 750µl fresh 75% ethanol (Sigma, 459836) 
was added and mixed by flicking then inverting the tube multiple times. Tubes were then 
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centrifuged 14,800RPM for 2 minutes, and the supernatant aspirated without disturbing 
the small pellet, and the ethanol wash repeated. Pellets were allowed to air dry after 
withdrawing as much remaining ethanol as possible, dissolved in 50µl sterile, RNase-free 
water (Life Technologies, 10977-015) and vortexed for 2 minutes.  
 cDNA libraries were prepared from bulk isolated RNA using SmartScribe reverse 
transcriptase (Clontech, Mountain View, CA; 634925). A schematic of the 5’SMARTer 
RACE and Unique Molecule Identified (UID) strategy is shown in Illustration 2.4. For 
each sample, 1µl of 12µM 5’ CDS Oligo (dT) primer (Table S2.1) was added to 10µl 
RNA in 8 well strip tubes on ice, and briefly vortexed. Denaturation and annealing were 
achieved in a two-step thermocycler protocol: 72°C×3 m, 4°C×1m. On ice, 9µl master 
mix was added with the following volumes per sample: 4µl 5x RT Buffer, 1µl 20mM 
DTT, 1µl 10mM dNTP mix, 1µl RNAse Out (Life Technologies, 10777-019), 1µl 12µM 
SMARTer 5IIA Oligo or UID-modified oligo (Table S2.1), and 1µl Superscript II RT. 
First-strand libraries were synthesized by incubating in a thermocycler at 42°C for 90 
minutes followed by 10 minutes at 70°C. On the same day, cDNA libraries were purified 
with Agencourt AMPure XP beads (Beckman Coulter, Indianapolis, IN; A63881). 1.6x 
volume beads were pipette mixed 10 times in each sample, incubated 5 minutes at room 
temperature and held on a magnetic plate 2 minutes or until the sample was clear. The 
solution was aspirated, and two washes were performed with 200µl fresh 70% ethanol 
added while still on the magnetic plate, incubated 30 seconds and aspirated. Beads were 
air dried, taken off the magnetic plate and re-suspended in 60µl RNase-free water. Beads 
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were incubated on the magnetic plate for another minute or until clear, then the cDNA 
elution transferred to an RNase-free tube.  
Amplification PCR was performed using 25µl of the KAPA Biosystems Real-
Time Library Amplification Kit 2x Master Mix, 0.7µl 12uM 5PIIA/universal primer, and 
5µl 2µM IgM or IgG primer per sample (Table S2.2) (KAPA Biosystems, KK2612). 
PCR was performed as follows: 95°C×5 min, 5 cycles of [98°C×15 s, 72°C×60 s], 5 
cycles of [98°C×15 s, 70°C×10 s, 72°Cx60s] and up to 20 cycles of [98°Cx15 s, 68°Cx10 
s, 72°Cx60 s]. Libraries were size selected using 2% E-gels (Life Technologies, 
G501802) from 350-450bp, resulting in ~60-100µl volume. Bead purification was 
performed as before, with 1.6x volume beads, two ethanol washes and elution in sterile 
water.  
Second round PCR for adaptor ligation was performed with the same KAPA RT-
PCR kit, using 25µl 2x Master Mix, 1µl P5 graft primer at 10µM, 1µl P5 forward (1µM) 
and P7 reverse (10µM) index-adapter primers per 22µl sample (Table S2.3). Indexed 
adapters were designed for unique forward and reverse combinations for multiplex 
libraries of 24 (UID tagged) or 48 samples (untagged). PCR was performed as follows: 
95°C×5 min, 2 cycles of [98°C×20 s, 54°C×30 s, 68°Cx60 s], 7 cycles of [98°C×20 s, 
68°C×60 s] and 72°Cx60 s. Samples were bead purified as before but using 1.8x volume 
beads to sample and elution in 40µl sterile water.  
Sample libraries were quantified using the KAPA Biosystems Universal Library 
Quantification Kit (KAPA Biosystems, KK4824). Ten-fold dilutions from 1:100 – 
1:10,000 in 10mM Tris-HCL(pH 8.0) (Teknova, Hollister, CA, T1083) with 0.05% 
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Tween 20 (ThermoFischer Scientific, 28320) were made for each sample. 96-well plates 
were prepared with 6µl 2x Master Mix and 4µl diluted sample were added in triplicate. 
4µl of each kit standard were also added to each measured plate in triplicate. Plates were 
sealed, briefly vortexed and centrifuged, and run on a thermocycler as follows: 95°C×5 
min, 35 cycles of [98°C×30 s, 60°C×70 s]. A standard curve was calculated using the 
controls, and initial library concentrations were derived. Melt curve functions were added 
as a quality control step for potential primer or adapter dimer contamination. We further 
calculated a size adjustment for variance in average fragment length based on 
BioAnalyzer High Sensitivity DNA Kit analysis of preliminary samples (Boston 
University Microarray Core; Agilent Technologies, Santa Clara, CA; 5067-4626): 
 𝑊 =
452𝑑𝐴
𝑙
 
where d is the dilution factor, A is the average concentration in pM, l is the average 
library fragment length and W, the size adjusted concentration of the undiluted library in 
pM. Standard curve-derived concentrations were excluded if they were greater or less 
than 0.25 mean Ct. Multiplex sample concentrations were calculated for even coverage. 
Combined, multiplex pools were re-run with the same qPCR kit to confirm a final 
concentration between 2-100nM and diluted in 10mM Tris-HCL with 0.05% Tween 20 if 
necessary. Library pools were run with BioAnalyzer High Sensitivity and 1000 DNA kits 
(Agilent Technologies, 5067-1504) as appropriate to confirm pool size distribution was 
reasonable. 
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Illustration 2.3. Schematic of bulk B cell immunoglobulin library preparation. 
B cells subsets were bulk sorted and prepared using a modified library preparation 
pipeline. This flowchart illustrates the “wet lab” sample processing steps performed by 
KS at Boston University prior to high throughput immunoglobulin sequencing. Each step 
is described in detail in “Methods: Library preparation.”  
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Illustration 2.4. 5’ Switching Mechanism at 5’ End of RNA Template (SMARTer) 
RACE strategy for high throughput immunoglobulin sequencing (Ig-seq).  
Ig heavy-chain cDNA pools are generated from total RNA using SMARTer reverse 
transcriptase (RT) with oligo (dT) primer (Clontech). A universal primer (“SMARTer 
oligo”) with an optional, nested, 10 n-nucleotide UID was included in the reaction mix 
for UID-tagged libraries. On reaching the nascent cDNA terminus, the RT adds an n-
nucleotide sequence that is complementary to the SMARTer oligo. The RT switches 
templates and polymerizes the SMARTer oligo sequence as a universal primer to the 
cDNA pool. The cDNA immunoglobulin library is PCR amplified using a forward 
universal primer and reverse IgG or IgM primer. Illustration is not to scale. 
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Sequencing  
HTS libraries were sequenced using the Illumina MiSeq platform and 300bp 
Paired End chemistry (v3) (Illumina, San Diego, CA; MS-102-3003) with 10-30% PhiX 
control (Illumina, FC-110-3001). Index read primers and Read 2 primers were mixed and 
diluted as in Table S2.4. Sequencing from Boston University prepared libraries was 
performed by the Vanderbilt VANTAGE Core (Nashville, TN). Ten untagged and 
thirteen UID-tagged libraries were sequenced resulting in 201,911,533 and 230,195,397 
raw reads, respectively. Examples of run quality scores and output statistics are given in 
Figure S3.2 and Table S3.1. 
Single cell libraries were sequenced using Roche 454 Titanium sequencing, and 
quality control and trimming was performed by Atreca, Inc., resulting in 10,479 full 
length, naturally paired heavy and light chain IgVRG. 
Production of recombinant human antibodies 
Antibody synthesis was performed by Sila Toksoz Ataca in Dr. Thomas B. 
Kepler’s laboratory at Boston University. 
 Recombinant antibody synthesis was carried out as previously described with 
modifications (Liao et al., 2009). Five antibodies (c2808, c2836, c2755, c5099  
and c4011) were produced by LakePharma, Inc. (Belmont, CA). All other antibodies 
were produced in-house as described. The human immunoglobulin heavy and light chain 
variable region genes were first synthesized as DNA sequences by LakePharma, Inc. or 
Blue Heron Biotech (Bothell, WA). LakePharma used the pcDNA3.3 mammalian 
expression vector. The leader and variable region heavy chain sequences synthesized by 
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Blue Heron were cloned into the pFUSE-CHIg plasmid (InvivoGen, San Diego, CA; 
pfuse-hchg1) and light chain sequences were cloned into the pFUSE2-CLIg plasmid 
(InvivoGen, pfuse2-hclk). Plasmids were transformed into a Zymo competent DH5α 
strain of E. coli (Zymo Research, Irvine, CA; T3007) by mixing and incubating on ice 2-
5 minutes. Cells were spread on warm LB agar plates with ampicillin (pcDNA3.3), 
zeocin (pFUSE-CHIg) or blasticidin (pFUSE2-CLIg), and incubated at 37°C overnight. 
Single colonies were isolated using Qiagen Spin Miniprep Kit (Qiagen, Hilden, 
Germany; 27104) and their sequences were verified by Sanger sequencing (Beckman 
Coulter). Verified isolates were amplified for transfection with PureLink HiPure Plasmid 
Filter Maxiprep Kit (Life Technologies, K210016) using manufacturer protocols. 
FreeStyle 293F cells (Life Technologies, R79007) were maintained for at least 
three, but no more than 30 passages in supplied FreeStyle™ 293 Expression Medium. 
60µl kit-provided 293fectin™ was diluted in 1ml Opti-MEM® I and incubated 5 minutes 
at room temperature. Antibody heavy and light chain DNA plasmids were diluted in 
provided Opti-MEM® I (heavy:light chain vector ratios 1:1 for pcDNA3.3 and 2:3 for 
pFUSE), added to the 293fectin™ dilution, mixed and incubated 30 minutes at room 
temperature. FreeStyle 293F cells were counted and aliquoted for ~3.0x106 cells per 
125ml Erlenmeyer flasks, and warm FreeStyle™ 293 Expression Medium added to 28ml. 
2ml of the plasmid-293fectin™ mix was added per flask. Transfected cells were 
incubated on a shaker (125rpm) for five days at 37°C with 8% CO2. Cells were harvested 
by centrifugation for 1 hour at 4000RPM at 4°C. Antibodies were purified using NAb 
Protein A/G Spin Columns (ThermoFisher Scientific, 89958) following manufacturer 
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protocols. Briefly, columns were prepared by equilibrating to room temperature and 
removing storage solution by centrifugation, then washing with and centrifuging out 
Binding Buffer for 1 minute at 1000RCF (ThermoFisher Scientific, 54200). Samples 
were diluted to 2mL in Binding Buffer, added to spin columns and incubated with 
constant mixing for 10 minutes. Columns were centrifuged 1 minute/1000RCF and flow-
through was discarded. Two additional 2ml Binding Buffer washes were performed as 
before, discarding flow-through. 1mL Elution Buffer (ThermoFisher Scientific, 21004) 
was added to column and centrifuged 1 minute/1000RCF into a new collection tube with 
100µl 1M Tris-HCL (pH 8.8) (neutralization buffer). The elution is repeated in two new 
collection tubes each, for three total elution fractions per sample. The antibody fraction 
was identified by SDS-PAGE and concentration (NanoDrop, Thermo Fisher). SDS-
PAGE was performed by mixing samples with 6x sample loading buffer to bring to 1x 
working dilution, and heating to 95°C for 5 minutes. Samples and protein ladder 
(ThermoFisher Scientific, 26619) were loaded into a 4–20% Mini-PROTEAN® TGX™ 
Precast Protein Gel (BioRad, Hercules, CA; 4561094) submerged in running buffer. The 
gel was run at 100 volts until the dye front reached the bottom of the gel. Gels were 
stained in GelCode Blue Safe Protein Stain (ThermoFisher Scientific, 24594) 45-60 
minutes with shaking and washed with regularly replaced water for 15 minutes with 
shaking. 
Surface plasmon resonance 
SPR was performed by Dr. Feng Feng and Sila Toksoz Ataca in Dr. Thomas B. 
Kepler’s laboratory at Boston University. 
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The affinities of the synthesized antibodies were measured using the Pioneer 
COOH2 biosensor (SensiQ, Oklahoma City, OK). COOH2 chips were coated first with 
Protein G (Sigma, P4689-5MG) in 10mM acetate buffer (pH 4.5) (BioRad, 1762121) 
following the standard EDC/NHS coupling chemistry provided by the manufacturer. 
Antibodies were then diluted in 0.05% PBST (running buffer) and flowed over the chip. 
Antibodies bind to protein G in a directional manner up to around 200-400RU (response 
units) to prepare the chip. The binding of anthrax recombinant Protective Antigen with 
the candidate antibodies was tested at six concentrations varying from 243 to 0nM 
(486nM to 0nM for 1635V5 and 1558V5). All experiments were performed at 25°C, with 
the sample compartment set to 10°C. The flow rate for antibodies with larger KD values, 
which reached steady state readily, was 30µl/min, while 5µl/minute flow rate was used 
for all other antibodies. The raw data were background-corrected using Qdat software 
(SensiQ) and then were exported as a text file. The analysis was carried out with an in-
house developed methodology which calculates affinity values by nonlinear fitting the 
steady state response of the association curve versus the antigen concentration values. 
Both the equilibrium dissociation constants and dissociation rate constants were obtained. 
In the cases of the “non-binding” antibodies, the upper limit of the affinity was 
estimated. In order to make the estimation, the Langmuir binding isotherm equation was 
rewritten as 
 
max eq
D
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where KD is the estimated equilibrium dissociation constant, C is the concentration of the 
analyte, Rmax is the maximum analyte binding capacity on the surface expressed in 
response units, Req is the observed ligand and analyte binding levels at the equilibrium or 
steady state. Among them, C is the input, Req is the experimental readout and Rmax can be 
inferred based on the level of immobilized ligand and the molecular weights of the ligand 
and the analyte. For the non-binding antibodies, the SPR sensorgrams showed noisy 
“flat” lines close to 0 RU. The upper limit of the affinity of such an antibody can be 
calculated assuming Req as a minimum of 1 RU, since the SensiQ Pioneer system has a 
constant noise level lower than this value. The actual affinity would be no better than this 
estimation and tends to have a larger KD. 
Protein microarray 
Protein microarrays were processed at Duke University in Dr. Garnett Kelsoe’s 
laboratory by Akiko Watanabe and Masayuki Kuraoka. Technical plate normalization 
and quantification were performed by Dr. Feng Feng in Dr. Thomas B. Kepler’s 
laboratory at Boston University.  
Antibodies were assayed for autoantigen binding on protein microarrays 
(ProtoArray®, v5.0, ThermoFisher Scientific, PAH0525101) with >9,400 human proteins 
printed in duplicate on a nitrocellulose-coated glass slide. Standard manufacturer protocol 
was used to screen antibodies as previously reported (Liu et al., 2015). Briefly, the 
ProtoArray® microarray was blocked in a pre-chilled incubation tray, and incubated 1 
hour at 4°C with gentle shaking. Blocking buffer was aspirated and 2µg/mL primary 
antibody probe or control human myeloma 151K antibody (IgG1/κ) (SouthernBiotech, 
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Birmingham, AL; 0151K-01) (Liu et al., 2015) was incubated for 90 minutes at 4°C 
without shaking. Primary probe was aspirated and microarray washed for 5 minutes in 
0.1% Tween-20 and 1X synthetic block (ThermoFisher Scientific, PA017) in PBS with 
gentle shaking. Secondary Alexa-Fluor 647 anti-human IgG (ThermoFisher Scientific, A-
21445) antibody was added at 1µg/mL and incubated 90 minutes at 4° C with gentle 
shaking. Microarrays were washed 5 minutes with gentle shaking and dried by 
centrifugation of 200RCF for 1 minute at room temperature. Microarrays were scanned 
using GenePix 4000B scanner (Molecular Devices) at a wavelength of 635nm, with 
10µm resolution, using 100% power and 650 gain. Fluorescence intensities were 
quantified with GenePix Pro 5.0 program (Molecular Devices) using lot-specific protein 
location information provided by the manufacturer.  
After acquisition, the ProtoArray® data were saved as .GPR files and exported 
into tab-delimited text files using the Prospector software (ThermoFisher Scientific). The 
data were then imported into R for analysis. The results were first background-corrected 
using R limma package (Ritchie et al., 2015), and then were logarithm-transformed and 
normalized using the robust linear model (RLM) in order to reduce the technical 
variability (Sboner et al., 2009). The control ProtoArray® Human Protein Microarray 
proteins, specifically anti-human IgGs, were used to fit the RLM model and estimate the 
parameters, which were then applied to normalize the human array protein binding 
intensities. Logarithmic fold-changes were calculated between the normalized protein 
interaction intensities for the testing antibodies and those for the control antibody, 151K 
(Yang et al., 2013; Liu et al., 2015). The positive interaction was identified with a 
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threshold of log2-fold change above 8.97 (log2500) between the intensity of protein for 
the array probed with testing antibody and that for the array with control 151K antibody 
(Yang et al., 2013; Liu et al., 2015). 
Statistical analyses 
 All statistical tests were performed using R. Except where otherwise noted, all 
statistical tests of significance are two-tailed, paired t-tests with a significance level of 
0.05.  
Technical error study 
Sample collection 
Two healthy, adult volunteers were enrolled at Boston University under an IRB-
approved protocol under Dr. Barbara Nikolajczyk. Two, 25mL blood draws were 
collected per subject, one from each arm in succession at Boston Medical Center. 
Blood processing 
Whole blood samples were processed to collect PBMC as follows. Blood was 
diluted 1:1 with room temperature PBS (pH 7.4) supplemented with 2mM EDTA (Sigma, 
E8008) and inverted to mix. For each 25mL of diluted blood, a 50mL conical was 
prepared with 18.75mL Ficoll-Paque PLUS (GE Healthcare Life Sciences, Chicago, IL; 
17-1440-02). Samples were gently added, and centrifuged at 400RCF for 40 minutes at 
20°C using slow acceleration and brake options. The top serum layer was pipetted out 
and discarded. The second PBMC layer was carefully pipetted into one conical per 
sample. Cells were washed twice by adding 3x volume warm RPMI-10, inverting to mix, 
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centrifuging at 200RCF for 10 minutes at 20°C and removing supernatant. After the 
second wash, cells were re-suspended in 2mL warm FBS and counted by hemacytometer. 
Samples were then diluted to a concentration of 107/mL in 90% FBS/10% DMSO and 
frozen overnight in a freezing container at -80°C, then moved to liquid nitrogen storage at 
-180°C after 24 hours.  
Library preparation and sequencing 
 Libraries were prepared and sequenced as in “Anthrax Vaccine Adsorbed: Library 
preparation” of high-throughput, bulk cell sequencing with the following modifications: 
All samples were UID-tagged with the modified SMARTer oligo, samples were split for 
side-by-side technical replicates (Figure 3.1), samples using different constant region 
reverse primers were not assigned unique barcodes and sequencing was performed by the 
Dana-Farber Cancer Institute Molecular Biology Core Facilities (Boston, MA). 
Sequencing resulted in 17,302,565 raw reads.  
Statistical analyses 
All statistical tests were performed using R. Except where otherwise noted, all 
statistical tests of significance are two-tailed, paired t-tests with a significance level of 
0.05 
Computational sample processing 
Sequence processing pipeline 
 Raw sequencing data in the form of FASTQ files were processed in-house. A 
schematic of this process is given in Illustration 2.5. Briefly, reads were analyzed for 
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quality using PrinSeq, filtered for quality using SeqCrumbs, and joined using optimized 
FLASH parameters (Illustration 2.5)(Magoc and Salzberg, 2011; Schmieder and 
Edwards, 2011). Cutadapt was used to de-index sequences, requiring the full 8 nucleotide 
overlap with no errors on both ends, and to trim remaining non-Ig primer sequences. 
UID-tagged data was processed by trimming the 5’-most 10 nucleotide (UID), 
then trimming the remaining SMARTer oligo primer sequence. Sequences that did not 
match the primer reference with no errors at these positions were discarded. UIDs were 
incorporated into the remaining sequences identifying metadata using Bash and R . 
Cloanalyst was used for consensus calling per library; consensus sequences were called 
by multiple sequence alignment of a UID-tagged group, followed by nucleotide calls 
based on the proportion and quality score at each position, allowing for IUPAC 
ambiguity.  
Sequences passing all filters and successfully de-indexed were analyzed for VDJ 
gene, rearrangement parameter and kinship inference using Cloanalyst. Phylogenetic 
analysis was performed using the DNAML routine in the PHYLIP software suite 
(Felsenstein, 2005); phylograms were made using FigTree v1.4.1. All sequence 
manipulation was performed using BioEdit (Hall, 1999). 
Immunoglobulin analysis 
All immunoglobulin analysis was performed using Cloanalyst software. The 
sequence collections were partitioned into estimated clonal groups using a variation of 
the method previously described (Kepler, 2013). Briefly, we used a statistical model 
combining a model of VDJ recombination with a Kimura model for nucleotide 
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substitution. When applicable, for each pair of heavy-chain/light-chain pairs, we 
computed the marginal likelihood under the hypothesis that the two pairs are clonally 
related and under the hypothesis that they are independently derived. We constructed a 
graph with gene pairs as nodes and edges indicating pairwise inferred kinship. The clonal 
partition was taken to be the connected components within the kinship graph.  
Sequence analysis was performed by inferring the unmutated common ancestor 
for each clone and treating as the root. DNAML was used with differential mutation rates 
on the heavy-chain and light-chain genes, and a three-class gamma-distributed rate 
variation model (Felsenstein, 2008).  
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Illustration 2.5. Schematic of Ig-seq bioinformatics processing. 
High throughput, bulk Ig-seq was processed using an optimized computational pipeline. 
All steps prior to Cloanalyst were performed using openSUSE Linux, and may be used 
on any Linux distribution. Cloanalyst software currently runs on Windows.  
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Model pipeline 
 Two data sets were used to build a UID-estimator model, then test it. The training 
set used is the UID-tagged Ig-seq from the six-subject, AVA study. The independent 
dataset is the two-subject, non-vaccine-associated technical error study. UID-tagged, 
consensus data with known raw read counts were assigned into estimated clones by 
Cloanalyst. These Cloanalyst-confirmed IgVRG were then isolated from the total 
processed data sets before and after consensus calling for analysis. Non-consensus called 
sequenced were collapsed into individual sequences with perfect identity (without 
overhang) using FASTX-Toolkit.  
UID-tagged, consensus data with known raw read counts were assigned into 
estimated clones by Cloanalyst. Two values were log10 normalized as potential predictor 
variables; 1. The raw read count per subject-clone-time point and 2. The total raw read 
counts per subject-clone. We used TreeBagger in MATLAB, a random forest algorithm, 
to first classify our predictor variables, then perform regression analysis. Starting values 
for classification were estimated using a sensitivity analysis for mu and sigma (~normal) 
and lambda (~exponential) values (Breiman, 2001). Nominal thresholds were selected 
and we tested the fit of reasonable distributions available on MATLAB, including 
gamma, Erlang, and Weibull, to compare the mean, standard deviation and shape of the 
data to idealized modeled distributions. Thresholds were adjusted until the modeled data 
reasonably approximated the observed data. TreeBagger random forest classifier was run 
with 100 decision trees and initial values input as: 
Raw read counts: Exponential, <1.7; Normal, >1.0 
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Total clone counts: Exponential, <1.6; Normal, >1.5 
TreeBagger random forest regression was then run on the log10 normalized predictors 
alone or previously classified predictors using 100 decision trees.  
Buffers and reagents 
Cell media for PBMC processing (RPMI-10) 
RPMI (ThermoFisher Scientific, 21870-076), 10% FBS (ThermoFisher Scientific, 
10082139), 1% Penicillin Streptomycin (ThermoFisher Scientific, 15070063) and 1% 
GlutaMAX™ (ThermoFisher Scientific, 35050061). 
FACS buffer 
PBS, 1% BSA (Sigma, A1933-1G), 0.22µM filtered, hold on ice before use. 
Sequencing primers 
Index mix, from 100µM stock index read primers, evenly mix to 0.5µM final dilution. 
Read 2 mix, from 100µM stock index read primers, evenly mix to 0.5µM final dilution. 
LB agar for antibody synthesis transformation  
10g NaCl, 15g Agar, 10g Tryptone, 5g Yeast extract, adjust pH to 7.0 with 5N NaOH. 
Autoclave 15psi 15 minutes, let cool, then add antibiotic based on plasmid to be selected 
as follows: pcDNA3.3, ampicillin, 100µg/mL; pFUSE-CHIg, zeocin, 50µg/mL; pFUSE2-
CLIg, blasticidin, 100µg/mL. 
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Sample loading buffer for antibody synthesis (SDS-PAGE) 
250mM Tris-HCl (pH 6.8), 10% SDS, 30% Glycerol, 5% β-mercapitalethanol, 0.02% 
bromophenol blue. 
Electrophoresis running buffer for antibody synthesis (SDS-PAGE) 
25mM Tris, 192mM glycine, 0.1% SDS, pH8.3  
Blocking buffer for Protoarray® 
5mL 1M HEPES (pH 7.5), 4mL 5M NaCl, 800μL 10% Triton®X-100, 50mL 50% 
Glycerol, 610mg Glutathione Powder, 10mL 10X Synthetic Block, pH is adjusted to 7.5 
with NaOH. Add 100μL of 1M DTT then water to 100mL. 
Washing buffer for Protoarray® 
100mL 10X PBS, 100mL 10X Synthetic Block, 10mL 10% Tween-20, 790mL deionized 
water.  
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Supplemental Material 
Primer sequences 
Primers are shown in the 5’ to 3’ direction. 
UID-modified SMARTer oligo is a custom RNA-DNA oligo from Sigma. 
All other primers ordered from IDT (Coralville, IA) with standard desalted oligos. 
Table S2.1. Primers for cDNA synthesis 
Forward Reverse 
UID-modified SMARTer oligo Poly-d(T) 
AAGCAGTGGTATCAACGCAGAGTNNNNNNNNNN
ATG*G*G* 
TTTTTTTTTTTTTTTTTTTTTT
TTTVN 
 
*RNA base 
Table S2.2. Primers for amplification PCR (PCR 1) 
Target Forward Reverse 
IgM 
AAGCAGTGGTATCAAC
GCAGAG 
AGGAGACGAGGGGGAAAAGGGTTGGG
GCGGATG 
IgG 
AAGCAGTGGTATCAAC
GCAGAG 
GCCAGGGGGAAGACCGATGGGCCCTTG
GTGGA 
 
Table S2.3. Primers for Illumina MiSEQ adaptor PCR (PCR2) 
P5 graft AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGAC
GCTCTTCCGATCT 
 
P5 forward adapter and index 
CACGACGCTCTTCCGATCTGGTCTAGCAAGCAGTGGTATCAACGCAGAGT 
CACGACGCTCTTCCGATCTTCGCCGCTAAGCAGTGGTATCAACGCAGAGT 
CACGACGCTCTTCCGATCTGACAGCCTAAGCAGTGGTATCAACGCAGAGT 
CACGACGCTCTTCCGATCTTCTTCCCGAAGCAGTGGTATCAACGCAGAGT 
CACGACGCTCTTCCGATCTTTGTTGCAAAGCAGTGGTATCAACGCAGAGT 
CACGACGCTCTTCCGATCTCACAGATGAAGCAGTGGTATCAACGCAGAGT 
CACGACGCTCTTCCGATCTAACCACTAAAGCAGTGGTATCAACGCAGAGT 
CACGACGCTCTTCCGATCTAACTCTAAAAGCAGTGGTATCAACGCAGAGT 
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CACGACGCTCTTCCGATCTAAGGCCCTAAGCAGTGGTATCAACGCAGAGT 
CACGACGCTCTTCCGATCTAATATGTCAAGCAGTGGTATCAACGCAGAGT 
CACGACGCTCTTCCGATCTAATCGTCAAAGCAGTGGTATCAACGCAGAGT 
CACGACGCTCTTCCGATCTACACGGCCAAGCAGTGGTATCAACGCAGAGT 
CACGACGCTCTTCCGATCTAGCAAACGAAGCAGTGGTATCAACGCAGAGT 
CACGACGCTCTTCCGATCTAGCGCTGGAAGCAGTGGTATCAACGCAGAGT 
CACGACGCTCTTCCGATCTAGCTCGCTAAGCAGTGGTATCAACGCAGAGT 
CACGACGCTCTTCCGATCTATCATTGAAAGCAGTGGTATCAACGCAGAGT 
CACGACGCTCTTCCGATCTTTCGATCGAAGCAGTGGTATCAACGCAGAGT 
CACGACGCTCTTCCGATCTCTAAGTGGAAGCAGTGGTATCAACGCAGAGT 
CACGACGCTCTTCCGATCTTCCATTCCAAGCAGTGGTATCAACGCAGAGT 
CACGACGCTCTTCCGATCTGTGTGATCAAGCAGTGGTATCAACGCAGAGT 
 
Target P7 IgG reverse adapter and index 
IgM 
CAAGCAGAAGACGGCATACGAGATTAGTGGTTAGGAGACGAGGG
GGAAAAGGGTTGGGGCGGATG 
IgM 
CAAGCAGAAGACGGCATACGAGATTTAGAGTTAGGAGACGAGGG
GGAAAAGGGTTGGGGCGGATG 
IgM 
CAAGCAGAAGACGGCATACGAGATAGGGCCTTAGGAGACGAGGG
GGAAAAGGGTTGGGGCGGATG 
IgM 
CAAGCAGAAGACGGCATACGAGATGACATATTAGGAGACGAGGG
GGAAAAGGGTTGGGGCGGATG 
IgM 
CAAGCAGAAGACGGCATACGAGATTGACGATTAGGAGACGAGGG
GGAAAAGGGTTGGGGCGGATG 
IgM 
CAAGCAGAAGACGGCATACGAGATGGCCGTGTAGGAGACGAGGG
GGAAAAGGGTTGGGGCGGATG 
IgM 
CAAGCAGAAGACGGCATACGAGATCGTTTGCTAGGAGACGAGGG
GGAAAAGGGTTGGGGCGGATG 
IgM 
CAAGCAGAAGACGGCATACGAGATCCAGCGCTAGGAGACGAGGG
GGAAAAGGGTTGGGGCGGATG 
IgM 
CAAGCAGAAGACGGCATACGAGATAGCGAGCTAGGAGACGAGGG
GGAAAAGGGTTGGGGCGGATG 
IgM 
CAAGCAGAAGACGGCATACGAGATTCAATGATAGGAGACGAGGG
GGAAAAGGGTTGGGGCGGATG 
IgM 
CAAGCAGAAGACGGCATACGAGATCGATCGAAAGGAGACGAGGG
GGAAAAGGGTTGGGGCGGATG 
IgM 
CAAGCAGAAGACGGCATACGAGATCCACTTAGAGGAGACGAGGG
GGAAAAGGGTTGGGGCGGATG 
IgM 
CAAGCAGAAGACGGCATACGAGATGGAATGGAAGGAGACGAGGG
GGAAAAGGGTTGGGGCGGATG 
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IgM 
CAAGCAGAAGACGGCATACGAGATGATCACACAGGAGACGAGGG
GGAAAAGGGTTGGGGCGGATG 
IgM 
CAAGCAGAAGACGGCATACGAGATGCTAGACCAGGAGACGAGGG
GGAAAAGGGTTGGGGCGGATG 
IgM 
CAAGCAGAAGACGGCATACGAGATAGCGGCGAAGGAGACGAGGG
GGAAAAGGGTTGGGGCGGATG 
IgM 
CAAGCAGAAGACGGCATACGAGATAGGCTGTCAGGAGACGAGGG
GGAAAAGGGTTGGGGCGGATG 
IgM 
CAAGCAGAAGACGGCATACGAGATCGGGAAGAAGGAGACGAGGG
GGAAAAGGGTTGGGGCGGATG 
IgM 
CAAGCAGAAGACGGCATACGAGATTGCAACAAAGGAGACGAGGG
GGAAAAGGGTTGGGGCGGATG 
IgM 
CAAGCAGAAGACGGCATACGAGATCATCTGTGAGGAGACGAGGG
GGAAAAGGGTTGGGGCGGATG 
IgG 
CAAGCAGAAGACGGCATACGAGATTAGTGGTTGCCAGGGGGAAG
ACCGATGGGCCCTTGGTGGA 
IgG 
CAAGCAGAAGACGGCATACGAGATTTAGAGTTGCCAGGGGGAAG
ACCGATGGGCCCTTGGTGGA 
IgG 
CAAGCAGAAGACGGCATACGAGATAGGGCCTTGCCAGGGGGAAG
ACCGATGGGCCCTTGGTGGA 
IgG 
CAAGCAGAAGACGGCATACGAGATGACATATTGCCAGGGGGAAG
ACCGATGGGCCCTTGGTGGA 
IgG 
CAAGCAGAAGACGGCATACGAGATTGACGATTGCCAGGGGGAAG
ACCGATGGGCCCTTGGTGGA 
IgG 
CAAGCAGAAGACGGCATACGAGATGGCCGTGTGCCAGGGGGAAG
ACCGATGGGCCCTTGGTGGA 
IgG 
CAAGCAGAAGACGGCATACGAGATCGTTTGCTGCCAGGGGGAAG
ACCGATGGGCCCTTGGTGGA 
IgG 
CAAGCAGAAGACGGCATACGAGATCCAGCGCTGCCAGGGGGAAG
ACCGATGGGCCCTTGGTGGA 
IgG 
CAAGCAGAAGACGGCATACGAGATAGCGAGCTGCCAGGGGGAAG
ACCGATGGGCCCTTGGTGGA 
IgG 
CAAGCAGAAGACGGCATACGAGATTCAATGATGCCAGGGGGAAG
ACCGATGGGCCCTTGGTGGA 
IgG 
CAAGCAGAAGACGGCATACGAGATCGATCGAAGCCAGGGGGAAG
ACCGATGGGCCCTTGGTGGA 
IgG 
CAAGCAGAAGACGGCATACGAGATCCACTTAGGCCAGGGGGAAG
ACCGATGGGCCCTTGGTGGA 
IgG 
CAAGCAGAAGACGGCATACGAGATGGAATGGAGCCAGGGGGAAG
ACCGATGGGCCCTTGGTGGA 
IgG 
CAAGCAGAAGACGGCATACGAGATGATCACACGCCAGGGGGAAG
ACCGATGGGCCCTTGGTGGA 
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IgG 
CAAGCAGAAGACGGCATACGAGATGCTAGACCGCCAGGGGGAAG
ACCGATGGGCCCTTGGTGGA 
IgG 
CAAGCAGAAGACGGCATACGAGATAGCGGCGAGCCAGGGGGAAG
ACCGATGGGCCCTTGGTGGA 
IgG 
CAAGCAGAAGACGGCATACGAGATAGGCTGTCGCCAGGGGGAAG
ACCGATGGGCCCTTGGTGGA 
IgG 
CAAGCAGAAGACGGCATACGAGATCGGGAAGAGCCAGGGGGAAG
ACCGATGGGCCCTTGGTGGA 
IgG 
CAAGCAGAAGACGGCATACGAGATTGCAACAAGCCAGGGGGAAG
ACCGATGGGCCCTTGGTGGA 
IgG 
CAAGCAGAAGACGGCATACGAGATCATCTGTGGCCAGGGGGAAG
ACCGATGGGCCCTTGGTGGA 
 
Table S2.4. Primers for Illumina MiSEQ sequencing 
Target Index Read Primer 
IgM CATCCGCCCCAACCCTTTTCCCCCTCGTCTCCT 
IgG TCCACCAAGGGCCCATCGGTCTTCCCCCTGGC 
 
Target Read 2 Primer 
IgM AGGAGACGAGGGGGAAAAGGGTTGGGGCGGATG 
IgG GCCAGGGGGAAGACCGATGGGCCCTTGGTGGA 
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CHAPTER THREE: TECHNICAL ERROR DURING IMMUNOGLOBULIN 
REPERTOIRE PROCESSING CAUSES VARIATION IN QUANTITATIVE AND 
QUALITATIVE OUTPUT 
Rationale 
 Transcriptomics and RNA-seq have rapidly become an important method to 
further our understanding of gene regulation, disease and treatment. Unlike genomic 
sequencing for diagnostic testing or reference library generation, studies of differential 
gene expression rely on accurate quantitative values of sequencing output for direct 
comparison of RNA between groups with different treatments or disease states (Dillies et 
al., 2013). Since the development of RNA-seq (Bainbridge et al., 2006; Mortazavi et al., 
2008), it has been observed that standard protocols can result in serious challenges with 
reproducibility (Marioni et al., 2008; 't Hoen et al., 2013; Kratz and Carninci, 2014; Su et 
al., 2014). Much of the work to address this has been focused on the bioinformatics side 
of sample processing, during sequencing analysis (Dillies et al., 2013; Su et al., 2014; 
Conesa et al., 2016).  
In general, bioinformatics processing of RNA-seq data to examine gene 
expression involves 1. Quality trimming or filtering of short reads, 2. Mapping to a 
genome reference sequence, 3. Counts of sequenced reads per genetic component (e.g. 
gene) and 4. Count normalization. Common approaches to mitigate systematic error at 
these steps are normalization for sequencing depth, gene length and GC content (Dillies 
et al., 2013) as well as sequencer-specific error correction (Molnar and Ilie, 2015; 
Schirmer et al., 2015). Post-sequencing normalization methods have been developed to 
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mitigate inter-library variation, but generally assume that individual samples do not also 
have intra-library biases. The wet lab component of RNA-seq has also been scrutinized, 
and even minor changes in sample storage and processing may lead to different 
conclusions. Finally, the biological sample collected may not be representative of the 
total population, particularly for very heterogeneous cell and molecular populations, and 
could result in significant outcome variation due to undercoverage (Auer and Doerge, 
2010). 
The most common methods used for Ig-seq are essentially targeted RNA-seq. 
Unlike most other genes, immunoglobulin variable region genes (IgVRG) are diverse by 
nature, each naïve B cell having been derived from an individual, independent 
recombination event. Ig-seq is similar to RNA-seq in that it is meant to isolate and cover 
a diverse pool of variable types and quantities of mRNA transcripts. As similar methods 
are used to process RNA-seq and Ig-seq samples, it is likely that they are prone to similar 
types of error.  
However, the common bioinformatics methods for normalization and correction 
are not appropriate for Ig-seq analysis, as the data are very different. RNA-seq 
normalization for gene length is not useful as immunoglobulin gene segments are roughly 
the same size. Error correction is problematic as IgVRG have important nucleotide 
differences via recombination and affinity maturation, thus k-mer cluster-based error 
correction is not appropriate. It’s also reasonable that identical IgVRG would be observed 
at very high counts when actively responding to antigen, so any attempt to avoid the issue 
by elimination of duplicate reads is inappropriate.  
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Finally, the extraordinary heterogeneity of the immunoglobulin repertoire has the 
potential to lead to serious challenges when comparing samples for biological differences 
based on experimental questions. It is unclear how representative of the overall repertoire 
any given blood draw is, and even less so for fully processed samples. Aliquots are 
necessarily used throughput library preparation, potentially missing unique clones. Many 
rounds of PCR amplification are standard, though it may randomly skew count data. 
There are any number of technical effects that can influence observed variation, and it is 
not trivial to separate variation that is attributable to error and not biological signal.  
 It is important to clarify what we mean by technical error. Here, we are using the 
statistical framework, where technical error is the difference between a “true” biological 
value and a measured valued: 
  𝑌 = 𝜇 +  𝜀 
where 𝑌 is the measured variable, 𝜇 is the biological value, and 𝜀 is error. Technical error 
is the difference in these values introduced by any intervention of the biological 
population by the investigator. This is inclusive of both biological variation that occurs 
when subsampling from a total population, and any bias introduced through library 
preparation and sequencing, such as nucleotide errors, or PCR over-amplification. 
To begin to investigate how technical error affects Ig-seq data, we used a newly 
established library preparation technique that adds a unique molecular identifier (UID) to 
nascent cDNA as the original mRNA is reverse transcribed for first-strand synthesis. UID 
tags are valuable here for three purposes: 1. consensus calling for sequences where PCR 
or sequencing-introduced errors may be present, 2. counts that are representative of the 
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original mRNA input, and 3. the estimation of PCR over-amplification during standard 
Ig-seq library preparation.  
We first take a tiered approach to estimate the variation from technical error and 
selection bias introduced at each stage of processing to better understand how to interpret 
observed differences in biological samples (Sections 3.1-3.4). In this section, two healthy 
donors with no recent illnesses or immunizations had two successive blood draws, one 
from each arm. UID-tagged Ig-seq was performed without cell sorting from peripheral 
blood mononuclear cells (PBMC), and samples were processed in a branched manner 
such that each step is represented by at least two independent samples per initial blood 
draw. 
In our hands, UID-tagging led to a significant decrease in total immunoglobulin 
throughput (Section 3.5). In cases where very high numbers of sequencing reads are 
necessary to address the question posed, untagged high throughput sequencing may be an 
appropriate approach to reach adequate coverage despite the technical error. Therefore, 
we asked if we could build a model to estimate “UID” counts from untagged HTS Ig-seq. 
We will use one UID-tagged dataset and machine learning to train and test our model, 
and an independent, UID-tagged dataset for model validation. For training, we utilized a 
dataset from the AVA component of this project (Chapter 4), though the immunization 
itself was irrelevant and not included in the model. We obtained 15 blood samples from 
four subjects over 18 months, and 9 samples from two subjects over 7 months. Sequences 
were analyzed to raw counts per subject-clone-visit, and 25% were randomly selected 
without replacement for training, with the remainder for testing. The independent 
  
81 
validation set used was from the previously discussed, two subject variation study 
(Sections 3.1-3.4).  
Results 
3.1 Unique molecular identifiers correct nucleotide errors from sequencing. 
Nucleotide errors may be introduced during library preparation and processing. 
We used KAPA Biosystems HiFi polymerase for library PCR amplification, which has a 
reported error rate of 2.77 x 10-7(2017). Given a common output of 20,000,000 raw reads 
from an Illumina MiSeq 2x300bp (v3) run, an average fragment length of 450bp, and up 
to 20 PCR cycles, we can estimate a hypothetical raw dataset will have an error in 0.25% 
of its products from this source (49,860 sequences). However, a much smaller proportion 
of reads pass quality, joining and immunoglobulin assignment processing. Our own total 
AVA project, with 23 sequenced libraries, resulted in 3,513,038 immunoglobulin 
sequences, with a mean size of 314bp after pre-processing (joining; adaptor, multiplex 
index, UID and SMARTer oligo trimming). The viable reads may then be estimated to 
have PCR error in 0.17% of its products, or 6,111 sequences. 
Sequencing errors are also a serious source of concern. Illumina quality scores are 
considered high quality at Q30 (quality score = 30), which represents a probability of an 
incorrect call of 1 in 1,000bp, which is acceptable for many applications (2011). For 
transcriptomics, quality trimming of read ends, many overlapping reads and k-mer-based 
error correction can be sufficient to lower this rate to negligible levels (Schirmer et al., 
2015). After pre-processing, our remaining sequences’ quality scores are high, with an 
average value across all nucleotides of Q36. With the caveat that FLASH read joining 
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outputs a FASTQ file that assigns quality scores per nucleotide to the highest single value 
in a match, and a value of 2 for any mismatch, we can estimate the number of errors 
using the Phred quality score calculation: 
𝑄 = −10𝑙𝑜𝑔10𝑃 
Where Q is the quality score and P is the probability of an erroneous base call. We then 
estimate that there are ~277,085 sequencing-induced nucleotide errors in our dataset. 
While this is actually a small proportion of the total nucleotides called, it is not evenly 
dispersed among the total read length. Based on the way Illumina sequencing and read 
joining is performed, the distribution of nucleotide errors is towards the end of reads, and 
much of read 2 (Figure S3.1). Looking at the joined reads, we can see that variation in 
quality scores is increased in one region (Figure S3.2).  
The region with the lowest mean nucleotide quality scores post-processing are 
near the effective joining region and into read 2, around nucleotides 310-390, which 
includes the CDR3. Prior to processing, there is a distinct drop in quality near the end of 
each read and phasing and pre-phasing variation accumulates, and this effect is especially 
precipitous in read 2. During joining, it is these low scoring regions in read 1 and 2 that 
overlap and nucleotide calls are made. Unfortunately during our library sequencing, a 
manufacturer issue regarding kit production emerged, and read 2 quality deteriorated, 
further worsening the problem (Figure S3.1). Therefore, despite the relatively high joined 
sequence mean quality score, we expect that sequencer-induced mutations may be 
problematic among many reads in the regions covered by read 2. 
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 Using our UID-tagged data from the variation study, we examined the nucleotide 
variation introduced within UID groups. Of 212,001 IgVRG sequences, we identified 
26,404 UIDs. Of these, 55% (14,560 UID-tag groups) were comprised of a single read. 
Of the remaining 11,844 UID-tag groups, 76% (9,000) had no errors by alignment, 
indicating that in 24% of UID-tag groups, at least 1 sequence is affected by nucleotide 
error . This may be due to a combination of true PCR and sequencing errors, as well as 
poor read 2 sequencing quality and challenges in joining of two low quality regions.  
To illustrate UID heterogeneity, UID-tagged Ig-seq data was processed without 
assigning UID consensus reads, and B cell clones were estimated using Cloanalyst 
(Figure 3.1). We see that in a subset of UID-tagged groups, there are many nucleotide 
errors that have been introduced, though UID-tagged group members are consistently 
most closely related to other members of the group. However, large UID-tagged groups 
may also be error free by alignment as in Figure 3.1B. Another interesting clone was 
observed to have a very high mutation frequency from the inferred clonal ancestor 
(Figure 3.2). Though this clone is naturally diverse between UID-tag groups, we 
identified one read with a large insertion. This insertion is of unknown origin, it does not 
appear elsewhere in any of the reads in the clone. An error of this sort is of particular 
concern as insertions and deletions (indels) are a common target of interest in 
immunoglobulin research. For example, functional broadly neutralizing antibodies often 
have long CDR3s, and insertions are often the cause. Additionally, duplication insertions 
are common in immunoglobulin genes, so errors of this sort may be mistaken for genetic 
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alleles in reference library generation. It is clear that until reagents and methods are 
improved, UID tags should be used in Ig-seq to mitigate this serious source of error. 
  
  
85 
A) 
 
B) 
 
Figure 3.1. Unique molecular identified (UID)-tagged clonal phylograms reveal 
technical error. 
UID-tagged Immunoglobulin sequencing (Ig-seq) data were computationally processed 
without calling UID consensus reads, and B cell clones were estimated by Cloanalyst. 
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Maximum likelihood phylograms of two clones were colored to describe sequences with 
identical UID-tags observed in each clone. A) Four distinct UIDs were observed within 
this clone, but no UID-tagged group with >1 member is error-free, though they are more 
genetically similar than between groups. B) Five UIDs were observed within this clone. 
One large UID-group (UID 5) is error-free between sequences.  
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A) 
 
B) 
 
Figure 3.2. A UID-tagged clone with an insertion erroneously added during sample 
processing. 
UID-tagged Ig-seq data was processed without UID consensus reads, B cell clones were 
estimated using Cloanalyst, and a highly mutated clone was chosen for further 
investigation. A) Four UIDs were identified within this clone. A maximum likelihood 
phylogram was colored to describe sequences with the same UIDs. B) The sequences of 
this clone were aligned using ClustalW and a large insertion was found in one sequence. 
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3.2 Standard library preparation introduces significant technical variation to biological 
sample output. 
We designed a branched PBMC processing experiment such that each step of Ig-
seq library generation is represented by at least two biological and technical replicates per 
initial blood draw (Illustration 3.1). Two subjects who were not involved with the AVA 
study donated two blood samples each during a single visit. One blood sample was drawn 
from each arm, representing the first “branch” of this study. Total PBMC was then 
isolated from these samples, and one sample from each subject split into two for replicate 
RNA isolation. Similarly, a single isolated RNA sample from both subjects was split into 
replicate cDNA first strand library samples. Given prior knowledge of PCR jackpot 
effect, we ran amplification PCR in triplicate for additional variance information. 
Adaptor PCR, for the addition of multiplex tags and Illumina-specific adaptor ends, as 
well as sequencing, were then performed in duplicate on one of each subjects’ samples. 
All samples were pooled and run as a single multiplexed library, save the two sequencing 
replicates. Total sequence output as well as their UID-consensus sequences were 
processed as described in methods (“Materials and Methods: Computational sample 
processing”), and all final samples (Subject A: 1-8, Subject B: 9-16) were combined by 
subject and processed by Cloanalyst into estimated clones.  
First, we considered the “raw” sequence data, that is, sequences that were 
analyzed without calculating consensus sequences based on their UID tags. This is 
valuable as it reveals the technical output from a standard sequencing run, despite the 
problems posed for interpretation of biological experiments. We observed that biological 
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sampling and technical error during library preparation and sequencing skew both 
coverage and counts of clonal analysis (Figure 3.3). Here, we see that even the binary 
appearance or non-appearance of an estimated clone without regard to sequence count is 
poorly overlapped among most paired samples, which can be potentially attributed to 
both undercoverage of biological samples and fragmentation of samples throughout 
processing. We observe a greater general overlap in clonal counts rather than clones 
alone. This is unsurprising as larger clones populated by more cells, or perhaps producing 
more immunoglobulin in the case of plasmablasts, are more likely to be selected at any 
given step. Another way of looking at this is that the larger the clone, the more likely it is 
to be identified in multiple sample draws and preparations. But even with this advantage, 
a number of steps show poor count overlap. 
We then reviewed our data to determine the appropriate statistical approach. We 
first confirmed the normality and homogeneity of the data by Q-Q plot (Figure S3.3) and 
Fligner-Killeen test (Table S3.1). We reviewed the data using side-by-side boxplots of 
the proportion of unique clones of the total clones by factor (as opposed to the “shared” 
clones observed in 2 or more replicates) (Figure 3.4.). Summary values are given in Table 
S3.2. It is not surprising that we observed a high proportion of unique clones at the early 
steps in sample processing as these groups will be affected by the variation introduced at 
all downstream steps. The large interquartile ranges for RNA isolation and sequencing 
indicate that these steps may be more affected by technical variation, though they both 
have relatively good sample overlap. We also tested samples for interaction where 
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applicable (Figure S3.4), and found that interactions between factors are likely to play a 
significant role in any observed main effect. 
Given these results, we will estimate where variance is introduced using ANOVA 
followed by post hoc tests. An omnibus ANOVA was calculated in R for unique 
proportion of clones by the point of sample branching (Table 3.1A) to confirm that 
observed variance is likely. To determine the factors that introduce significant variance 
we used a Tukey-Kramer test (Table 3.1B), which did not result in significant values. 
Despite a difference in means, the familywise variance is high, making isolation of 
specific effects with high confidence complicated. We then performed n-way ANOVA 
(Table 3.1C). In this test, we see that sequencing and adaptor PCR (PCR2) the most 
downstream steps, appear to contribute the most to the observed variance. In summary, 
raw clone data are highly dissimilar between biological and technical replicates. There 
are strong interactions between sample groups, as expected due to the successive nature 
of sample processing, but the independent contributions of variance by adaptor PCR and 
sequencing are primary drivers of observed differences between samples.  
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Illustration 3.1. Schematic of replicate study sample processing. 
Two healthy volunteers without recent illness or vaccinations donated blood during a 
single visit. Two blood samples were drawn from each subject, one from the right and 
left arms, and processed for Ig-seq using our established protocols (“Materials and 
Methods: Blood processing” and “Library preparation and sequencing”). At each step 
where potential sample fragmentation or bias is introduced (e.g. aliquots, PCR jackpot 
effect), at least one technical replicates was prepared, resulting in 16 multiplexed 
samples. Fourteen samples (to “Adap PCR”) were run on a single MiSeq flowcell (single 
lane). The last two samples were run together in a separate multiplex pool to test bias at 
the sequencing step. Amp PCR refers to amplification PCR, Adap PCR to adaptor PCR, 
and Seq to sequencing.   
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Figure 3.3. Observed clonal overlap between non-UID-consensus sequences from 
biological and technical replicates. 
Biological and technical replicate blood samples from two volunteers resulted in sixteen  
Ig-seq datasets (Illustration 3.1). These Ig-seq libraries were combined per subject 
without UID-based consensus calling and clones were inferred by Cloanalyst. For each 
step of library processing, the clones observed in biological or technical replicates were 
compared for presence or absence in the sister replicate. The leftmost column refers to 
the number of shared clones, and the rightmost column is the number of sequences within 
shared or unique clones. For instance, at the biological replicate step of blood collection, 
6,450 total clones were identified. Of these, 2,037 were only observed in the first blood 
draw, and 3,575 were only observed in the second blood draw. 419 clones were observed 
in both blood draws. In this same comparison, 97,707 immunoglobulin sequences were 
observed. Of these, 35,561 sequences were assigned to clones only observed in the first 
blood draw, and 32,205 were assigned to clones only observed in the second blood draw. 
29,941 sequences were assigned to the 419 clones that were observed in both samples. 
  
  
94 
 
 
Figure 3.4. The proportion of total observed clones per sample which are unique to 
that sample. 
Biological and technical replicate blood samples from two volunteers resulted in sixteen  
Ig-seq datasets (Illustration 3.1). These Ig-seq libraries were combined per subject 
without UID-based consensus calling and clones were inferred by Cloanalyst. For each 
step of library processing, the clones observed in biological or technical replicates were 
compared for presence or absence of the same clone in the sister replicate. The proportion 
of unique clones per subject-replicates were calculated. A value of 1.00 indicates that all 
clones in a sample are unique and were not observed in its analogous replicate. A value 
of 0 indicates that all clones in a sample were observed in its analogous replicate. 
Horizontal lines represent the median value, and vertical lines, the interquartile range. 
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A) 
 Df Sum Sq Mean Sq F value Pr(>F) 
Factor 5 0.5956 0.11912 2.926 0.0385* 
Residuals 20 0.8142 0.04071   
B) 
 Difference Lower limit Upper limit Adj. p-value 
cDNA-Blood -0.0118 -0.5676 0.5441 1.0000 
PCR1-Blood -0.1522 -0.6596 0.3552 0.8461 
PCR2-Blood -0.0604 -0.6162 0.4955 0.9980 
RNA-Blood -0.2862 -0.8420 0.2697 0.3735 
Seq-Blood -0.4347 -0.9905 0.1211 0.0608 
PCR1-cDNA -0.1405 -0.6479 0.3670 0.8842 
PCR2-cDNA -0.0486 -0.6045 0.5072 0.9993 
RNA-cDNA -0.2744 -0.8302 0.2815 0.4176 
Seq-cDNA -0.4229 -0.9788 0.1329 0.0717 
PCR2-PCR1 0.0918 -0.4156 0.5992 0.9791 
RNA-PCR1 -0.1339 -0.6413 0.3735 0.9028 
Seq-PCR1 -0.2825 -0.7899 0.2249 0.2945 
RNA-PCR2 -0.2258 -0.7816 0.3301 0.6185 
Seq-PCR2 -0.3743 -0.9301 0.1815 0.1372 
Seq-RNA -0.1485 -0.7044 0.4073 0.8983 
C) 
 Df Sum Sq Mean Sq F value Pr(>F) 
Blood 1 0.1167 0.11671 3.402 0.088 
RNA 1 0.0281 0.02811 0.819 0.3819 
cDNA 1 0.0728 0.07285 2.123 0.1688 
PCR1 1 0.0273 0.0273 0.796 0.3886 
PCR2 1 0.2511 0.25112 7.319 0.018* 
Seq 1 0.2301 0.23014 6.708 0.0224* 
Blood:RNA 1 0.0588 0.05877 1.713 0.2133 
Blood:cDNA 1 0.0554 0.05536 1.614 0.2262 
cDNA:PCR1 1 0.0473 0.04731 1.379 0.2613 
RNA:PCR2 1 0.001 0.00101 0.029 0.8667 
RNA:Seq 1 0.0513 0.0513 1.495 0.2431 
PCR2:Seq 1 0.0238 0.02384 0.695 0.4195 
Residuals 13 0.446 0.03431   
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Table 3.1. Analysis of variance (ANOVA) and post hoc tests to determine factor 
contribution to variance. 
Following confirmation of data normality (Figure S3.3 and Table S3.1), statistical tests 
were performed to estimate the points of sample collection and processing that contribute 
the most variance to clonal observation. The values used for these tests are the proportion 
of unique clones of the total observed clones per subject-replicate for non-UID-consensus 
sequences. For instance, Subject A has two biological blood draw replicates; following 
comparison of observed clones for shared and unique clones, we can calculate the 
proportion of unique clones for both blood draw 1 and blood draw 2. A) Omnibus 
ANOVA of all steps was performed to determine if the observed variance between 
factors was significant and appropriate for further tests. B) Tukey-Kramer multiple 
comparison procedure was used to test pairwise relationships for significant changes in 
the mean. C) N-way ANOVA was used to test independent and interacting factors for 
significant contributions to variance. The significance level was set at 0.05. 
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3.3 Technical errors are not resolved by unique molecular identifier tagging. 
UID-tagging has been proposed as a way to minimize errors in observed count 
variation that are due to technical error, namely, PCR over-amplification. Therefore, we 
added UID-tags to our libraries during cDNA library synthesis, calculated the consensus 
sequences and performed parallel analysis to the raw data, discussed in Section 3.2. 
The proportional clonal and count outcomes do not significantly differ from raw 
Ig-seq except in amplification PCR, which is sensible as sequence count discrepancies in 
observed raw versus UID-tagged output are introduced during PCR (Figure 3.5). As with 
raw data, the overall shared clonal representation is still poor among technical and 
biological replicates (Figure 3.6). As we observed with the non-consensus, non-UID 
count normalized data, there is little overlap in clonal capture between blood samples. 
Proportional count values show a greater overlap in general, but as before, this is likely a 
product of larger clones or clones with more immunoglobulin transcript production. 
As in Section 3.2, we performed parallel exploratory analysis to determine the 
normality and variance of the data to determine appropriate statistical tests (Figure S3.5 
and Table S3.3). The consensus data had similar characteristics to the raw, so we 
continued by performing an omnibus ANOVA to confirm significant variance, followed 
by post hoc Tukey-Kramer and n-way ANOVA tests. As before, the Tukey-Kramer 
analysis did not reveal any specific factor that significantly contributed to the observed 
variance. Interestingly, the n-way ANOVA only resulted in one significant factor, which 
was an interacting factor, cDNA:PCR1. This is somewhat surprising as this represents 
two relatively upstream steps, however the interaction effect in this analysis (Figure 
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S3.5C) is more extreme than in the raw data (Figure S3.4). As with the raw data, these 
analyses are likely to be affected by the successive processing of samples and 
propagation of error.  
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Figure 3.5. Comparison of proportion unique clones and counts in raw versus 
consensus-called immunoglobulin sequencing (Ig-seq). 
Ig-seq libraries were combined per subject with and without UID-based consensus calling 
(“UID” and “Raw,” respectively), and clones were inferred by Cloanalyst. For each step 
of library processing, the clones observed in biological or technical replicates were 
compared for presence or absence of the same clone in the sister replicate. The number of 
sequences within unique or shared clones was then summed per subject-replicate. The 
proportion of unique clones and sequence counts within these clones per subject-
replicates were calculated. A value of 1.00 indicates that all clones or sequences in a 
sample are unique and were not observed in its analogous replicate. A value of 0 
indicates that all clones or sequences in a sample were observed in its analogous 
replicate. Horizontal lines represent the median value, and vertical lines, the interquartile 
range. Asterisks represent significance at p <0.05.  
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Figure 3.6. Clonal overlap of UID-tagged consensus sequences from biological and 
technical replicates. 
Biological and technical replicate blood samples from two volunteers resulted in sixteen  
Ig-seq datasets (Illustration 3.1). These Ig-seq libraries were combined per subject with 
UID-based consensus calling and clones were inferred by Cloanalyst. For each step of 
library processing, the clones observed in biological or technical replicates were 
compared for presence or absence in the sister replicate. The leftmost column refers to 
the number of shared clones, and the rightmost column is the number of sequences within 
shared or unique clones. For instance, at the biological replicate step of blood collection, 
6,088 total clones were identified. Of these, 1,867 were only observed in the first blood 
draw, and 3,427 were only observed in the second blood draw. 397 clones were observed 
in both blood draws. In this same comparison, 11,287 immunoglobulin sequences were 
observed. Of these, 2,544 sequences were assigned to clones only observed in the first 
blood draw, and 5,410 were assigned to clones only observed in the second blood draw. 
3,333 sequences were assigned to the 397 clones that were observed in both samples. 
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A) 
  Df Sum Sq Mean Sq F value Pr(>F) 
Factor 5 0.7233 0.14466 2.883 0.0405* 
Residuals 20 1.0036 0.05018     
B) 
 Difference Lower limit Upper limit Adj. p-value 
cDNA-Blood -0.0138 -0.5117 0.48411 1 
PCR1-Blood -0.417 -0.8715 0.03756 0.08401 
PCR2-Blood -0.0679 -0.5658 0.42999 0.99787 
RNA-Blood -0.3089 -0.8068 0.18898 0.40287 
Seq-Blood -0.2789 -0.7768 0.21895 0.51066 
PCR1-cDNA -0.4032 -0.8577 0.05134 0.10093 
PCR2-cDNA -0.0541 -0.552 0.44377 0.99928 
RNA-cDNA -0.2951 -0.793 0.20276 0.45115 
Seq-cDNA -0.2652 -0.7631 0.23273 0.5629 
PCR2-PCR1 0.34906 -0.1055 0.80356 0.19836 
RNA-PCR1 0.10804 -0.3465 0.56255 0.9732 
Seq-PCR1 0.13801 -0.3165 0.59252 0.92688 
RNA-PCR2 -0.241 -0.7389 0.25687 0.65525 
Seq-PCR2 -0.211 -0.7089 0.28684 0.7643 
Seq-RNA 0.02997 -0.4679 0.52786 0.99996 
C) 
 Df Sum Sq Mean Sq F value Pr(>F) 
Blood 1 0.1876 0.18763 4.301 0.0585 
RNA 1 0.0123 0.01233 0.283 0.6039 
cDNA 1 0.1459 0.14591 3.345 0.0904 
PCR1 1 0.1391 0.13905 3.188 0.0975 
PCR2 1 0.1355 0.1355 3.106 0.1015 
Seq 1 0.1137 0.11373 2.607 0.1304 
Blood:RNA 1 0.0455 0.04553 1.044 0.3256 
Blood:cDNA 1 0.012 0.01197 0.275 0.6091 
cDNA:PCR1 1 0.2693 0.26925 6.172 0.0274* 
RNA:PCR2 1 0.0099 0.00994 0.228 0.641 
RNA:Seq 1 0.0615 0.06146 1.409 0.2565 
PCR2:Seq 1 0.0275 0.02751 0.631 0.4414 
Residuals 13 0.5671 0.04362   
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Table 3.2. ANOVA and post hoc tests to determine contribution to variance in UID 
consensus Ig-seq. 
Following confirmation of data normality (Figure S3.3 and Table S3.1), statistical tests 
were performed to estimate the points of sample collection and processing that contribute 
the most variance to clonal observation. The values used for these tests are the proportion 
of unique clones of the total observed clones per subject-replicate for UID-consensus 
called Ig-seq. For instance, Subject A has two biological blood draw replicates; following 
comparison of observed clones for shared and unique clones, we can calculate the 
proportion of unique clones for both blood draw 1 and blood draw 2. A) Omnibus 
ANOVA of all steps was performed to determine if the observed variance between 
factors was significant and appropriate for further tests. B) Tukey-Kramer multiple 
comparison procedure was used to test pairwise relationships for significant changes in 
the mean. C) N-way ANOVA was used to test independent and interacting factors for 
significant contributions to variance. The significance level was set at 0.05. 
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3.4 Both biological and technical replicates are valuable for overcoming random error. 
 Investigating sources of technical variation and error among biological samples is 
necessary for proper interpretation of experimental results. Here, we are able to examine 
two primary sources of random error for Ig-seq, 1. Representation of the total repertoire 
for any given blood draw and 2. Stochastic selection of variable clonal lineages and 
throughout library preparation. We represent this variation in our experiment as 
  𝑌 = 𝜇 +  𝜀 
where 𝑌 is the measured variable, 𝜇 is the “true” biological value, and 𝜀 is error, which is 
comprised of measurement error and biological variation. Measurement error can be 
estimated using technical replicates, and biological variation, through biological 
replication. As measurement error contributes to the observable error for biological 
replicates, and this error propagates through sample processing, measurement error can 
be estimated with higher confidence at the more downstream points of replication. 
We shifted our model of variation to define the error as: 𝜀 = 𝑌 −  𝜇 , and 
estimated the error per step using a simplified approach (Table 3.3). Here, we define the 
“true” population as the total estimated clones observed in the factor-associated replicate 
samples. The measured variable is defined as the proportion of these total clones that are 
shared, that is, observed between replicates. These are purposefully loose definitions that 
gives each factor a best reasonable chance for no error. It is clear that every step of 
sample collection and processing is seriously affected by error. The first source of 
variation is during blood collection, and can represent both biological variation and 
technical error. For instance, if clonally related B cells are more likely to circulate in the 
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blood at closer proximity than other B cells, or if clone heterogeneity is very high, it is 
reasonable to infer that any given blood draw will include different clonal members from 
the total population. Following processing, technical error may also propagate, 
influencing these error values.  
 In general, biological replicates are considered the gold standard for capturing 
true population differences. Biological replicates are primarily valuable for appropriately 
estimating sample variation, but they can also be useful for acquiring adequate sample 
coverage in high diversity populations. It is clear that biological replicates of Ig-seq will 
improve total population capture, as multiple samples taken at the same time are 
measured to have a large quantity of novel clones (Figure 3.3). Standard blood draws do 
not approach total repertoire coverage, which is likely to be a result of undercoverage due 
to high heterogeneity.  
We also observed that the simplest case of random error, measurement precision 
by the sequencer, significantly contributes to measured outcomes. In this case, technical 
replicates can address this source of error when maximum coverage is important, though 
the cost associated with each sequencing run makes this an expensive option. In the case 
of Ig-seq, technical replicates at earlier steps are somewhat special as they may be used as 
a functional biological replicate, whereby highly heterogeneous libraries are re-sampled 
to capture additional biological diversity. This “fragmentation” effect is not usually 
problematic in standard RNA-seq, but it causes a demonstrable bias in Ig-seq, and 
technical replicates at these steps are likely to contribute valuable, novel data.  
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Branch 
"True" 
clones 
Measured clones 
(shared) 
Proportion 
measured Error Mean error 
Blood 3416 330 0.0966 0.9034 0.8680 
Blood 3034 508 0.1674 0.8326  
RNA 2369 262 0.1106 0.8894 0.7521 
RNA 2175 838 0.3853 0.6147  
cDNA 1250 144 0.1152 0.8848 0.9331 
cDNA 1290 24 0.0186 0.9814  
PCR1 648 112 0.1728 0.8272 0.7138 
PCR1 1597 638 0.3995 0.6005  
PCR2 2282 238 0.1043 0.8957 0.8046 
PCR2 656 188 0.2866 0.7134  
Seq 272 132 0.4853 0.5147 0.5361 
Seq 357 158 0.4426 0.5574  
 
Table 3.3. Error estimation for biological and technical replicates. 
The total number of observed clones per replicate for each subject was determined, and 
the number of shared clones was found and expressed as a proportion of the total clones. 
A simplified model for error was calculated as 𝜀 = 𝑌 −  𝜇, where 𝜀 is the combined 
technical and biological error, 𝑌 is the measured variable, and 𝜇 represents the true 
biological variable. 
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3.5 UID-tags decrease the proportion of Ig-Seq that is immunoglobulin. 
The RACE and MiSeq-based approach we adopted has limited immunoglobulin-
specific output, likely due to non-specific priming and elongation during cDNA synthesis 
and PCR (Table S3.4). It is clear that this limitation in throughput is exacerbated by 
molecular tagging, which significantly adversely affects Ig-seq efficiency (Figure 3.7). 
However, a loss in throughput is not necessarily a loss in repertoire coverage. For 
instance, untagged molecules may be more prone to over-amplification.  
To examine this, we performed rarefaction assessments of UID-tagged (with and 
without consensus) and untagged Ig-seq (Figure 3.8, Figure S3.6). Here, we consider the 
number of clones identified per increasing fraction of the data as an estimator of 
repertoire coverage. A sharply increasing curve indicates that many new clones are still 
being identified, and more data is required for good coverage. As the curve approaches 
plateau, clonal coverage nears total repertoire values for the given sample. In addition to 
using these data to estimate the amount of IgVRG sequences required for appropriate 
coverage, here, we may compare the results from different types of library preparation. 
First, diversity capture efficiency can be approximated by the total count of estimated 
clones identified using the same number of IgVRG input sequences. For instance, fewer 
clones may be observed for the same amount of input, possibly due to poorer cDNA 
capture efficiency (loss of diversity) or more PCR over-amplification (increase in 
homogeneity). Second, the slope of the line may differ, suggesting differences in the 
biological diversity of the sampled population.  
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Despite the high number of IgVRG sequences, the total untagged, HTS data does 
not appear to near total clonal coverage (Figure 3.8A). When these data are stratified by 
isotype, the slope of IgG+ IgVRG clonal capture is less steep than IgM+ IgVRG, but both 
are still increasing (Figure S3.6). A similar pattern is seen when B cells are stratified by 
subset. IgM+ naïve B cell clones are still increasing, while plasmablasts, which are often 
IgG+, have a less severe slope with many few IgVRG. The more mixed isotype memory 
B cells show an intermediate effect. The same pattern is seen in the UID-tagged data 
prior to consensus calling (Figure 3.8B). In this comparison, we also observe that the 
clonal capture for the same amount of input sequences in much lower in UID-tagged data 
as compared to untagged data, even without consensus calling. Rarefaction assessment of 
UID-tagged consensus IgVRG shows that only the plasmablast capture slope is 
noticeably distinct from the total repertoire, which is still increasing (Figure 3.8C).  
We did not observe a distinct plateau in any dataset, nor in its B cell subsets, even 
with many millions of IgVRG sequences. Thus, as coverage of the total immunoglobulin 
repertoire cannot be approached without very high individual IgVRG counts, the loss in 
Ig capture efficiency and diversity during library preparation may make current UID-
tagging methods inappropriate for some applications.  
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Figure 3.7. Immunoglobulin-specific output from UID-tagged and untagged high 
throughput sequencing. 
Ten non-UID-tagged and 13 UID-tagged Ig-seq libraries were prepared at Boston 
University and sequenced using optimized methods. Raw sequences were processed as in 
Illustration 2.5, during which, some sequences are excluded due to quality and non-
immunoglobulin content. The percent of fully processed, Cloanalyst clone-assigned 
immunoglobulin sequences from the initial raw reads were calculated per sequencing run. 
Significance was tested by Student’s t-test (two-sided, unpaired) at a significance level of 
0.05.  
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A) 
 
B) 
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C) 
 
Figure 3.8. Rarefaction assessment to estimate immunoglobulin repertoire coverage. 
Ig-seq datasets were randomly sampled at increasing sequence counts and the number of 
clones per subsample was inferred by Cloanalyst. A) HTS Ig-seq without UID tagging, 
B) UID-tagged, but non-consensus called sequences (blue) as compared to the HTS Ig-
seq without UID tagging shown in A (red), and C) UID-tagged, consensus called 
sequences from the same dataset in B (blue). The subsample sequence intervals were 
calculated to be increasing amounts of ~1/6 the total sequence number from either UID-
tagged, non-consensus sequences (A and B), or UID-tagged, consensus sequences (C). 
Subsets of the total datasets (All) by B cell isotype (IgM+ and IgG+) and subset (naïve, 
memory and plasmablast) were analyzed separately. We expect that a homogenous 
sample will sharply increase with a small proportion of sequences then plateau, whereas a 
completely heterogeneous sample will continually increase at a 1:1 sequence to clone 
ratio. Each dataset is shown with independent, continuous axes in Figure S3.6.  
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3.6 Observed raw reads are from a bimodal distributions.  
To start building a model to evaluate high throughput Ig-seq data without UID-
tags, we evaluated the distribution of the population. Raw data from the AVA, UID-
tagged dataset was processed as in methods (“Anthrax Vaccine Adsorbed: Sequence 
processing pipeline”) (Illustration 2.5). We first asked what the relationship is between 
the number of UIDs and non-consensus sequence counts (Figure 3.9). There is a bimodal 
distribution with two local peaks at 1, indicating that many single sequences are 
identified with unique UID, and ~100, where a single UID molecule has been amplified 
and observed many times. As the model is intended for data without UIDs, we then asked 
if there is a clear relationship between the count of sequences within clones and the 
number of UIDs in those same clones.  
Data was sorted into estimated clones using Cloanalyst. Ig-seq data is, by nature, 
highly repetitive and difficult to sort into biological clusters without gene-specific 
parameterization. Here, clones are used as a more biologically relevant and precise form 
of clustering. Two potential predicator variables were considered for model generation. 
Processed data was sorted by subject, clone and time point, and the raw read counts were 
log10 normalized, here called “raw read count.” For each subject-clone, regardless of time 
point, the total number of raw reads were summed and log10 normalized, called “total 
clone count.” For evaluation purposes, the previously discussed ratio of sequence counts 
to measured UIDs was log10 normalized, called “raw-UID ratio.” 
As with the prior distribution, initial histograms for each predictor variable 
suggest a bimodal mix of two distributions (Figure 3.10). The consistency between 
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variable distributions is primarily due to the connected origin of these values, but is 
useful in confirming that this pattern is consistent among all potential predictor variables 
for model building purposes. We observe for all variables a sharply sloped, left-most, 
right-tailed distribution and a gentler second peak with a larger mean and standard 
deviation. 
Furthermore, simple plotting of measure raw read count by UID count also shows 
a non-linear relationship with significant noise, though one might still predict two 
separate clusters along the raw count axis (Figure 3.11). This mix of distributions 
complicates our model building, but also suggests that our initial observations were not 
incidental, and that random variation introduced during sample processing is a potentially 
important source of raw count bias. Were this not the case, we would expect a stronger 
linear relationship between raw count and UID. 
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Figure 3.9. Distribution of the number of sequences per UID-tag from AVA 
vaccinated individuals. 
UID-tagged library preparation and immunoglobulin sequencing was performed on 
samples collected prior to and after AVA vaccination as described in “Materials and 
Methods: Anthrax Vaccine Adsorbed.” All sequences passing quality control and 
containing appropriate UID tags within the universal primer sequence were processed 
without calling UID consensus reads, and B cell clones were estimated by Cloanalyst. 
The number of output immunoglobulin sequences successfully assigned to clones were 
then sorted by UIDs per library, and the number of sequences per UID summed. The 
distribution of these values is shown. 
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B) 
 
 
Figure 3.10. The distribution of total, non-consensus sequences per clone. 
UID-tagged, non-consensus sequences (raw) passing quality control and clonal 
assignment (as described in Figure 3.9) were subset by A) subject and visit or B) subject 
alone. The total number of sequences per clone for each dataset were summed. The 
distribution of these values is shown.  
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Figure 3.11. The relationship between clone and UID counts is non-linear. 
UID-tagged, non-consensus sequences passing quality control and clonal assignment (as 
described in Figure 3.9) were sorted by subject and visit. The number of sequences per 
clone was summed and compared to the number of observed UIDs in the same clone 
grouping.  
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3.7 UID-tagged data can be used to develop a regression model to estimate read counts 
from non-UID-tagged Ig-seq. 
From the total UID-tagged, AVA dataset, we randomly selected 25% of the 
IgVRG to be used for model training. The remaining 75% was used only to test the 
model. In order to use this training set to build a model to predict UID count from 
observed, untagged data, we will use machine learning to 1) classify predictor values to 
an appropriate distribution and 2) perform regression analysis. For the former, the 
bimodal distribution of the potential predictor values suggests initial classification of data 
points into their distinct distribution may result in more accurate regression. 
To determine appropriate starting values for distribution classification, we first 
approximated the distributions from which a given predictor is derived. We estimated 
nominal thresholds to test the fit of reasonable distributions to compare the mean, 
standard deviation and shape of the data to idealized modeled distributions in MATLAB 
(Figure S3.7). The left-most data most closely approximates an exponential distribution, 
and the right-most, a normal distribution. Starting thresholds for random forest 
classification were set as described in methods (“Anthrax Vaccine Adsorbed: Model 
pipeline”). 
With these distributions and starting values, we then used the data to train a 
random forest classifier. This will predict the number of discrete distributions in the data 
and classify to which distribution to which each data point belongs. We passed the initial 
values to TreeBagger in MATLAB, a random forest algorithm, then visualized to which 
distribution classification each data point was assigned (Figure 3.12). In this case, we 
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have maximum information pertaining to the UID-raw count relationship, which will not 
be available in untagged datasets. Here, we see that when we accept values with a 
likelihood estimate of 0.8, the majority of the data are classified for raw read count-based 
analyses, and these classifications appear distinct and sensible. In contrast, it is more 
difficult to classify total clone count values with high likelihood, particularly low raw-
UID ratio values, though two classes are still identified and separated. Without UID 
information, separate classifications cannot be distinguished with any of the available 
predictor variables. 
As classification is likely to contribute to more accurate regression, we asked if it 
is correlated with other parameters that will be available in any given Ig-seq dataset. 
First, we tested for direct, pairwise correlation and found little individual contribution to 
classification by other variables (Figure S3.8A). We also considered that multiple 
variables may interact and still contribute to a correlative signal, and performed PCA. 
The classed data primarily stratified using the input variables of the random forest 
classification, indicating that no other tested variable is likely to contribute additional 
class information (Figure S3.8B).  
Following data normalization, we may now use random forest regression to build 
a model to estimate UID counts with our predictor values. This algorithm performs 
bootstrapped bagging by repeatedly sampling the data and the predictor values, and 
training individual regression trees, then averaging over these regressions. This approach 
results in a regression with 95% confidence intervals. We trained the regression using the 
training dataset then applied it to the test set to confirm goodness-of-fit (Figure 3.13).  
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A) 
 
B) 
 
C) 
 
Figure 3.12. Random forest classification identifies two classes within UID-tagged 
data. 
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UID-tagged, non-consensus sequences from the AVA study passing quality control and 
clonal assignment (as described in Figure 3.9) were sorted by subject, visit and clone. 
Raw read counts per subject-visit-clone were log10 normalized (raw read count), as well 
as per subject-clone (total clone count). Three potential predictor variables were tested 
using the log10 values of the A) raw read count versus UID count per subject-visit-clone; 
B) raw read count versus the ratio of sequences to UIDs (raw-UID ratio) and C) the total 
clone count versus raw-UID ratio. Each dataset was analyzed to estimate the number of 
distinct data classes of which it is comprised. The MATLAB Treebagger random forest 
classification package was run using a training set (25% of total data, exclusive of the test 
set) with start values estimated from model bimodal distributions with exponential and 
normal distribution cutoffs (Figure S3.7). Two classes were identified in all cases, and 
data points classified with likelihood values > 79% were colored by their estimated class 
(blue and black). Red circles indicate <80% certainty in classification.   
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A) 
 
B) 
 
Figure 3.13. Random forest regression model of UID-tagged data for UID 
estimation. 
UID-tagged, non-consensus sequences from the AVA study were processed as in Figure 
3.12 and used to estimate the ratio of sequences to UIDs (raw-UID ratio) given the raw 
read count per subject-visit-clone. MATLAB Treebagger random forest regression was 
run using A) the training set (25% of total data) and 100 decision trees and the model was 
applied to B) the test set (remaining 75% of total data). Plotted are the mean regression 
(blue), bottom (2.5%) of 95% CI (red), median (yellow), top (97.5%) of 95% CI (purple).  
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3.8 Evaluation of model prediction. 
We then tested the random forest regression model to determine how accurately it 
is able to predict UID count (raw-UID ratio) from sequence data alone (Figure 3.14). 
Using the training set, UID prediction is highly accurate, and the confidence intervals are 
small (Figure 3.14A). This is expected given our bootstrapping approach, which is able to 
capture and solve for wide variation within its training data. When the model is applied to 
the remaining test data from the same samples, greater variation emerges between 
measured and predicted values, but the overall fit is still acceptable given the extreme 
variation of the input data (Figure 3.14B). One source of deviation is at the upper limit, 
where the ratio >>1. Here, a few molecules are extremely over-amplified and do not fit 
well into the tail of the normal distribution.  
Finally, we tested the model on an independent dataset from our previously 
discussed variation study (Sections 3.1-3.4) (Figure 3.14C). These Ig-seq data are derived 
from different subjects and represent baseline repertoire values without recent 
immunization or illness, and were separately prepared and sequenced. Here, the output is 
comparable to that of the test set derived from the same source as the training set. 
In light of the distinct distribution sources for our read count data, we also 
developed a dual random forest regression to process class-stratified data. We ran the 
previously classified training data through the model to estimate prediction accuracy 
(Figure S3.9). This additional machine learning step resulted in two distinct fits for 
classified data, further supporting that knowing from which each distribution a data point 
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was derived is valuable. When classification is not feasible, the output regression has an 
intermediate slope as compared to the classified output, but still fits well.  
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A) 
 
 
B) 
 
C) 
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Figure 3.14. Random forest regression model estimates of raw-UID ratio. 
The random forest regression model described in Figure 3.13 was used to predict raw-
UID ratios without knowledge of UID counts on A) the training set, B) the remaining test 
set (exclusive of the training set) and C) an independent, UID-tagged dataset from 
different subjects, and plotted against the measured raw-UID ratio values. The solid red 
line represents the regression and the dashed lines are 95% CI. Regression slope, CI 
values, adjusted R2 and root-mean-square error are included per regression. 
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Discussion 
Biological and technical error associated with sample processing are 
underappreciated sources of variation in Ig-seq and, RNA-seq. In large studies which 
emphasize deep sequencing over breadth of sampling, it’s difficult to estimate the 
biological variation that affects the measurable outcomes. Similarly, while biological 
replicates are a gold standard for statistical analyses of large datasets, the potential for 
significant variation to be introduced during sample processing is often not considered. 
We have shown that using common protocols and tools, the variation of qualitative and 
quantitative outcomes of Ig-seq is strongly influenced and skewed by both biological and 
technical sources of error. At least two of these sources, nucleotide errors and over-
amplification, can be mitigated by the use of UIDs and/or model-based estimation. 
However, our results suggest the immunoglobulin repertoire is highly heterogeneous and 
cannot be captured by or within individual samples and standard preparation, therefore 
both biological and technical replicates should be considered in experimental design. 
In general, high fidelity polymerases are used for amplification PCR, and have 
sufficiently low error rates that they are unlikely to seriously affect output. In contrast, 
sequencer-induced errors have been a major point of concern for other genetic 
applications with requirements for high accuracy or sequencing of error-prone regions. 
For instance, most next-generation sequencing platforms have difficulty accurately 
sequencing long repeat and homopolymer regions (Nakamura et al., 2011). This issue is 
underscored by the reported substitution rates of 1.05 x 10-3 for read 1 and 2.5 x 10-3 for 
read 2 of the MiSeq 2x250bp kit (Schirmer et al., 2016). The genetic plasticity of the 
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IgVRG means that it is more capable of possessing problematic motifs than most genes 
of inquiry, compounding the problem. Illumina platform sequencing is further predicated 
on the ability to clearly distinguish between pinpoint “clusters” of bridge-amplified DNA 
on a flow cell. Ig-seq libraries, by nature, have very low diversity compared to more 
common NGS applications, and clusters are more difficult to microscopically and 
computationally resolve. This lowers base call quality scores, which is strongly correlated 
with mismatches (Nakamura et al., 2011). The routine method to handle this weakness is 
PhiX spike-in control, which increases library and nucleotide diversity, but decreases 
throughput. Even with PhiX controls, Ig-seq runs are difficult to optimize for next-
generation sequencers. 
Affinity maturation naturally results in clones of very similar sequences that may 
be uniquely mutated. Therefore, established NGS library approaches, such as 
fragmentation and 50-100bp libraries are not viable, as it is not possible to pair 
fragmented IgVRG with reasonable certainty. Due to the length of the full length IgVRG 
and the required primers for 5’RACE, the only Illumina platform kit that can theoretically 
cover the total region without fragmentation is the 2x300bp chemistry. Unfortunately, 
current methods, tools and reagents for 2x300bp sequencing do not yet result in high 
quality over the entire read length, leading to additional uncertainty in pairing and base 
calling. This is especially problematic in IgVRG as a primary region of read overlap is 
the CDR3, an area prone to biological mutation such that induced nucleotide errors may 
not be identifiable.  
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Reads derived from sequencing-by-synthesis of long fragments systematically 
lose quality as the read length increases and phasing (nucleotide non-incorporation) and 
pre-phasing (>1 nucleotide incorporations) leads to decreased nucleotide synchronization. 
For other applications, such as genome assembly, suites of tools may be used to identify 
and remove questionable nucleotide calls based on references, inter-data clustering, and 
known problematic motifs. In the case of Ig-seq, because IgVRG are expected to differ 
from the reference, we expect many closely related but unique sequences, and biological 
mutations may be mistaken for technical ones, making common error-reduction tools 
inappropriate (Kircher et al., 2009; Schirmer et al., 2015). 
 Indels also pose a special problem for Ig-seq. Illumina HiSeq indel errors are 
relatively rare, at a rate of ~4.7x10-6 (Schirmer et al., 2016), and indels are not a common 
basis of inquiry for large scale sequencing. Therefore, little consideration has gone into 
the bioinformatics processing of indel-inclusive data. Common tools such as TopHat will 
automatically eliminate deletions to improve the alignment score, and others rely on 
hardcoded indel site annotation (Sun et al., 2016). In contrast, it is common for 
immunoglobulins to have indels (when aligned to reference gene segments) both from 
initial recombination and affinity maturation. In fact, an important emerging class of 
antibodies, broadly neutralizing antibodies, commonly has indels in their CDR3, and 
researchers are interested in immunoglobulins that exhibit such features.  
 Furthermore, variation is also introduced upstream of the actual sequencing 
process. During sample preparation for Illumina sequencing, diluted library is washed 
over a flow cell for low density binding to be followed by cluster generation. It is 
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inevitable that during this process, some molecules will not bind and be washed out. For 
most purposes, this is acceptable as there are generally many copies of the molecule. If an 
Ig-seq library has extremely high diversity, the loss of these molecules may lead to 
skewed output. Variability in the read output counts obtained from any given sample pose 
the same problem of potential fragmentation of sample coverage.  
The potential for undercoverage of sampling is also shared in more upstream steps 
as samples are continuously aliquoted. For instance, if a 40µL cDNA library approaches 
near complete heterogeneity, it would be impossible to capture this if a 20µL aliquot is 
used for the next step, PCR amplification. Half of the unique molecules will never be 
used. In this hypothetical example, qualitative readout will be skewed, meaning that 
many B cell clonal families that exist in the sample and biological population will not and 
cannot be observed. 
Our rarefaction analysis of our Ig-seq libraries revealed that the total repertoire 
doesn’t approach complete coverage even with dozens of deep sequenced libraries. While 
the slope of plasmablast and IgG+ IgVRG suggest that they may be more readily covered 
than naïve and memory B cells, the data suggest that the biological population is likely to 
have many more clones in these subpopulations. We are particularly concerned about the 
relative loss of clonal coverage and capture inefficiency in UID-tagged data. The 
rarefaction results are consistent with our observation that UID-tagged libraries have a 
lower percent of raw reads pass through analysis to computational clonal assignment. 
These data suggest that there is a methodological inefficiency in this approach as opposed 
to untagged library preparation.  
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In addition to biological variation, we investigated technical errors that might 
result in biased counts. During PCR, random error may occur as the molecular count 
increases. It is generally assumed in RNA-seq that all molecules have an equal 
probability of primer annealing and extension. This is, of course, more nuanced, as 
amplification is affected by nucleotide composition as well as systematic and random 
effects. This effect can clearly be seen in Figure 3.9; in a perfect amplification scenario, 
all observed UIDs would have the same number of observed sequences, whether it be 1 
or 1 million. Instead, we observed a bimodal distribution. The presence of two 
distributions suggests that samples populating them were either derived from different 
sources, or were subject to technical error. As these distributions are consistent between 
subjects (and thus independent samples), it is likely that the observed effect is technical. 
In particular, the normally distributed population, which has very high raw read counts in 
comparison to their UID counts, are an excellent candidate to represent PCR over-
amplification.  While this count bias is resolved by UIDs, this method is not always 
feasible, nor is UID-tagged data always available. 
Untagged high throughput Ig-seq results in more immunoglobulin sequences per 
read than its UID-tagged counterpart, and is particularly valuable for total repertoire or 
non-plasmablast-based questions. One application where maximum Ig-seq output is 
necessary is an emerging body of research concerning the “antibodyome,” or the total 
collection of immunoglobulins in an individual and the public as a whole. This approach 
has been used for data mining to identify candidate broadly neutralizing or otherwise 
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valuable antibodies against HIV (Kwong et al., 2009; Zhu et al., 2013; Williams et al., 
2015). 
In addition, publically available Ig-seq data is not likely to be consistently given 
UIDs until the method is optimized and higher throughput results are common. Historical 
Ig-seq data are also without UIDs, compounding the problem as researchers may not 
consider that read count is a potential source of serious quantitative bias. We 
demonstrated that Ig-seq count values without UIDs can be estimated using a model 
developed from a UID-tagged dataset. This normalization will mitigate the effect of 
random selection and over-amplification during standard library preparation of samples 
for high throughput sequencing.  
During our model development, we used machine learning to determine if our 
UID-tagged data was, in fact, comprised of two identifiable distributions. Random forest 
classification identified two classes of data which were assigned as we would expect for 
our exponential/Gaussian hypothesis. This outcome is valuable for two reasons; first, the 
outcome passes a sanity check when the classes are overlaid over plots of the data, 
suggesting that a random forest approach is an appropriate method to estimate the 
likelihoods and second, our hypothesis that there are two distinct distributions is 
supported by unsupervised machine learning. 
Importantly, when we revisit the source of this data bias, PCR amplification, we 
are reminded that variation in molecular counts is known to arise in part from a jackpot 
effect, where a molecule is selected for replication in an early PCR cycle, increasing the 
probability of future selection in a propagating effect in all subsequent cycles. In this 
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case, we would expect these data to be described by a normal distribution of values with 
high raw read counts relative to their UID count (ratio >> 1). This is precisely what we 
observe using classification of the raw read to UID ratio, affirming that this class of data 
should be considered separately from the reads that display a ratio nearer to 1. When we 
repeat the random forest classification for the raw and total clone counts alone without 
UID input, the classifications poorly describe the data and classes are interspersed. This 
emphasizes the importance of UID tagging in future Ig-seq data collection as this is a 
systematic limit to the accuracy of normalization by modeling.  
Further insight into classification correlates may help refine the model. While we 
were unable to identify one or more correlative variables, it is possible that correlations 
exist and can be exploited. For instance, over-amplification may result in 
disproportionate clone size or read count to clone ratios. In the event that a class 
“surrogate” variable can be identified, data can be pre-processed by stratification, and 
processed by a more optimized and appropriate regression. 
The independent dataset prediction accuracy and variation is highly comparable to 
that from the test set derived from the same dataset source. This suggests that this model 
is applicable with similar, estimable variation and error across any similarly prepared Ig-
seq dataset. Further evaluation may be performed on Ig-seq HTS that is collected from 
subjects with different disease or treatment states, or prepared in a different way, such as 
by using alternate amplification methods or sequencers, to determine if the model is truly 
universal or must be refined per protocol or experiment.  
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The importance of technical and biological replicates in RNA-seq has been well 
documented, though not necessarily well adopted in the field. A common strategy is to 
maximize sequencing depth for single, or even mixed, biological samples (Auer and 
Doerge, 2010; Liu et al., 2014). This necessarily limits the power of these studies, but 
also increases the risk of underrepresentation at the biological level which cannot be 
overcome with even the best normalization and statistics. It is clear that biological 
replicates should be seriously considered and used when at all possible, particularly in an 
era where deep sequencing of >20 million reads is trivial (Liu et al., 2014).  
Technical replicates provide a substantial amount of unique clonal data to our Ig-
seq dataset. This may be due to either very high molecule heterogeneity such that any 
aliquot is essentially a limiting dilution for the next reaction, or by random selection of a 
subset of molecules within the total population. To address both potential concerns, 
technical replicates can be used to both increase the probability that a molecule might be 
randomly selected (e.g. for PCR amplification or flow cell binding), and also to maximize 
the total molecules available. Importantly, when attempting to investigate a question that 
is served by near-total repertoire coverage, preliminary and routine use of technical 
replicates can act to inform that the experiment is designed with appropriate biological 
coverage, and that this coverage is consistent between groups. For instance, if a technical 
replicate includes many novel clones not observed in the original sample, the coverage is 
likely to be too low and additional aliquots from the same sample may be appropriate to 
increase population capture.  
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It is important to note that despite the substantial statistical work that goes into 
even basic analyses of NGS data, sequencing data is often interpreted as either observed 
or unobserved, and the non-observation of data is often conflated with its biological 
absence. It is abundantly clear to us from our replicate study, and particularly its top level 
analysis, that this fallacy is of particular importance to current Ig-seq methods and data 
interpretation. While NGS platforms offer unprecedented depth of sample analysis, the 
diversity of the immunoglobulin repertoire still overwhelms its capacity. 
We would like to acknowledge an unexpected challenge encountered during UID-
tagging methods development. In our hands, we were unable to produce consistent Ig-seq 
output using a UID at the 5’ end (on IGHJ gene primers), and were limited to a single 10 
nucleotide UID on the 3’ end. While this is theoretically sufficient for unique labels of 
the Ig-repertoire (1,048,576 combinations), our data strongly suggests that the 10 
“random” nucleotide sequence provided by the primer manufacturer is not random. While 
this may be resolved in the future by an additional clustering step during consensus 
calling, it seems more prudent to instead increase the number of random nucleotides or 
optimize a protocol whereby a second UID may be added to the opposite end. While the 
latter option is likely to better resolve this, it brings its own challenge of the length of the 
sequenced fragment. While the Illumina 300 PE kit is theoretically more than able to 
cover the entire IgVRG length, the mean lengths of high quality output follow a bimodal 
distribution between full length and partial (~200 V nucleotides) IgVRG sequences, thus 
limiting extraneous nucleotides is important in improving the probability of true, full 
length sequences.   
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Supplemental Material 
A) 
 
B) 
 
C) 
 
 
Figure S3.1. Example Phred quality score analyses for raw, 2x300bp MiSeq runs. 
Raw, 2x300bp FASTQ immunoglobulin sequencing data following AVA immunization 
were analyzed for quality using PRINSEQ, and quality score descriptive statistics were 
calculated per binned nucleotide position. Quality scores are calculated as:  
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𝑄 = −10𝑙𝑜𝑔10𝑃, where Q is the quality score and P is the probability of an erroneous 
call per base. Figures on the left are from read 1, and figures on the right are read 2. Each 
is a representative example of an individually prepared library with A) good, B) moderate 
and C) poor read 2 quality.  
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Figure S3.2. Quality score analysis for joined reads passing quality filtering. 
Raw, 2x300bp FASTQ Ig-seq data following AVA immunization were filtered for mean 
quality over Q25, joined with optimized FLASH parameter, and all adaptor and 
identifying tag information trimmed. The remaining 9,350,502 sequences were analyzed 
for quality through PRINSEQ, and quality score descriptive statistics were calculated per 
binned nucleotide position. FLASH joining results in per-base quality scores that are 
assigned to the higher single value in a match, and a value of 2 for any mismatch. 
Therefore the actual quality score values shown are not necessarily indicative of true 
confidence, but a regional decrease is indicative of a higher proportion of mismatches.  
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Figure S3.3. Q-Q plot of unique proportions of clones observed from raw Ig-seq. 
Biological and technical replicate blood samples from two volunteers were analyzed to 
determine the proportion of clones only observed in a single subject-replicate as 
described in Figure 3.4. Unique proportion values per subject-replicate were fit into a 
simple, linear ANOVA model, and a quantile-quantile plot against standard residuals was 
made to determine if the Ig seq data used for the ANOVA model and post hoc tests is 
normally distributed. 
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 Chi-sq df p-value 
Blood 3.6973 1 0.0545 
RNA 2.0861 1 0.1486 
cDNA 2.7889 1 0.0949 
PCR1 1.9823 1 0.1591 
PCR2 0.8643 1 0.3525 
Seq 3.4769 1 0.0622 
 
Table S3.1. Fligner-Killeen Test of Homogeneity of Variances for raw Ig-seq. 
Biological and technical replicate blood samples from two volunteers were analyzed to 
determine the proportion of clones only observed in a single subject-replicate as 
described in Figure 3.4. Fligner-Killeen Tests were performed in R to determine if 
variance between factors is significantly different. The significance level was set at 0.05. 
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A) 
 Clones Shared Unique Population 
Branch Mean Std. dev 
Blood 0.1393 0.8607 0.0443 
RNA 0.4255 0.5745 0.2772 
cDNA 0.1511 0.8489 0.1302 
PCR1 0.2915 0.7085 0.1412 
PCR2 0.1997 0.8003 0.0994 
Sequencing 0.574 0.426 0.2608 
 
B) 
Counts  Shared Unique Population 
 Branch Mean Std. dev 
Blood 0.2915 0.7085 0.1062 
RNA 0.6223 0.3777 0.3465 
cDNA 0.2951 0.7049 0.2049 
PCR1 0.3854 0.6146 0.2204 
PCR2 0.4629 0.5371 0.3818 
Sequencing 0.8796 0.1204 0.099 
 
Table S3.2. Summary of unique and shared clonal observations in biological and 
technical replicates. 
Biological and technical replicate blood samples from two volunteers were analyzed to 
determine the proportion of clones only observed in a single subject-replicate as 
described in Figure 3.4. Summary statistics are shown describing the mean proportion of 
unique A) clones and B) sequence counts comprising those clones between replicates at 
the given library preparation and sequencing steps.  
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Figure S3.4. Interactions between pairwise steps during Ig-seq library preparation 
and sequencing. 
Biological and technical replicate blood samples from two volunteers were analyzed to 
determine the proportion of clones only observed in a single subject-replicate as 
described in Figure 3.4. Mean unique clone proportions were analyzed for potential 
interaction between all factors with appropriate sample combinations in R. For each 
comparison, solid lines (1) and dashed lines (0) represent samples that were and were not 
replicates at the step indicated, respectively. Parallel lines are not likely to interact, non-
parallel but non-crossing lines may interact given sufficient statistical power and crossing 
lines interact.  
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A)  
 
B) 
 
C) 
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Figure S3.5. UID consensus Ig-seq data exploration. 
Biological and technical replicate blood samples from two volunteers were processed and 
the immunoglobulin variable region sequenced. UID consensus sequences from the 
replicate study were estimated using Cloanalyst. The Ig-seq data were then analyzed to 
determine the proportion of clones only observed in a single subject-replicate as 
described in Figure 3.4. A) Unique proportion values per subject-replicate were fit into a 
simple, linear ANOVA model, and a quantile-quantile plot against standard residuals was 
made to determine if the Ig seq data used for the ANOVA model and post hoc tests is 
normally distributed. B) Side-by-side boxplots of the proportion of unique clones by 
factor. A value of 1.00 indicates that all clones in a sample are unique and were not 
observed in its analogous replicate. A value of 0 indicates that all clones in a sample were 
observed in its analogous replicate. Horizontal lines represent the median value, and 
vertical lines, the interquartile range. C) Mean unique clone proportions were analyzed 
for potential interaction between all factors with appropriate sample combinations in R. 
For each comparison, solid lines (1) and dashed lines (0) represent samples that were and 
were not replicates at the step indicated, respectively. Parallel lines are not likely to 
interact, non-parallel but non-crossing lines may interact given sufficient statistical power 
and crossing lines interact.  
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A) 
UID Chi-sq df p-value 
Blood 3.7 1 0.05 
RNA 3.86 1 0.05 
cDNA 1.02 1 0.31 
PCR1 0.13 1 0.71 
PCR2 1.38 1 0.24 
Seq 3.46 1 0.06 
 
B) 
Clones Shared Unique Population 
Branch Mean Std. dev 
Sequencing 0.4202 0.5798 0.2794 
PCR2 0.2092 0.7908 0.1090 
PCR1 0.5582 0.4418 0.1791 
cDNA 0.1550 0.8450 0.1367 
RNA 0.4502 0.5498 0.3031 
Blood 0.1413 0.8587 0.0476 
 
C) 
Counts Shared Unique Population 
Branch Mean Std. dev 
Sequencing 0.6460 0.3540 0.2767 
PCR2 0.3698 0.6302 0.1676 
PCR1 0.7225 0.2775 0.1228 
cDNA 0.4439 0.5561 0.2659 
RNA 0.6423 0.3577 0.3124 
Blood 0.4731 0.5269 0.1015 
 
Table S3.3. UID consensus Ig-seq data exploration. 
Biological and technical replicate blood samples from two volunteers were processed and 
the immunoglobulin variable region sequenced. UID consensus sequences from the 
replicate study were estimated using Cloanalyst. The Ig-seq data were then analyzed to 
determine the proportion of clones only observed in a single subject-replicate as 
described in Figure 3.4. A) Fligner-Killeen Tests were performed in R to determine if 
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variance between factors is significantly different (α=0.05). Summary statistics are shown 
describing the mean proportion of unique A) clones and B) sequence counts comprising 
those clones between replicates at the given library preparation and sequencing steps. 
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Library UID 
Raw 
count 
Ig 
count 
Percent Ig of 
raw 
AVA_A No 20261972 290873 1.44 
AVA_B No 20921229 283726 1.36 
AVA_C No 21482625 235259 1.10 
AVA_D No 11982100 321895 2.69 
AVA_E No 21607917 125895 0.58 
AVA_F No 20399940 113664 0.56 
AVA_G No 20398226 746038 3.66 
AVA_H No 22913177 111913 0.49 
AVA_I No 22498652 169973 0.76 
AVA_J No 19445695 57208 0.29 
AVA_K Yes 20928384 191729 0.92 
AVA_L Yes 23632008 205439 0.87 
AVA_M Yes 19667947 42080 0.21 
AVA_N Yes 11933486 118000 0.99 
AVA_O Yes 15264460 117964 0.77 
AVA_P Yes 14569396 197551 1.36 
AVA_Q Yes 18007079 54419 0.30 
AVA_R Yes 20085388 7095 0.04 
AVA_S Yes 20174736 29548 0.15 
AVA_T Yes 19395580 34626 0.18 
AVA_U Yes 19990265 18650 0.09 
AVA_V Yes 8278230 25922 0.31 
AVA_W Yes 18268438 13571 0.07 
Var_A Yes 17302565 96044 0.56 
 
Table S3.4. Total raw reads and immunoglobulin output for all sequencing runs. 
MiSeq 2x300bp sequencing of 24 UID-tagged and untagged Ig-seq libraries was 
performed by the Vanderbilt VANTAGE core. Raw, paired-end reads were counted per 
library, and processed data were analyzed for immunoglobulin content. 
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A) 
 
B) 
 
C) 
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Figure S3.6. Rarefaction assessment to estimate immunoglobulin coverage per 
library preparation method. 
Ig-seq datasets were randomly sampled at increasing sequence counts and the number of 
clones per subsample was inferred by Cloanalyst. A) HTS Ig-seq without UID tagging, 
B) UID-tagged, but non-consensus called sequences and C) UID-tagged, consensus 
called sequences from the same dataset in B. The subsample sequence intervals were 
calculated to be increasing amounts of ~1/6 the total sequence number from either UID-
tagged, non-consensus sequences (A and B), or UID-tagged, consensus sequences (C). 
Subsets of the total datasets (All) by B cell isotype (IgM+ and IgG+) and subset (naïve, 
memory and plasmablast) were analyzed separately. The red line represents a 1:1 
diagonal for comparison. 
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A) 
 
B) 
 
C) 
 
  
150 
Figure S3.7. Modeled and real data distributions to determine initial values for 
random forest classification. 
Two potential predictor variables, A) raw read count per clone-subject-visit and B) total 
raw read count per clone count per clone-subject and one comparison value C) raw-UID 
ratio (the count of raw sequences per UID), were log10 normalized and their distributions 
matched for acceptable fits using standard MATLAB distributions. Observed data is 
shown in orange and is overlaid with model distributions in blue. For all data types, a best 
fit was achieved with an exponential (left) and normal (right) distribution. Optimal cutoff 
values for each distribution were used as starting values for machine learning. 
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A) 
 
B) 
 
Figure S3.8. Correlation analyses for class predictors. 
UID-tagged, non-consensus sequences from the AVA study passing quality control and 
clonal assignment (as described in Figure 3.9) were sorted by subject, visit and clone. 
Raw read counts per subject-visit-clone were log10 normalized (raw count) and compared 
to the raw-UID ratio (sequence count pet UID) for each subject-visit-clone. MATLAB 
Treebagger was used to estimate to which unique distribution each value belongs, called 
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“class,” as in Figure 3.12B. Additional quantitative variables associated with these data 
were then tested for correlation to this classification. A) Individual variables were tested 
for correlation to distribution classification (class) in R. The size of the circle and color 
intensity are proportional to the correlation coefficients. B) Potential class correlates were 
used for unsupervised PCA and the output colored by assigned classification. Arrows 
indicate the directional influence of data subclasses, and the circles are data within 95% 
confidence intervals for the given classes.  
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Figure S3.9. Random forest regression prediction with classification. 
Random forest classification was performed on the training set as in Figure 3.12, and 
classes were assigned per data point. Random forest regressions were then independently 
run independently of data assigned to A) class 1 and B) class 2, without UID-count 
knowledge and used to predict raw-UID ratios as in Figure 3.14. The solid red line 
represents the regression and the dashed lines are 95% CI. Regression slope, CI values, 
adjusted R2 and root-mean-square error are included per regression. 
 
  
154 
CHAPTER FOUR: HIGH THROUGHPUT IMMUNOGLOBULIN REPERTOIRE 
SEQUENCING FOLLOWING ANTHRAX VACCINE ADSORBED 
IMMUNIZATION REVEALS POTENTIAL CLONAL CORRELATES OF THE 
VACCINE RESPONSE 
 Rationale 
Vaccination is the most successful medical intervention in history. Advancements 
in the understanding of immunology, such as the discovery and description of antibodies 
(Behring and Kitasato, 1890) and antitoxins, and more efficient methods of attenuation 
(Woodruff and Goodpasture, 1931; Enders et al., 1949) led to a boom in vaccine 
development in the mid-20th century. These vaccines were developed empirically, and a 
number of diseases with high health burdens, such as diphtheria, measles and mumps 
were diminished upon the dissemination of their respective vaccinations (Centers for 
Disease and Prevention, 1999). Today, there is extensive knowledge of and active 
research into the mechanisms of immunological responses to infection, pathogen biology 
and virology. Despite this, the development of efficacious vaccines against some diseases 
such as HIV/AIDS, malaria and Lyme disease has proven difficult, and will require new 
approaches (Rappuoli and Aderem, 2011). Furthermore, no vaccine is perfect; most 
require multiple doses, do not provide lifelong protection, and no vaccine is 100% 
efficacious in all people. 
One outstanding question in vaccine development is in understanding the 
correlates of vaccine protection, that is, what measurable molecular parameters are 
associated with an efficacious vaccine response in different populations (Pulendran et al., 
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2010). Routine vaccinations elicit protection through a humoral, antigen-specific 
response. Functional assays, such as antibody titration and neutralization assays are 
useful in understanding the kinetics and efficacy of vaccinations, but do not provide 
much value for rational design of improved or new antigens. With knowledge of the 
correlates of protection of vaccination in humans, it is possible that new approaches may 
be developed to better target the elicitation of these responses. This could lead to more 
efficient screening of novel vaccine candidates given knowledge of protection-correlated 
outcomes. In addition, prior knowledge of host factors that predict a protective response 
may be used to stratify vaccinees for personalized medicine (Kuri-Cervantes et al., 2016). 
AVA is a homologous prime-boost immunization, which elicits a humoral 
response against Bacillus anthracis Protective Antigen, the primary component of 
anthrax toxin (Smith and Keppie, 1954; Sawada-Hirai et al., 2004; Pittman et al., 2006; 
Reason et al., 2008). PA titers correlated to protection in animal models are regularly 
observed following the 3rd dose, which is administered at 6 months (Pitt et al., 2001; 
Little et al., 2004; Pittman et al., 2006). While AVA efficacy is estimated to be 92.5% 
(Smith and Keppie, 1954), it is not an efficient vaccine; the full schedule includes 5 doses 
over 18 months, and must be maintained with annual boosters. These are clear 
disadvantages and improvement of the vaccine is of interest to stakeholders.  
We investigated the potential use of discrete IgVRG correlates to the production 
of antibody responses that may be visible by high throughput immunoglobulin repertoire 
sequencing (Ig-seq). In particular, we are interested in these data at clonal resolution. 
While functional assays are effective at understanding antigen-specific and affinity 
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matured antibodies, the lifespan of the B cells producing these antibodies begins with low 
affinity, naïve IgVRG, and may include a variety of B cell subsets and antibody isotypes. 
Understanding the development of clones within the repertoire may reveal discrete 
characteristics of vaccine-responding versus baseline clonal lineages. Furthermore, it is 
possible that homologous prime-boost vaccines may share features of their clonal 
development, and potential signals of AVA clonal correlates may be applicable to more 
routine immunizations. Ig-seq allows the capture of a broad variety of IgVRG, and our 
approach includes the separate preparation of different B cell subsets and isotypes for 
deeper analysis.  
In this study, we enrolled six healthy subjects for AVA immunization. Four 
subjects completed the five-dose series and two dropped out for unrelated reasons prior to 
the 4th dose. Blood samples were collected on the days of, and one and two weeks 
following each immunization (Illustration 2.1). Peripheral blood mononuclear cells 
(PBMC) were isolated, and naïve, memory and plasmablast B cells were sorted. From 
these B cell subsets, isotype-specific IgVRG were sequenced using Illumina platform 
technology. Both UID-tagged and untagged IgVRG are included in this study. We 
analyzed the data for both individual and clonal characteristics as measured by genetic 
composition and proportional representation. 
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Results 
4.1 Memory B cells and plasmablasts do not increase until following 3rd and 4th 
immunizations. 
 Following an event causing inflammation, such as natural infection or 
immunization, it is common to observe an increase in effector B cells, particularly 
plasmablasts. Blood samples from six volunteers was collected on the day of, as well as 
one and two weeks post-immunization with BioThrax®, an anthrax vaccine. We 
performed fluorescence-activated cell sorting (FACS) of total peripheral blood 
mononuclear cells (PBMC) to isolate cells expressing markers associated with naïve, 
memory and plasmablast B cell subsets (Figure 4.1, Figure S4.1). 
 As expected, naïve B cells make up the bulk of PBMC, followed by memory B 
cells and distantly followed by plasmablasts, which are known to make up a very small 
proportion of PBMC (Mei et al., 2009). There is a trend of negative correlation between 
naïve and plasmablast counts, and the memory B cell pattern is similar to plasmablasts, 
though neither is perfectly consistent. We performed paired, one-tail t-tests of all samples 
versus week 0, pre-immune values, as well as sequential visit-to-visit tests. We were 
surprised to find that even with the less statistically rigorous, one-tail test, there is no 
significant increase in plasmablasts from the pre-immune repertoire. In fact, the only time 
points tested that show an increase in plasmablasts are from week 26 to 27, the day of and 
one week following the third immunization (p<0.05). The memory population was also 
relatively stable, increasing from weeks 0 and 53 to week 54 (2 weeks post-fourth dose; 
week 0 to 54, p<0.05; week 53 to 54, p<0.005).   
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Figure 4.1. B cell counts of total peripheral blood mononuclear cells (PBMC) before 
and after Anthrax Vaccine Adsorbed (AVA) immunization. 
Blood samples were collected from six subjects prior to and following AVA vaccination 
and PBMC was isolated and processed for fluorescence-activated cell sorting (FACS) as 
described in “Materials and Methods: Anthrax Vaccine Adsorbed.” Cells were stained to 
tag B cell subsets, and the proportion of these subsets was calculated per 100,000 
observed events (Naïve, green; memory, orange; and plasmablast, purple). The mean 
subset proportion was calculated between subjects. The red shaded areas indicate the 
sampling period per vaccination (Day of and 1- and 2- weeks post-vaccination). Vertical 
lines represent the standard error of the mean between subjects. Paired, one-tail t-tests 
were performed at α=0.05. *: p<0.05; **: p<0.005. 
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4.2 There is no observable change in repertoire IgVRG mutation frequencies following 
AVA immunization. 
Upon primary antigen exposure, we expect that naïve B cells will be activated and 
elicit an early response comprised of IgVRG with low mutation frequencies. Any effector 
plasmablast or memory B cell that is elicited by vaccination from a naïve source will be 
unable to acquire many mutations within 7 days. We expect that B cells with low 
mutation frequencies are indicative of a primary response, though it is of course possible 
for previously affinity matured B cells to retain low mutation frequencies. In contrast, B 
cells with higher mutation frequencies are definitively not from a naive response initiated 
1-2 weeks earlier. 
UID-tagging corrects many nucleotide errors from library preparation and 
sequencing, as discussed in chapter one, so we will use only UID-consensus sequences 
here. We first looked at the overall mean mutation frequency and standard deviation per 
subject to get an idea of if and how the populations shift (Figure 4.2). It is apparent that 
any antigen-specific output may be obfuscated by the high standard deviation within 
subject populations, as well as the variability between subjects. We therefore expanded 
our analysis to consider the distribution of these data, as expressed by cumulative 
proportion (Figure 4.3). Here, we focus on samples one week-post immunization, and 
week 0 for comparison (All time points shown in Figure S4.2). Vaccine kinetics research 
suggest these are appropriate time points to observe potential vaccine-induced IgVRG 
(Cox et al., 1994; Galson et al., 2015a).  
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As before, there is no consistent signal between subjects following vaccination by 
this metric. In fact, by this method of data collection, there is often no shift even from the 
pre-immune repertoire. This suggests that observations at the total repertoire level may 
add too much noise to the vaccine-elicited “signal” output. It is interesting to note that 
neither the memory nor plasmablast populations have a time point that stands out as 
shifting left, towards a higher proportion of low mutation frequency IgVRGs, as would 
be expected with a primary, naïve B cell driven response. 
One way we might minimize repertoire noise is by focusing on clones, and more 
specifically, the first observed appearance of differentiated subsets in each clone. For 
instance, soon after exposure to a neo-antigen, response-specific memory and 
plasmablasts will have low mutation frequencies, assuming they are not polyreactive and 
have been previously affinity matured to another antigen. We measured the mean 
mutation frequency of memory B cells and plasmablasts upon their first observation per 
estimated clone (Figure 4.4). The memory B cell population did not shift until, 
surprisingly, one week after the fifth vaccination, in which all available subjects’ data 
show a consistent response to a lower mutation frequency phenotype. Unfortunately, 
there are few clones that have early appearing plasmablasts in this dataset, but those that 
are observed do not have strong representation by low mutation frequency IgVRG. In 
fact, the only observed instance where the population shifts left is in subject 5 following 
the 3rd vaccination. As vaccine-specific antibodies are being produced by the 2nd 
vaccination (Pittman et al., 2006), this approach also does not correlate to functional 
outcomes at this level of data collection.  
  
161 
A) 
 
B) 
 
Figure 4.2. Mutation frequencies of memory and plasmablast immunoglobulin 
variable region genes (IgVRG) over time. 
UID-tagged Ig-seq libraries from six subjects before and following AVA vaccination 
were analyzed as described in “Materials and Methods: Anthrax Vaccine Adsorbed.” 
UID-consensus sequences that were successfully assigned into clones were sorted by A) 
memory and B) plasmablast subsets. The mutation frequency for each IgVRG was 
estimated by Cloanalyst, and the mean (point) and standard deviation (error bar) 
calculated per subject.  
  
162 
A) 
 
B) 
 
C) 
 
 
Figure 4.3. Cumulative substitution frequencies before and after AVA 
immunization. 
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UID-tagged Ig-seq libraries from five subjects (no data for subject 4 for included weeks) 
before and following AVA vaccination were analyzed as described in “Materials and 
Methods: Anthrax Vaccine Adsorbed.” UID-consensus sequences that were successfully 
assigned into clones were sorted by A) all subsets, B) memory B cells and C) 
plasmablasts. The mutation frequency for each IgVRG was estimated by Cloanalyst and 
the total mutation frequency values were plotted as cumulative proportions, separated by 
week of observation.  
   
  
164 
A) 
 
B) 
 
Figure 4.4. Distribution of mutation frequency in the earliest observed differentiated 
B cells by clone. 
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UID-tagged Ig-seq libraries from five subjects (no data for subject 4 for included weeks) 
before and following AVA vaccination were analyzed as described in “Materials and 
Methods: Anthrax Vaccine Adsorbed.” Clones were sorted by the week of first 
observation, and only UID-consensus sequences from this time point per clone were 
included. Each distribution represents the mutation frequency or mean mutation 
frequency for clones with >1 sequence, of the earliest observed A) memory B cell and B) 
plasmablast members of all clones by subject (rows, S1-6) and week (columns). 
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4.3 IgVRG CDR3 lengths do not change following any AVA administration. 
 One measurement that has been seen to change following other immunizations is 
the length of the CDR3 (Galson et al., 2015a; Truck et al., 2015). This region is more 
prone to somatic hypermutation and insertions, thus affinity maturation can lead to a 
change in CDR3 size, particularly as an increase in nucleotides. Population-level changes 
may also indicate active clonal selection, as a few clones may expand resulting in h 
proportional representation. We measured the distribution of CDR3 length by clone-time 
point and saw no movement from baseline following any vaccination in five of six 
subjects (Figure 4.5). The same effect is seen when the data is stratified by B cell subset. 
Subject 6 shows a more variable CDR3 population in general, including very long 
CDR3s that are likely a technical error. At least for AVA, CDR3 length is not likely to be 
a valuable correlate of the vaccine response. 
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Figure 4.5. Density distribution of clone CDR3 lengths by week. 
UID-tagged Ig-seq libraries from six subjects before and following AVA vaccination 
were analyzed as described in “Materials and Methods: Anthrax Vaccine Adsorbed.” 
Cloanalyst-estimated B cell clones were sorted by the week of observation, and the mean 
CDR3 length in nucleotides calculated for each clone-week. CDR3 length was estimated 
by Cloanalyst. The distribution of the CDR3 lengths is shown as population density per 
subject. 
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4.4 Clones do not proliferate or persist following AVA immunization. 
 Following efficacious vaccination, antigen-specific clones undergo selection and 
dynamic proliferation (Pinna et al., 2009; Laserson et al., 2014). We analyzed the UID-
consensus Ig-seq data set by comparing the mean and distribution of observed clone sizes 
by the number of member sequences. Clone size was first scaled to the proportional 
representation per week between subjects to account for different overall sequence 
counts. Then the mean clone size was calculated per subject-week (Figure 4.6). Despite 
the number of repeated immunization and the visual appearance of an upward trend 
following immunization, there was no significant change in clone size between the pre-
immune repertoire and any observed thereafter. A major contributor to this is the high 
variation we see between subject means, as can be inferred by the elongated boxplots at 
some time points. As there is a different representation of subject data available at each 
time point, paired t-tests are not appropriate, so while it is possible there are consistent 
changes within individuals, we cannot perform those tests this using these data. 
 Given the quantity and diversity of Ig-seq data, we then asked if the distribution 
of clone sizes changed between weeks. Histograms of the direct count data appeared to 
regularly shift (Figure S4.3), so we focused on the pre-immune versus one-week post-
immunization samples. Smoothed density plots of the clonal proportion counts were 
scaled to 1 and overlaid to compare the distributions (Figure 4.7, Figure S4.4). The weeks 
following 1st and 2nd immunization show a good fit, as do those following the 4th and 5th. 
From these data, it appears that clone size begins at a relative maximum prior to 
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immunization, then contract to a minimum following the 3rd immunization, after which 
they trend back towards pre-immune levels. 
 Thus far, we have only looked at averaged and somewhat abstracted data output 
to understand clonal dynamics. To get a better picture of the repertoire, we plotted the 
lifespan of all observed clones measured as a proportion of the total clones per time point 
(Figure 4.8). It is clear that despite the patterns of clonal size distribution and trends of 
increasing size over time, the immunoglobulin repertoire is highly dynamic and transient. 
The most striking outcome in light of the vaccination schedule is a lack of clonal 
expansion and persistence following the third vaccination, when vaccine recipients are 
considered protected. Another interesting point is the observation of a persistent, large 
clone from subject 6, seen prior to and following immunizations. We further investigated 
this clone and found that it has a high mean mutation frequency (10.4%) that does not 
change over time (max: 10.8%, min: 10.3%), with a large, 63 nucleotide CDR3.  
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Figure 4.6. Mean clone size prior to and following AVA immunization. 
UID-tagged Ig-seq libraries from six subjects before and following AVA vaccination 
were analyzed as described in “Materials and Methods: Anthrax Vaccine Adsorbed.” For 
all subject-weeks, the mean value of all clone proportions of the total count were 
calculated. Standard boxplots are comprised of the per-subject mean values by week. 
Arrows indicate dates of AVA vaccination. 
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Figure 4.7. The distribution of clone sizes before and one-week following AVA 
immunizations.  
UID-tagged Ig-seq libraries from five subjects (no subject 4 data for included weeks) 
before and following AVA vaccination were analyzed as described in “Materials and 
Methods: Anthrax Vaccine Adsorbed.” For the day of primary vaccination and one week 
after all vaccinations, the value of each clone proportion of the total count per subject-
week were calculated. The proportional density of the combined values is shown as 
distributions sorted by week of observation. 
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Figure 4.8. The immunoglobulin repertoire is highly diverse and transient before 
and after AVA immunization. 
UID-tagged Ig-seq libraries from five subjects before and following AVA vaccination 
were analyzed as described in “Materials and Methods: Anthrax Vaccine Adsorbed.” 
UID-consensus sequences were counted per clone and the fractional proportion of the 
total clonal repertoire calculated per week. Each stacked, colored area represents a single 
observed clone. This is most clearly represented in subject 6 during weeks 0-29 where a 
single clone, represented by a dark green, makes up ~25% of all observed Ig at week 0, 
and is seen with variable representation through week 29. Note that not all weeks were 
covered in all subjects in this dataset (See Table S1.1 for a list of subject-weeks with 
included data). Subject four only had data available for a single visit, and thus did not 
have continuous data appropriate for this analysis.  
  
  
173 
4.5 B cell subset-specific IgVRG reveals dynamic clonal lineages and delayed elicitation 
of potential vaccine response correlates. 
 The lifespan of a clonal lineage is often generalized as beginning with a naïve B 
cell that, following specific antigen exposure, enters secondary lymphoid tissue, where it 
proliferates and differentiates into short lived plasmablasts, then antigen-specific memory 
B cells and plasmablasts. However, the clonal kinetics we previously observed show a 
highly diverse population that may not so neatly conform. To understand how clones 
change their composition over time, we looked at the subset composition of all observed 
clones in the high throughput Ig-seq data over the full time course (Figure 4.9). Each row 
represents an individual clone, and the colors represent the presence of naïve, memory, 
plasmablast B cells or any combination thereof at each time point.  
As we already saw in Figure 4.8, the majority of clones are transient and do not 
persist. However, those that do persist do not neatly cluster, instead, they show a diverse 
range of subset outcomes. In particular, there appears to be a persistent population of 
clones prior to immunization comprised of memory and plasmablast B cells. These 
clones regularly shift in their composite subsets, and this pattern is common in all six 
subjects (Figure S4.5). A second population of more persistent clones also first appears 
following the 2nd immunization, at weeks 5 and 6. As with the persistent baseline 
population, there is not a consistent shift to memory B cells or plasmablasts, but a 
dynamic composition. This pattern is conspicuously not seen following the 3rd 
immunization, but persistent clones appear again upon subsequent vaccinations.  
  
174 
 While naïve cells make up the bulk of the B cell peripheral population, they do 
not produce nearly as much immunoglobulin mRNA as active effector plasmablasts. It is 
possible that despite the lack of an increase in the cellular population, we may observe 
vaccine-induced effects in the overall quantity of IgVRGs observed which are derived 
from distinct B cell subsets. To increase our overall study coverage, we used model-
estimated UID counts from our high throughput Ig-seq, which had successful data 
collection from all subject-time points. We then calculated the proportion of observed 
subset-specific IgVRGs (Figure 4.10). When we average the proportional representation 
of all subjects, it is tempting to think that plasmablast IgVRG sequentially increases after 
the first two vaccinations, but, in fact, paired t-tests do not reach significance from pre-
immune values until two weeks following secondary vaccination. This indicates that 
though the overall trend appears to be plasmablast growth, the relative values for each 
subject do not consistently increase until week 6. 
 We then asked if the isotypes of IgVRG change within these B cell subsets 
(Figure 4.11). IgM constitutes the primary early responding class of antibodies on antigen 
exposure, before class switch recombination occurs (Alberts et al., 2002). As expected, 
naïve B cells are always primarily IgM+, and the proportion that is IgG+ indicates a 
source of error, either in cell sorting, non-specific binding of the IgG+ primer, 
contamination or otherwise. Contrary to expectations, IgM+ IgVRG from either memory 
or plasmablast populations do not increase following either primary or secondary 
vaccination. In fact, the proportion of IgM+ IgVRG from memory B cells never 
significantly changes from the week 0 baseline proportion (Figure S4.6). The plasmablast 
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population may better represent the antigen-specific response, and we observe an increase 
in IgM+ IgVRG in this subset late in the schedule, following 3rd and 4th vaccination. If 
IgM+ IgVRG here does represent the initial antigen-specific response, it is severely 
delayed.  
This analysis is focused on bulk IgVRG mRNA which does not necessarily 
correspond to either antigen-specific or expressed immunoglobulin. Thus, we further 
performed enzyme-linked immunosorbent assays (ELISA) against Protective Antigen 
using capture antibodies against IgM and IgG (Figure 4.12). Here, the effective IgM+ 
antibody response appears to rarely make consistent changes, though there is a slight 
increase following 2nd immunization, as 5 of the 6 subjects relative signal increases. As 
expected, the IgG+ population signal increases following vaccination, indicative of a 
mature, specific response. 
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Figure 4.9. B cell subsets within clones in total high throughput Ig-seq. 
All IgVRG data from high throughput sequencing were analyzed for clonal subset 
composition. Each row represents a single, estimated clone, and columns, each week of 
the AVA vaccination study. The tile color represents the B cell subset(s) observed within 
that clone at that time point. Estimated clones were organized by week of first 
observation and clustered by the B cell subset(s) observed in that clone by time point. 
Immunization time points are in red text. (B cell subsets: N, naïve; M, memory; P, 
plasmablast; N+M, naïve and memory; N+P, naïve and plasmablast; M+P, memory and 
plasmablast; N+M+P, naïve, memory and plasmablast.) 
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Figure 4.10. Plasmablasts, then memory B cells increase in the IgVRG repertoire 
following AVA immunization.  
Non-UID-tagged Ig-seq libraries from six subjects before and following AVA 
vaccination were analyzed as described in “Materials and Methods: Anthrax Vaccine 
Adsorbed.” Model-estimated UID counts from were calculated as described in Chapter 
3.7, and the proportion of B cell subsets comprising each clone was calculated. Clone-
subset values were then scaled using the total number of estimated UIDs per visit for 
comparison between subjects. Error bars represent the standard error of the mean 
between subjects. The significance level was set at 0.05.  
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Figure 4.11. Isotype composition of IgVRG before and after AVA immunization. 
Non-UID-tagged Ig-seq libraries from six subjects before and following AVA 
vaccination were analyzed as described in “Materials and Methods: Anthrax Vaccine 
Adsorbed.” Model-estimated UID counts from were calculated as described in Chapter 
3.7, and the proportion of IgM versus IgG comprising each clone was calculated. Clone-
subset-isotype values were then scaled using the total number of estimated UIDs per 
subset-visit for comparison between subjects. Plotted is the mean proportional 
composition of isotypes from all six subjects.  
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A) 
 
B) 
 
Figure 4.12. IgM+ and IgG+ Protective Antigen (PA)-specific serum reactivity by 
week.  
Blood samples were collected from six subjects prior to and following AVA vaccination 
and serum was isolated as described in “Materials and Methods: Anthrax Vaccine 
Adsorbed.” ELISAs were performed in triplicate on serially diluted sera using A) IgM+ 
and B) IgG+-specific secondary antibodies. A) There is not a standard anti-PA IgM+ 
antibody available, and relative OD measurements are shown. B) IgG+ antibodies were 
quantified based on standards prepared from a known anti-PA IgG+ mAB (BAP-0105, 
Abcam, Cambridge, MA). Immunizations are indicated by dashed vertical lines. Serum 
samples were tested from the day of and one and two weeks post-immunization.   
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4.6 Gene usage does not suggest robust purifying interclonal selection. 
 One possible signal of a vaccine-specific response in the repertoire is the 
movement towards specific gene segment selection. For instance, if a V gene segment is 
moderately utilized at baseline, but grows to dominate the overall repertoire, then this is 
strong evidence that despite the clonal diversity, antigen-specific selection is occurring. 
Relative gene segment usage over time can be specific to individuals, but it can also be 
common between people when many individuals show selection of the same gene 
segments against the same antigen. This approach helps clarify if there is a “public 
repertoire” that can be exploited for data mining, antibody development or improved 
vaccine design. 
Thus far our efforts to analyze these data have been susceptible to 
overrepresentation of individual clone IgVRG. However, we saw that the overall 
repertoire encodes tremendous diversity. Therefore we will perform this analysis using 
clonal proportions per visit instead of IgVRG. This essentially gives a value of 1 to each 
clone observation per visit. 
 As there are numerous IGHV gene segments to compare, we prepared a row 
clustered heatmap describing the relative changes over time (Figure 4.13). Here, the 
proportional representation per time point for all observed IGHV gene segments are 
averaged between subjects. Subject-specific heatmaps are included in Supplemental 
Material (Figure S4.7-8). It is clear that no individual gene has robust, consistent 
increasing representation in the repertoire following vaccination. This analysis makes it 
clear that only a handful of IGHV gene segments make up the majority of the total 
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repertoire, as there is a large cluster of red, representing very low values. A few of these 
increase somewhat over the time course, such as IGHV3-9, which increases somewhat 
from baseline following the first few immunizations, but then drops off upon boost. A 
similar pattern is seen in IGHV4-39, which is generally present at higher proportions. 
This gene segment increases following the first three immunizations, then drops after the 
late boosts. IGHV3-23 also exhibits an interesting pattern; this is already a highly utilized 
gene segment at baseline, but it impressively increases one week following the second 
vaccination, which is not replicated at any other time point. More consistently 
proportional growth following vaccination can be seen in specific individuals, but no 
effect is shared by all or most subjects. IGHJ gene segment usage does not shift with 
vaccination, and adheres to previously observed, proportional representation (Bagnara et 
al., 2015; Wu et al., 2016).  
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B) 
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Figure 4.13. IGHV and IGHJ gene segment usage of bulk IgVRG through AVA 
vaccination. 
Non-UID-tagged Ig-seq libraries from six subjects before and following AVA 
vaccination were analyzed as described in “Materials and Methods: Anthrax Vaccine 
Adsorbed.” IgVRG sequences were assigned into clones with estimated gene segment 
usage by Cloanalyst. The proportion of A) IGHV and B) IGHJ gene segment usage was 
calculated per clonal observation at all time points, regardless of sequence count. The 
average proportion observed in all six subjects is represented by color, red tiles indicate 
genes with the fewest clones, with increasing values from white to blue. Rows represent 
an IGHV or IGHJ gene segment, and columns, each week of the AVA vaccination study. 
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4.7 A closer inspection of individual clones. 
Thus far, the primary outcome of our analysis of this large-scale dataset is that 
clonal persistence and subset usage late in the overall schedule are potential indicators of 
vaccine responding clones. We took a closer look at a few of these clones, and compared 
them to randomly selected clones to see if there are clear differences at very high 
resolution of IgVRG. We randomly selected 10 clones comprised of full length IgVRG 
with ten or more members. We then randomly selected 10 clones from a subset list of 
candidates for vaccine-specific responses, which were categorized as clones first 
observed at weeks 5 or 6 (post-2nd immunization), that were later observed (week 27 or 
later) for at least one time point as a memory B cell or plasmablast.  
We first prepared clonograms to describe the genetic relationships between the 
sequences and their unmutated common ancestor (UCA) as inferred by Cloanalyst 
(Figure 4.14). Despite having a strict selection criteria, clones from the candidate samples 
look very similar to the random controls. Both exhibit long root branches to the UCA, 
indicating many mutations have been acquired (e.g. S6C4, S5C4). Most clones also show 
intraclonal diversity, as branches break off and move further apart (e.g. S2C4, S5C3). 
We look more specifically at intraclonal diversity over the length of the IgVRG 
by measuring entropy at each nucleotide position in the trimmed and aligned clones 
(Figure 4.15). Despite the similarly branched clonograms, the candidate clones have both 
fewer sites of mismatch nucleotides, and where they exist, a lower magnitude of entropy, 
indicating that they are less diverse than the random control clones. Where the control 
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clones appear to have stronger peaks and valleys, the candidate clone entropy appears 
more randomly dispersed.  
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A) 
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B) 
 
 
 
Figure 4.14. Clonograms of random and candidate clones of the AVA response. 
Clones identified from UID-consensus and untagged data were compiled, and all clones 
with full length IgVRG (>274 identified IGHV gene segment nucleotides) and ten or 
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more sequence members isolated. A) Ten random clones were selected from this dataset 
using a random number generator. B) Candidates for potential vaccine-elicitation were 
required to be first observed at visit 5 or 6, with later observation of memory B cells of 
plasmablasts at week 27 or later. From these data, 10 clones were randomly selected 
using a random number generator. Clonograms were generated in Cloanalyst using 
aligned and trimmed IgVRG nucleotide sequences. Colored branches represent the week 
the given IgVRG was observed, and the B cell subsets are listed per clonogram. Black 
lines indicate the root branch to the UCA. Clones with more than 50 members were 
filtered for duplicates. S5C4 (B) was further randomly down-sampled to 50 sequences 
due to its size. 
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A) 
 
B) 
 
 
Figure 4.15. IgVRG entropy of random versus vaccine-responding candidates 
clones. 
Clones identified from UID-consensus and untagged data were selected as described in 
Figure 4.14 representing A) ten randomly selected clones and B) ten potential vaccine-
responding clones. Clones were aligned to V(D)J segments using Cloanalyst and the 
mean nucleotide entropy calculated in BioEdit. Entropy was calculated as: 
  𝐻(𝑙) = − ∑ 𝑓(𝑏, 𝑙) ∗ (ln(𝑓(𝑏, 𝑙))) 
where 𝐻(𝑙) is the entropy (uncertainty) at position 𝑙, 𝑏 is an observed residue and 𝑓(𝑏, 𝑙) 
is the frequency of observation 𝑏 and position 𝑙 (Hall, 1999). Estimated FR and CDRs are 
shown in an overlay of alternating red and white backgrounds. 
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Discussion 
 In this study, we performed sorting and high throughput IgVRG sequencing of 
bulk naïve, memory and plasmablast B cells prior to and throughout AVA immunization 
to determine if there were molecular or clonal correlates of protection. We found that 
plasmablast populations do not increase following vaccination until the 3rd dose, which 
runs counter to prior observations following other immunizations and natural infections 
which show growth seven days following first exposure (Mei et al., 2009). With prior 
knowledge of B cell activation and affinity maturation, we asked if the mutation 
frequencies of IgVRG shift as a total population following vaccination. We were 
surprised to find that this measurement does not consistently vary by immunization 
status, even when the data are stratified by B cell subset and time point of first 
observation. We similarly investigated CDR3 length, which has been previously 
identified as a potential correlate of vaccination, and found no change over time.  
We then reevaluated the immunoglobulin repertoire at clonal resolution. We 
expected that antigen-specific clones would undergo purifying selection and proliferate. 
Instead, we observed the opposite effect; one week following primary AVA 
administration, clones actually reduce in size, and this trend continues to a nadir one 
week following the 3rd dose, after which clones move back towards baseline values. The 
observable lifetime of clones is also remarkably transient, with most clones measured at 
just a single time point. The repertoire is characterized by tremendous clonal diversity, 
even following vaccinations when an antigen-specific antibody response has already been 
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observed. This diversity extends to the gene segment usage, where proportional shifts in 
IGHV and IGHJ representation appear to be unrelated to immunization status.  
Together these data contribute to our knowledge of why AVA is not an efficient 
vaccine. In theory, the components of AVA should be enough to elicit a robust response 
– both alum and bacterial proteins (from the attenuated B. anthracis filtrate) are in the 
vaccine (Whiting et al., 2004). The lack of a significant increase in the proportion of 
plasmablasts in the periphery until the third vaccination (and never again) points to a 
vaccine formulation that is relatively non-immunogenic. Despite this, a response is 
eventually elicited following the second vaccination. 
One potential sign of the vaccine-induced response is a shift in clone size. This 
shift, however, is somewhat counterintuitive given current knowledge of immune 
responses. Instead of antigen selection leading to clonal expansion and interclonal 
purifying selection, we observe a decrease in proportional clone size, which indicates that 
the repertoire is comprised of a greater number of clones. In the context of the vaccine 
response, this may be indicative of a polyclonal response, whereby many low affinity B 
cells are recruited and poorly proliferate without strong, positive T cell help and 
signaling. This interpretation is further supported by our analysis of clonal persistence. 
When we visualize the total repertoire by clonal size over time per clone (Figure 4.8), it is 
immediate apparent that the repertoire does not lead to clonal dominance and persistence. 
Even when a clone does reach a proportionally significant value, it does not continue 
upon further immunization.  
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Two primary results stood out to us when we analyzed the subset composition of 
B cell clones over time. First, there appears to be a population of persistent clones that do 
not exist as memory B cells, but constantly change their composition to and from 
plasmablasts, as well as naïve B cells. This population is particularly tempting for future 
study, as it appears to represent a kind of B cell pool that is constantly present and 
responding to some insult. It is not unexpected that there are regular, low level antigen 
exposures, but it is somewhat surprising that the same clones appear to be repeatedly 
responding to them. This implies that either the antigen is the same, or very similar, and 
is being constantly re-exposed, or the clones have some polyreactive function and are 
able to respond to a number of antigens. In either case, the diverse  
The proportional changes in B cell subset IgVRGs hint at an interesting 
underlying phenomenon. When we look at naïve IgVRGs, they do not significantly 
change until late vaccinations, two weeks following the 4th and one week following the 
5th, which both decrease from baseline. The timing of the changes in the plasmablast, 
then memory pool, are suggestive of a vaccine-specific response that either does not start 
until or reach the periphery until secondary vaccination. Instead of seeing an expansion in 
plasmablasts 1-2 weeks after primary vaccination, the first increase is observed two 
weeks after the 2nd dose, then again one week following the 5th dose. It is also reasonable 
to expect an increase in memory B cell IgVRG following both a primary and repeated 
exposure response, as antigen-specific B cells undergo proliferation and differentiation. 
Instead of observing such a change in early vaccinations, it is only following the 4th dose 
that this population increases. 
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 Though these data are highly complex, we identified a few potential IgVRG 
correlates of the AVA-induced response. Upon primary immunization, clonal proportion 
of the total repertoire decreases and reaches a minimum following tertiary immunization, 
after which the value increases back, approaching baseline. Though the repertoire is 
highly diverse at all time points, this measurement points to an increase in clonal 
diversity, which is diminished as higher affinity clones develop. We also found that 
clones that were first observed following secondary immunization are unusually 
persistent, though they are not necessarily observed in large clonal expansions at later 
time points. Clones that first appear at this visit may be less intraclonally diverse, having 
lower entropy per nucleotide, as well as less well defined regions of common mutation 
occurrences. 
As a large dataset with many factors, this analysis is not an exhaustive one. 
Additional analyses of other IgVRG characteristics or machine learning may further 
discover valuable relationships to vaccination.  
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Supplemental Material 
 
 
Figure S4.1. Proportion of naïve, memory and plasmablast B cells of total B cells 
isolated during bulk FACS sorting. 
Blood samples were collected from six subjects prior to and following AVA vaccination 
and PBMC was isolated and processed for fluorescence-activated cell sorting (FACS) as 
described in “Materials and Methods: Anthrax Vaccine Adsorbed.” Cells were stained to 
tag B cell subsets, and the proportion of these subsets of total PBMC were calculated per 
subject-week (Naïve, green; memory, orange; and plasmablast, purple). The red dashed 
lines indicate dates of AVA vaccination. 
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B) 
 
C) 
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Figure S4.2. Cumulative substitution frequencies before and after AVA 
immunization. 
UID-tagged Ig-seq libraries from six subjects before and following AVA vaccination 
were analyzed as described in “Materials and Methods: Anthrax Vaccine Adsorbed.” 
UID-consensus sequences that were successfully assigned into clones were sorted by A) 
all subsets, B) memory B cells and C) plasmablasts. The mutation frequency for each 
IgVRG was estimated by Cloanalyst and the total mutation frequency values were plotted 
as cumulative proportions, separated by week of observation.  
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Figure S4.3. Clone size distribution from UID-consensus Ig-seq by week. 
UID-tagged Ig-seq libraries from six subjects before and following AVA vaccination 
were analyzed as described in “Materials and Methods: Anthrax Vaccine Adsorbed.” The 
number of consensus IgVRG sequences comprising each clone per week was calculated, 
and these values combined for all six subjects. Each histogram represents the distribution 
of the observed clone sizes for all clones in all subjects per week. Weeks of vaccination 
are denoted with red text.  
  
  
198 
 
 
Figure S4.4. The distribution of clone size (proportion of all observed clones) by 
week. 
UID-tagged Ig-seq libraries from six subjects before and following AVA vaccination 
were analyzed as described in “Materials and Methods: Anthrax Vaccine Adsorbed.” The 
proportion of each UID-consensus clone of the total clone count per subject-week was 
calculated. These values are shown as proportional densities of the distributions plotted 
by week. Note that weeks are plotted vertically for easier comparison between sequential 
time points. Dates of vaccination are shown in red. 
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Subject 
Visit 
1 2 3 4 5 6 
0 2 763 109 NA 570 596 
1 57 2460 184 NA 154 305 
2 NA 484 145 199 319 70 
4 NA 210 NA NA NA 109 
5 NA 1604 514 NA NA 620 
6 NA 584 NA NA 173 41 
26 229 268 NA NA NA 122 
27 NA 4448 570 NA 629 2598 
28 173 59 NA NA NA 40 
52 72 1113     NA 401 
53 170 1354     99 70 
54 NA 411     NA 53 
78 NA 1130     NA 395 
79 228 1765     313 115 
80 NA 225     405 391 
 
Table S4.1. UID-consensus sequence counts per subject and visit. 
UID-tagged Ig-seq libraries from six subjects before and following AVA vaccination 
were analyzed as described in “Materials and Methods: Anthrax Vaccine Adsorbed.” 
1,023,648 raw, UID-tagged IgVRG sequences were processed for quality, consensus 
calling and clonal assignment by Cloanalyst, and the final sequence counts per subject-
visit are described. 
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Figure S4.5. B cell subsets within clones in total HTS Ig-seq by subject. 
All IgVRG data from high throughput sequencing were analyzed for clonal subset 
composition. Each row represents a single, estimated clone, and columns are the total 
timespan of the AVA vaccination. The tile color represents the B cell subset(s) observed 
within that clone at that time point. Estimated clones were organized by week of first 
observation and clustered by the B cell subset(s) observed in that clone by time point. 
  
201 
Immunization time points are in red text. (B cell subsets: N, naïve; M, memory; P, 
plasmablast; N+M, naïve and memory; N+P, naïve and plasmablast; M+P, memory and 
plasmablast; N+M+P, naïve, memory and plasmablast.) 
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Figure S4.6. Isotype composition of IgVRG before and after AVA immunization. 
Non-UID-tagged Ig-seq libraries from six subjects before and following AVA 
vaccination were analyzed as described in “Materials and Methods: Anthrax Vaccine 
Adsorbed.” Model-estimated UID counts from were calculated as described in Chapter 
3.7, and the proportion of IgM versus IgG comprising each clone was calculated. Clone-
subset-isotype values were then scaled using the total number of estimated UIDs per 
subset-visit for comparison between subjects. Plotted is the mean proportional 
composition of isotypes from all six subjects. Error bars represent standard error the 
mean. For convenience, significance bars are shown only for the isotype where the 
change was an increase. The corresponding value also significantly decreases.  
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Figure S4.7. IGHV gene segment usage of bulk IgVRG through AVA vaccination, 
by subject. 
Non-UID-tagged Ig-seq libraries from six subjects before and following AVA 
vaccination were analyzed as described in “Materials and Methods: Anthrax Vaccine 
Adsorbed.” IgVRG sequences were assigned into clones with estimated gene segment 
usage by Cloanalyst. The proportion of IGHV gene segment usage was calculated for 
each subject per clonal observation at all time points, regardless of sequence count. The 
proportional gene segment usage is represented by color, red tiles indicate genes with the 
fewest clones, with increasing values from white to blue. Rows represent an IGHV gene 
segment, and columns, each week of the AVA vaccination study. 
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Figure S4.8. IGHJ gene segment usage of bulk IgVRG through AVA vaccination, by 
subject. 
Non-UID-tagged Ig-seq libraries from six subjects before and following AVA 
vaccination were analyzed as described in “Materials and Methods: Anthrax Vaccine 
Adsorbed.” IgVRG sequences were assigned into clones with estimated gene segment 
usage by Cloanalyst. The proportion of IGHJ gene segment usage was calculated for each 
subject per clonal observation at all time points, regardless of sequence count. The 
proportional gene segment usage is represented by color, red tiles indicate genes with the 
fewest clones, with increasing values from white to blue. Rows represent an IGHJ gene 
segment, and columns, each week of the AVA vaccination study. 
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CHAPTER FIVE: ANTHRAX VACCINE ADSORBED IMMUNIZATION 
ELICITS HIGHLY TRANSIENT, VACCINE-RESPONSIVE PLASMABLAST 
CLONES FOLLOWING SECONDARY PRIMING DOSE 
Rationale 
Most successful vaccines provide immunological protection against infectious 
diseases caused by a microorganism by establishing long-lived humoral memory specific 
to antigenic components of that organism. That memory takes the form, in part, of 
memory B-cells and plasmacytes, both of which are generated through affinity 
maturation. The established model for the mechanism of the humoral response comprises 
several stages. First, an enormous variety of B cells bearing B cell receptors (BCR) with 
random specificities is continually produced in the bone-marrow and shaped by both 
positive and negative selection on BCR signaling before being released into the periphery 
as mature naïve B cells. 
Next, mature B cells in the peripheral B cell repertoire may be activated through 
engagement of their BCR and the transduction of co-stimulatory signals from cognate T 
helper cells further develop through one of two pathways. In the extrafollicular pathway, 
activated B cells differentiate to plasmablasts (PBs) and secrete antibody for a few days 
before undergoing programmed cell death. In the follicular pathway, they become 
germinal center (GC) B cells where they rapidly divide and establish distinct lineages 
called clones that are founded by a single unmutated progenitor B cell. Here, B cells 
undergo affinity maturation and class switch recombination before differentiating into 
long-lived plasmacytes or into memory B cells, which are able to rapidly elicit specific, 
  
207 
protective responses on reinfection up to many decades (Yu et al., 2008; Oracki et al., 
2010; Pieper et al., 2013; Kurosaki et al., 2015). 
Most routinely administered vaccines require multiple homologous prime-boost 
administrations, where the same immunization composition is used for both starting and 
maintaining a protective memory population (Siegrist, 2008; 2016b). For many repeated 
immunizations, the priming dose results in a small but discernable population of naïve-
derived antibody secreting cells (ASCs) one week post-inoculation, which continue to 
affinity mature following subsequent immunizations (Jackson et al., 2014; Laserson et 
al., 2014; Galson et al., 2015a). While it is clear that multiple immunizations can elicit 
enhanced humoral memory, the actual B cell clonal dynamics underlying these processes 
have not been systematically investigated.  
At least two plausible scenarios can be envisaged. In the first, enhancement of 
protective immunity is accomplished by continual re-elicitation of clones of memory 
cells induced in the primary immunization. These clones would re-enter germinal centers 
and continue affinity maturation. Interclonal competition would be achieved by mixing 
into single secondary germinal centers clones that had initially arisen in distinct germinal 
centers (Victora and Nussenzweig, 2012). Alternatively, recruitment of naïve cells 
continues after each immunization, with improvement in the response achieved through 
increased stringency of selection due to competition from plasmacytes and serum 
antibody produced in earlier immunizations. The mechanism for any given vaccine is 
likely to involve both processes.  
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We set out to examine the dynamics of neo- and memory-derived clones 
following repeated vaccination using Anthrax Vaccine Adsorbed (AVA), the only FDA-
approved vaccine against anthrax. AVA confers protection by eliciting an 
immunodominant antibody response against Bacillus anthracis Protective Antigen, a 
component of the tripartite anthrax toxin (Smith and Keppie, 1954; Sawada-Hirai et al., 
2004; Pittman et al., 2006; Reason et al., 2008). The protocol for administering this 
vaccine calls for five injections over 18 months, permitting us to examine the clonal 
composition of the elicited plasmablasts after each administration. We obtained 
sequences from natively paired heavy-chain/light-chain immunoglobulin variable region 
genes (IgVRG) of individually sorted plasmablasts from four subjects at one-week post-
immunization over the whole course of the immunization series, plus sequences from two 
additional subjects who completed part of the course. In contrast to Chapter Four, this 
study utilizes B cells that have been individually sorted and sequenced such that one 
IgVRG is equivalent to one plasmablast. Despite the lowered throughput, this is a 
powerful approach as it lends us greater certainty to the proportional representation of 
clones, and cannot mislead on IgVRG count by over-amplification. We studied the 
evolutionary genetics of the responding clones over the immunization series and 
synthesized several antibodies from observed and phylogenetically-inferred IgVRG to 
characterize their phenotypic evolution.  
In this study, we primarily focus on the plasmablast repertoire. PBs are early 
humoral responders and secrete large amounts of antibodies. This population provides an 
important window into the functional response of the B cell repertoire, which is 
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proportionally dominated by non-antibody secreting, naïve B cells. By focusing on the 
plasmablast repertoire, we increase the signal of the functional response to the noise of 
the total Ig repertoire. It should also be noted that AVA provides effective protection, 
though to do so requires a five injection series and annual boosts. In addition to providing 
a model for investigating the response to repeated immunizations in humans, such studies 
may in turn suggest ways to improve the vaccine. 
Results 
5.1 Anti-PA serum antibody and increased IgG+ peripheral blood plasmablasts are 
observed following secondary immunization and increase until after the fourth. 
Six healthy, adult volunteers who met all of the IRB-approved inclusion criteria 
and none of the exclusion criteria were enrolled to receive AVA according to the FDA-
approved protocol: five immunizations over 18 months with injections at 0, 4, 26, 52 and 
78 weeks (Illustration 5.1). Blood samples were taken at the time of each immunization 
and one and two weeks after. Four subjects completed the full vaccine schedule; two 
dropped out after completing three immunizations and subsequent blood draws. We used 
Enzyme-linked immunosorbent assays (ELISA) to measure PA-specific IgG+ antibodies 
in serum (Figure 4.12A) and found that titers did not rise above pre-immune values until 
after the second immunization and did not approach a plateau at or near the level at which 
protection is thought to occur until the third, consistent with prior studies in humans 
(Brachman et al., 1962; Pittman et al., 2006). The same effect was observed in PA-
specific IgG+, IgA+ and IgM+ ELISA (Figure 5.1). Subject 4 characteristically displays 
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heterogeneous responses by our metrics and is often delayed by one immunization for 
similar outcomes.  
Peripheral blood mononuclear cells (PBMC) from before immunization and one 
week after each dose were isolated and processed by fluorescence-activated cell sorting 
(FACS) to isolate IgM-IgA- plasmablasts (PB), which we conclude are IgG+ PB, among 
all B cells (Representative example, Figure 2.1). Prior to primary immunization, PB 
proportions were consistent with known steady-state levels (Figure 5.2)(Mei et al., 2009). 
One week following primary AVA immunization, we did not observe a significant 
increase in this proportion (p=0.432, one-tailed, paired t test). Using the same test 
parameters, PB proportions only significantly increase from baseline levels following the 
third and fifth immunizations. The variance of these values among subjects is also 
striking; overall variance is low between subjects in the pre-immune state and following 
primary immunization, but dramatically increases, emphasizing the potential diversity of 
immunologic characteristics that result in plausible protection (Figure S5.1). 
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Illustration 5.1. Schematic of plasmablast-focused Anthrax Vaccine Adsorbed 
(AVA) experimental design  
Six healthy volunteers within age ranges from 25-50 years old (yo) were administered 
AVA vaccine as per manufacturer directions, intramuscularly at 0, 1, 6, 12 and 18 
months. 50mL blood was collected on the day of each vaccination, as well as 1 and 2 
weeks after. Two subjects dropped out for non-study related reasons prior to the 4th 
vaccination. Serum and PBMC for high-throughput sequencing of naïve, memory and 
plasmablast B cells were isolated from all time points. Single-cell sorted plasmablasts 
were collected prior to primary immunization at week 0, and from 1 week post-
immunization samples.  
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Figure 5.1. Total IgG+, IgM+ and IgA+ Protective Antigen (PA)-specific serum 
reactivity expressed as equivalent concentrations of anti-PA monoclonal antibody 
by week following AVA vaccination.  
Blood samples were collected from six subjects prior to and 1- and 2- weeks following 
AVA vaccination and serum was isolated as described in “Materials and Methods: 
Anthrax Vaccine Adsorbed.” ELISAs were performed in triplicate on serially diluted sera 
and quantified based on standards prepared from a known anti-PA IgG+ mAB (BAP-
0105, Abcam, Cambridge, MA). Peroxidase-tagged secondary containing anti-human 
IgA, IgG and IgM (H+L) antibodies were used to label rPA-bound antibodies, and 
developed with HRP substrate. Immunizations are indicated by red, dashed, vertical lines. 
Serum samples were tested from the day of and one and two weeks post-immunization as 
available.  
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Figure 5.2. Plasmablast dynamics prior to and following AVA immunizations.  
Blood samples were collected from six subjects prior to and one week following AVA 
vaccination and PBMC was isolated and processed for single cell sorting of plasmablasts 
as described in “Materials and Methods: Anthrax Vaccine Adsorbed.” The proportion of 
plasmablasts was calculated per 100,000 B cells. Dates of immunization are represented 
by dashed, red vertical lines. 
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5.2 There is a population of persistent, non-immunization responsive clones in the B cell 
repertoire.  
We performed paired heavy-chain/light-chain full length Ig variable-region 
sequencing on single isolated IgG+ PB from each one-week post-immunization blood 
sample, acquiring 10,479 natural pairs (Table S5.1). For each subject, we estimated the 
clonal relationships among their IgVRG pairs using methods adopted from statistical 
phylogenetics to partition the paired sequences into sets (Kepler, 2013). With the caveat 
that these sets are statistical estimates of the biological phenomena, we will refer to them 
henceforth as “clones”. For each clone, a phylogenetic tree, or clonogram, was estimated 
by maximum likelihood methods jointly on the heavy and light chain variable-region 
genes.  
To supplement these data, we performed high-throughput, heavy-chain IgVRG 
FACS and sequencing of bulk-sorted naïve, memory and plasmablast B cells using 
samples from the entire time course, resulting in 5,218,041 immunoglobulin sequences, 
and estimated clones as before, using the available heavy-chain data (Representative 
example, Figure 2.2). We identified clones that had at least one member from the single-
cell sorted plasmablast population, and asked how these clones persist and change their 
subset composition following each immunization (Figure 5.3). This analysis is 
unsurprisingly dominated by plasmablasts, as that is the classification of our query.  
First, we see that there is a small population of constitutively expressed, highly 
persistent clones which are primarily composed of plasmablast and memory B cells. 
These are first observed at week 0, prior to immunization and is consistent among all 
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subjects (Figure S5.2). This suggests that in any given sample, we should expect a small 
population of clones that will persist through subsequent time points, but are not 
necessarily part of a specific response to immunization. Second, despite the increased 
repertoire coverage and inclusion of naïve and memory B cells, the persistent clonal 
population following the first AVA immunization appears similar to the baseline clones 
previously observed. It is only following subsequent immunizations that there is an 
expansion in persistent clones. 
We further characterized clonal composition using the total high-throughput 
dataset alone. These data are somewhat more representative of the primary peripheral B 
cell population, naïve B cells, but are less likely to primarily represent AVA-specific 
responses. Despite this noise from the total repertoire, we again observe a population of 
clones that are identified at baseline prior to immunization which persist and are not 
likely to be responding specifically to AVA (Figure 4.9). As with the Atreca-inclusive 
clonal subset, an expanded, persistent clonal population emerges following the second, 
but not the first immunization. However, this approach reveals that for some subjects, 
steady-state clones are more prevalent than our plasmablast-based data suggest (Figure 
S4.4). For instance, subject one’s clones observed at week zero are more abundant and 
persistent than the population of clones observed after any immunization. 
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Figure 5.3. B cell subset usage within clones in high throughput sequencing inclusive 
Atreca immunoglobulin sequencing (Ig-seq). 
IgVRG sequence data from single-cell sorted plasmablasts (P) was combined with high-
throughput Ig-seq of naïve (N), memory (M) and plasmablast B cells. All IgVRG were 
analyzed for shared clones and clonal subset composition by Cloanalyst. All estimated 
clones with at least one member from the single-cell sorted dataset are shown. Each row 
represents a single, estimated clone, and columns, each week of the AVA vaccination 
study. The tile color represents the B cell subset(s) observed within that clone at that time 
point. Estimated clones were organized by week of first observation and clustered by the 
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B cell subset(s) observed in that clone by time point. Immunization time points are in red 
text (B cell subsets: N, naïve; M, memory; P, plasmablast; N+M, naïve and memory; 
N+P, naïve and plasmablast; M+P, memory and plasmablast; N+M+P, naïve, memory 
and plasmablast.). 
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5.3 Clonal responses are highly transient and do not move towards homogeneity 
following immunization. 
Our further analyses will focus on the single-cell sorted plasmablast dataset 
before and one week following immunization. These data are proportionally 
representative of the cellular sample population, full length and high quality across the 
IgVRG.  We expect the plasmablast population at these time points are representative of 
the specific immunization response (Wrammert et al., 2008). The majority of observed 
PB clones, 3839/4958 (77.43%), appear at only one time point (Figure 5.4). There is no 
trend to homogenous clonal dominance in the PB repertoire, even after the appearance of 
concentrated PA-specific IgG in serum. We quantified this interclonal diversity by 
computing the inverse of the bias-corrected Simpson index (Figure 5.5).  This measure of 
diversity is high among all subjects, though it is relatively dissimilar between them, and 
only significantly changes from the pre-immune repertoire after the 3rd immunization, 
where it reaches a minimum mean value (Mean reciprocal SDI: 89.83). Furthermore, the 
mean clone size per first clonal observation invariably peaks at the time of first 
appearance (Figure 5.6). Here, we see that where clones do persist, it appears to be 
through prolonged waning rather than robust re-elicitation. 
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Figure 5.4. Clones are highly transient following AVA immunization. 
Single cell sorted plasmablast IgVRG libraries from six subjects before and following 
AVA vaccination were analyzed as described in “Materials and Methods: Anthrax 
Vaccine Adsorbed.” The number of sequences per clone was counted, and the fractional 
proportion of the total clonal repertoire calculated per week. Each stacked, colored area 
represents a single observed clone. This is most clearly represented in subject 5 during 
week 0 where a single clone, represented by a light green, makes up ~13% of all 
observed Ig at that time point, and is seen again at week 27 as ~20% of the repertoire.  
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Figure 5.5. Interclonal diversity is variable, but reaches a minimum following the 
third AVA immunization. 
Single cell sorted plasmablast IgVRG libraries from six subjects before and following 
AVA vaccination were analyzed as described in “Materials and Methods: Anthrax 
Vaccine Adsorbed.” Clones were estimated for all subjects using Cloanalyst. Interclonal 
diversity was computed using a weighted reciprocal Simpson’s Index (SDI = 1 ÷
∑ 𝑛(𝑛−1)
𝑁(𝑁−1)
 
, where n is the plasmablast/sequence count per clone-visit and N is the total 
plasmablast/sequence count per visit). A zero value indicates a single clone is observed 
and there is no diversity, and increasing values indicate increasing diversity in clonal 
representation. 
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Figure 5.6. Clone size invariably peaks at first observation throughout AVA 
immunization. 
Single cell sorted plasmablast IgVRG libraries from six subjects before and following 
AVA vaccination were analyzed as described in “Materials and Methods: Anthrax 
Vaccine Adsorbed.” Clones were estimated for all subjects using Cloanalyst. Estimated 
clones were then grouped by the week of first observation, and mean clone proportion 
was calculated per subject-week, inclusive of time points when no members were 
observed. Each color represents clones which were first observed at week 0 (black), 1 
(green), 5 (purple), 27 (orange), 53 (blue) and 79 (fuchsia).  
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5.4 Plasmablasts observed following the primary dose are similar to the pre-immune 
repertoire, while those following secondary immunization are naïve-derived. 
Plasmablast mutation frequency in the IgVRG can provide evidence about the 
minimum time from activation of a naïve clonal founder to the point of observation. The 
average mutation frequency among PB IgVRG is above 6% (heavy chain) one week after 
the first immunization in all subjects, declines after one or two more immunizations, then 
increases to approach plateau, with a consistent effect observed in the light chains (Figure 
5.7). The IgVRG also displays a distinct shift in the frequency of nucleotide substitutions 
only after the second vaccination (Figure 5.8). This effect was strongest in the youngest 
subjects, and was also consistent in the light chains (Figure S5.3). We also asked if the 
nucleotide diversity introduced during somatic hypermutation (intraclonal diversity) 
differs by immunization. This is distinct from calculating overall mutation frequency as it 
is possible that highly mutated clones are highly homogenous by purifying selection and 
have low intraclonal diversity. We see a trend of increasing intraclonal diversity over 
time, but there is only a significant change from week 5 to 27, between the 2nd and 3rd 
immunization (Figure 5.9). 
 To better identify the source of newly elicited clones, we selected the first 
observed member(s) of each clone and determined the earliest IgVRG mutation or mean 
mutation frequency (Heavy chain, Figure 5.10; Light chains, Figure S5.4). At the 
baseline prior to immunization, all subjects’ heavy chains display a right-tailed 
distribution, with a mean of 0.056 ± 0.035, and a median of 0.051 (Table S5.2). These 
values do not significantly change from pre-immunization to one week post-primary 
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immunization, but do significantly decrease from baseline to 2nd and 3rd immunizations. 
We then asked if the observed mutation values after each immunization were likely to be 
derived from the same probability distribution. Using a two-sample Kolmogorov-
Smirnov (KS) test, the baseline distribution was compared to the values observed at all 
other time points by subject (Table 5.1). No subject shows a shift before and after 
primary immunization, while all subjects save subject 4 have distinct, significant shifts 
after the 2nd dose. Subject 4 significantly changes after the 3rd dose. This effect can be 
clearly seen in the histograms of observed percent mutations (Figure 5.10), where a 
bimodal distribution occurs after the 2nd immunization, with the dominant peak at a very 
low mutation frequency and another at a moderate percent mutation. We observed a 
similar effect in the light chains (Figure S5.4). 
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Figure 5.7. Observed mutation dynamics in IgG+ plasmablasts following AVA 
immunization. 
Single cell sorted plasmablast IgVRG libraries from six subjects before and following 
AVA vaccination were analyzed as described in “Materials and Methods: Anthrax 
Vaccine Adsorbed.” The observed mutation frequency per clone was calculated as base 
pair mismatches compared to the IGHV and IGHJ gene segment usage in the Cloanalyst-
inferred unmutated common ancestor. The mean percent mutation was calculated in all 
six subjects over IgVRG heavy (green), kappa (orange), and lambda (purple) chain 
sequences. Error bars represent standard errors of the mean. 
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Figure 5.8. Cumulative nucleotide substitution by week and subject following AVA 
immunization.  
Single cell sorted plasmablast IgVRG libraries from six subjects before and following 
AVA vaccination were analyzed as described in “Materials and Methods: Anthrax 
Vaccine Adsorbed.” The observed mutation frequency per clone was calculated as base 
pair mismatches compared to the IGHV and IGHJ gene segment usage in the Cloanalyst-
inferred unmutated common ancestor. These values were combined and plotted as the 
cumulative proportion of all IgG+ plasmablast heavy chains by nucleotide substitution 
frequencies, separated by subject and week.  
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Figure 5.9. Intraclonal nucleotide diversity following AVA immunization. 
Single cell sorted plasmablast IgVRG libraries from six subjects before and following 
AVA vaccination were analyzed as described in “Materials and Methods: Anthrax 
Vaccine Adsorbed.” Clones were estimated for all subjects using Cloanalyst. Intraclonal 
diversity was measured as alignment by pairwise comparisons between members of the 
same clone with more than one member, heavy and light chain exclusive, where 
increasing value represents increasing nucleotide diversity. Results are shown by subject 
for the IgVRG heavy (green), kappa (orange), and lambda (purple) chains. *: p<0.05;  
**:p<0.005. 
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Figure 5.10. Distribution of mutation frequency in the earliest observed heavy chain 
members following AVA immunization. 
Single cell sorted plasmablast IgVRG libraries from six subjects before and following 
AVA vaccination were analyzed as described in “Materials and Methods: Anthrax 
Vaccine Adsorbed.” Clones were sorted by the week of first observation, and only 
IgVRG heavy chains from this time point per clone were included. Each distribution 
represents the mutation frequency or mean mutation frequency for clones with >1 
sequence, of the earliest observed plasmablast members of all clones by subject (rows, 
S1-6) and week (columns). 
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Table 5.1. Kolmogorov-Smirnov tests to compare baseline to post-AVA 
immunization clone mutation frequencies.  
Two sample Kolmogorov-Smirnov nonparametric tests were performed in R to compare 
the distributions of observed IGH mutation frequencies prior to AVA immunization and 
one week following each vaccination. P-values are shown for each pairwise comparison 
to week 0 values by subject. Significant p values indicate that the null hypothesis (the 
observed mutation frequency distributions are from the same distribution/population) is 
rejected with an alpha of 0.05.  
  
Subject 1 5 27 53 79 
1 0.118 <2.20E-16 2.38E-12 3.21E-05 3.86E-11 
2 0.638 6.98E-11 6.00E-03 0.737 0.743 
3 0.848 6.60E-08 0.191 NA NA 
4 0.794 0.835 9.25E-13 NA NA 
5 0.183 <2.20E-16 4.45E-09 6.48E-04 4.17E-05 
6 0.396 4.15E-04 9.49E-12 0.093 5.84E-06 
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5.5 The dynamics of the responding clones exhibits two distinct patterns of growth and 
succession. 
While the difference between clonal mutation frequencies between baseline and 
neo-clones after the 2nd doses are clear, pairwise KS testing also revealed some 
heterogeneity in the distributions of later appearing clones (Table S5.3). In general, 
significant shifts are observed between the 2nd dose and all subsequent doses, but no 
significant change is seen after the 3rd and all subsequent doses. These results may 
indicate that true neo-clonal populations are arising following the 3rd dose, or that 
previously unobserved clones elicited by the 2nd dose are undergoing affinity maturation. 
To examine this, we investigated the count and mutation dynamics of the largest clones 
by subject (Figure 5.11). 
IgG+ PB clones isolated one-week post immunization over the course of the 
immunization protocol can be largely classified under one of two distinct patterns of 
evolution, with variations. The first is exemplified by the clone shown in the fifth row of 
subject 1 (S1) in Figure 5.11. This clone was not observed until after the second 
immunization, at which time its average heavy-chain mutation frequency was less than 
1%. It was observed and had an increased average mutation frequency after each 
subsequent immunization. The relative size of this clone held stable until the fifth 
vaccination at which time it diminished. The common characteristics of this pattern are: 
1) first observation at or after the second immunization; 2) Initially low mutation 
frequency; 3) multiple recurrence with higher mutation frequency after each subsequent 
immunization. 
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The second pattern is exemplified by the clones under Figure 5.11, S1 in row 
four. This clone was observed after the first immunization and at that point had a heavy-
chain mutation frequency greater than 10%. It was not observed after any subsequent 
immunizations. The characteristics of this pattern are 1) observation after the first 
immunization; 2) high mutation frequency at first observation; 3) rapid diminishment 
with subsequent immunizations.  
Note that growth and diminution are described here in relative terms. The PB pool 
grows steadily throughout the first three immunizations, so apparent diminution of any 
given clone may be attributable to growth in the others and not necessarily indicative of 
absolute decrease in population size. 
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Figure 5.11. Distinctive patterns of clonal evolution suggest two population sources 
following AVA immunization. 
Single cell sorted plasmablast IgVRG libraries from six subjects following AVA 
vaccination were analyzed as described in “Materials and Methods: Anthrax Vaccine 
Adsorbed.” Clones were estimated for all subjects using Cloanalyst, and the thirty largest 
clones per subject were selected. Each row of square symbols represents a single clone of 
isolated one week after the immunization indicated at the top of each column. The area of 
the symbol is proportional to the size of the clone per week. The color of the square 
represents the mean IGH mutation frequency as described by the cumulative distribution 
function, where blue represents low mutation frequencies, with increasing values in red.  
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5.6 Preexisting memory clones decline over time, do not diversify, and do not bind PA. 
Naïve-derived clones grow and diversify. 
To investigate the dynamics of naïve- versus preexisting-memory PBs (PreMPB), 
we selected persistent clones that were first observed before immunization and after 
either the first or second dose. While putative naïve-derived B cells observed following 
secondary immunization show increasing mutation frequency in four of five subjects, 
PreMPBs do not undergo additional mutation (Figure 5.12). As with mutation and 
persistence metrics, there is no distinction between pre- and post-primary immunization 
repertoire by this measurement. A similar effect is observed when all IgVRG are included 
regardless of persistence (Figure S5.5). 
Using the genetic and kinetic criteria we have established for putative vaccine-
elicited, naïve-derived clones, we selected one clone from subject 1 for characterization 
by surface plasmon resonance (SPR)-based kinetic analysis against PA. The clone, 
designated C2202, was selected for study because of its increasing mutation frequency 
and clonal growth between the third and fourth immunizations, suggesting that it was 
naïve-derived and being selectively driven by AVA. We selected five observed IgVRG 
heavy-light chain pairs from different phylogenetic clone branches, five inferred pairs 
from their internal nodes, and the inferred unmutated common ancestor (UCA) for 
recombinant synthesis. The IgG antibody produced from these IgVRG genes exhibit 
increasing affinity to PA with increasing distance from the UCA (Figure 5.13), increasing 
from KD 667nM in the founder to 4.2nM is the farthest removed species. We additionally 
selected 11 sequence-pairs from 601 putative preMPB clones in four subjects for 
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synthesis and characterization. None of these antibodies had detectable binding (KD > 
100µM) to PA by SPR (Table 5.2, Figure S5.6).  
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Figure 5.12. Persistent clones have distinct patterns of somatic hypermutation 
following AVA immunization. 
Single cell sorted plasmablast IgVRG libraries from six subjects before and following 
AVA vaccination were analyzed as described in “Materials and Methods: Anthrax 
Vaccine Adsorbed.” Clones were selected if they were first observed before 
immunization (black) or one week following the 1st (green) or 2nd (purple) immunization 
and had at least one member observed in two or more time points. Mean mutation 
frequencies were calculated per clone-week, and the standard boxplot is comprised of all 
clone means per week by subject. 
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Figure 5.13. Phylogram describing clone 2202. 
The IgVRG heavy chain sequences comprising clone 2202 from the single cell sorted 
plasmablast data were aligned, and a phylogenetic tree made using Cloanalyst. The tree is 
displayed in decreasing node order, from the leftmost inferred unmutated common 
ancestor (UCA). Branch length indicates IGH mutation frequency as compared to the 
UCA. Observed sequences are colored by the week of observation. Synthesized IgVRG 
and inferred nodes are indicated by red boxes.  
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ID Subject 
 Week of first 
clonal appearance 
Week 
observed 
 
IGHV Subclass KD 
s5572 1 1 1 & 79* 1-8 IGG3 >100mM 
s5811 1 1 1 & 79* 1-8 IGG3 >100mM 
s6010 1 1 1 4-34 IGG1 >100mM 
s6047 1 1 1 3-21 IGG1 >100mM 
s6189 1 1 1 3-7 IGG2 >100mM 
s6192 1 1 1 4-34 IGG1 >100mM 
c4011 3 0 1 1-69 IGG3 >100mM 
c2836 5 0 1 5-51 IGG2 >100mM 
c2755 5 1 1 3-43 IGG2 >100mM 
c2808 5 1 1 3-66 IGG1 >100mM 
c5099 6 1 1 4-59 IGG4 >100mM 
UCA 2 27 inferred 4-4 IGG1 667nM 
i60 2 27 inferred 4-4 IGG1 28.6nM 
i54 2 27 inferred 4-4 IGG1 17.2nM 
i8 2 27 inferred 4-4 IGG1 35.8nM 
c7364 2 27 27 4-4 IGG1 6.7nM 
i5 2 27 inferred 4-4 IGG1 3.0nM 
c7310 2 27 27 4-4 IGG1 22.3nM 
i14 2 27 inferred 4-4 IGG1 2.9nM 
c4126 2 27 53 4-4 IGG1 4.2nM 
c4087 2 27 53 4-4 IGG1 10.5nM 
c4077 2 27 53 4-4 IGG1 5.7nM 
Table 5.2. Selected naïve- but not preMPBs have measurable affinity for PA. 
Week of first clonal appearance indicates the earliest time point at which at least one 
shared clonal member was observed, and observed immunization specifies the time 
point(s) at which the specific antibody being tested was observed. Putative preMPBs and 
naïve-derived PBs are sorted top to bottom, respectively. KD was calculated from 
optimized SPR protocols using a two-state model. *Identical sequences were observed 
after both 1st and 5th immunization.  
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5.7 The naïve-derived response is driven by IgG1+ plasmablasts. 
The IgG antibody subclasses observed before and after the first immunization 
were equally distributed between IgG1 and IgG2, which together accounted for nearly 
90% of all subtypes (Figure 5.14). Despite the changes in the source and clonal 
composition of the observed plasmablasts between 1st and 2nd immunization, there is not 
a significant difference in subclass population from baseline until visit 3, when IgG1+ 
PBs increase (p<0.005). IgG1 remains dominant after increasing to a mean of 85% after 
the third immunization.  
We then examined the mutation dynamics of just IgG1+ and IgG2+ PBs in the 
repertoire (Figure 5.15). Despite IgG2+ PB’s high representation in the data, the mean 
mutation frequency of this population stayed relatively constant over time, not 
significantly changing between any consecutive time points. This is in contrast to IgG1+ 
PBs, which significantly decrease in mutation frequency from the 1st to the 2nd then 
increase from the 3rd to the 4th immunization. This stratification is consistent with the 
mutation pattern observed between naïve-derived plasmablasts and preMPBs. 
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Figure 5.14. The proportion of IgG subclass observed by week following AVA 
immunization. 
Single cell sorted plasmablast IgVRG libraries from six subjects following AVA 
vaccination were analyzed as described in “Materials and Methods: Anthrax Vaccine 
Adsorbed.” Atreca, Inc. provided IgG subclass information for all sequences, and the 
proportion of plasmablast IgG subclasses were calculated per week by subject. IgG 
subclasses are represented by color (IgG1, green; IgG2, purple; IgG3, orange; IgG4, red). 
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Figure 5.15. IgG subclass mutation frequencies following AVA immunization. 
Single cell sorted plasmablast IgVRG libraries from six subjects following AVA 
vaccination were analyzed as described in “Materials and Methods: Anthrax Vaccine 
Adsorbed.” Atreca, Inc. provided IgG subclass information for all sequences, and the two 
most dominant subclasses, IGHG1 and IGHG2 (Figure 5.14) were selected. The observed 
mutation frequency was calculated per clone-week by Cloanalyst, and the mean value 
plotted by subject. Vertical bars show the standard deviation. Subclasses are represented 
by color (IgG1, green; IgG2, purple). 
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5.8 Gene segment usage is dynamic. 
To further characterize repertoire-level, interclonal selection, we calculated the 
relative abundance of IGHV gene segments observed per subject-time point (Figure 
5.16). On a per-subject basis, there is no conserved sign of specific gene segment 
selection, negative or purifying, consistent among all individuals. However, there are a 
few genes which have similar patterns in two or more subjects, which are denoted by red 
stars. Of these, IGHV3-21 increases in the repertoire of three subjects, suggesting 
positive selection, and IGHV3-7 and IGHV3-74 decrease in two, suggesting purifying 
selection. IGHJ gene segment proportions are more dynamic that expected given current 
knowledge of usage and our own high throughput sequencing data (Chapter Four). While 
IGHJ4 is highly represented, as expected, the next most dominant gene segment, IGHJ6, 
noticeably lessens following primary vaccination in 4 subjects. IGHJ3 also increases 
following at least one vaccination in 5 subjects, above its low baseline ratio.  
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Figure 5.16. IGHV and IGHJ gene segment usage in plasmablasts following AVA 
immunization. 
Single cell sorted plasmablast IgVRG libraries from six subjects following AVA 
vaccination were analyzed as described in “Materials and Methods: Anthrax Vaccine 
Adsorbed.” A) IGHV and B) IGHJ gene segment usage per IgVRG was estimated by 
Cloanalyst, and the proportion of IgVRG represented was calculated per sequence 
observation at all time points and normalized. The relative abundance of each observed 
gene segment is represented by color, blue tiles indicate genes with the fewest clones, 
with increasing values from white to red. Rows represent an A) IGHV or B) IGHJ gene 
segment, and columns, each week of the AVA vaccination study. 
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Discussion 
We examined the clonal population dynamics of the IgG+ plasmablast response to 
repeated immunization in humans receiving AVA using IgVRG repertoire sequencing 
and functional assays. We first identified baseline measures of clonal persistence and 
mutation, and found two discrete types of clones involved in the post-immunization 
response. The clones that dominate the response following primary immunization exhibit 
mutation frequencies high enough to indicate conclusively their origin in preexisting B 
cell memory, and share kinetic and genetic characteristics of baseline, constitutive clones. 
Where observed at more than one time point, this population does not show evidence of 
further somatic mutation and antibodies from these clones do not detectably bind PA. The 
second population are likely to be naïve-derived and specific to PA, and are somewhat 
more persistent.  
We were surprised by the lack of a significant increase in the proportion of 
plasmablasts in the blood one week following primary immunization. It has been well 
established in other immunizations and natural infections that, even when protection is 
not immediately established, this is a common outcome (Mei et al., 2009; Fink, 2012; 
Wang et al., 2015; Kauffman et al., 2016). In fact, the proportion of PBs do not seem to 
increase until after the second and third immunizations, when putative naïve-derived 
clones are observed. It is possible that poorly elicited, polyreactive preexisting memory 
may be interfering with the establishment of a protective response, but the lack of any 
distinguishing features from the pre-immune state make this seem unlikely. Another 
explanation may be that the priming dose is unable to elicit a robust response that can 
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move from secondary lymphoid tissues into the periphery. Nevertheless, it is only after 
the second dose that the clonal repertoire exhibits the accumulation of further somatic 
mutations and continued affinity maturation. The role of further recruitment from naïve 
cells in later immunizations is variable among subjects, with one subject exhibiting 
substantial potentially naïve recruitment after the fifth immunization. Together, our data 
suggest that there is not a meaningful subdominant PA-specific response after the first 
immunization that is simply unmasked by the depletion of preexisting memory cells.  
Despite the putative naïve-derived, PA-specific PB population, there is not a 
robust repertoire movement towards purifying clonal selection. Previous studies 
examining the induced IgVRG repertoires to vaccines or infections have found a 
narrowing of the response over time and even interclonal convergence to shared 
structural motifs (Krause et al., 2011; Six et al., 2013; Jackson et al., 2014; Martins and 
Tsang, 2014; Galson et al., 2015a; Truck et al., 2015). Here we observe a persistently 
diverse response in which individual clones vanish from the observed PB repertoire by 
the next immunization, maintaining high interclonal diversity. Clones that were not 
previously observed appear and have mutation frequencies that indicate that they are not 
newly derived from naïve B cells. Clones also have a stereotypical rise-fall lifetime. No 
clone grows, as a proportion of the total plasmablast population, throughout the five-
immunization series. While this may be due to under sampling during blood collection, 
we regularly observe clones with multiple, independent PB members per visit, suggesting 
that the PB repertoire is not so heterogeneous that it cannot be captured. We also 
performed rarefaction of the Atreca data as previously used (Chapter Three). While novel 
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clones are still being collected, the slope is well under that expected for a maximally 
diverse sample (Figure S5.7).  
We expect that strong, purifying repertoire selection, distinct from the selection 
associated with GC cycling, would decrease diversity, favoring the highest affinity clones 
with the most resources. We observed variable patterns of interclonal diversity, with little 
agreement between subjects as to which dose increases or decreases clonality as 
compared to either the baseline or prior immunization. The one clear outcome is that 
interclonal diversity reaches an average minimum following the 3rd immunization. With 
the prior knowledge that 1) Sequences that are observed after the 3rd dose are largely 
from the naïve-derived clones elicited following 2nd immunization, 2) These sequences 
increase in overall mutation frequency to near plateau after the 3rd dose and 3) 
Intraclonal diversity significantly increases from the 2nd to 3rd dose, we propose that 
following secondary immunization, many non-diversified, neo-clones are activated and 
not yet subject to strong positive selection. After the 3rd immunization, the clones with 
competitively high affinity BCRs are positively selected and diversify in the now less 
competitive GC space. 
The extraordinary clonal transience and lack of a naïve-derived, specific response 
following primary immunization were surprising. It is perhaps historical methodological 
biases in the field that have underappreciated this observation in immunization; 
establishing studies focused on antigen-specific B cells, and empirical methods of clonal 
inference may have underestimated repertoire diversity. Recent advances in technology 
have allowed observation of similar phenomena in other vaccines (Laserson et al., 2014; 
  
247 
Galson et al., 2015a). Therefore, although we observe a distinct type of preexisting 
memory PB population following primary AVA immunization, we do not necessarily 
interpret these clones as being elicited by the vaccination. 
It has been established that alum-based adjuvants, such as Alhydrogel®, used in 
AVA, elicit robust IgG1 responses through TH2 help (Grun and Maurer, 1989; 
Eisenbarth et al., 2008; Marrack et al., 2009; Jin et al., 2013). Our own Ig subclass data 
suggests that the naïve response is primarily driven by IgG1, but the subclass correlates 
were not as clear as expected in the repertoire context. First, the ratio of Ig subclasses in 
the pre-immune repertoire differed from previously published steady-state values, and 
exhibited a higher than expected proportion of IgG2 from blood-derived plasma cells 
(Mayumi et al., 1983; French and Harrison, 1984; Galson et al., 2015b). Second, this 
proportional representation did not change after primary immunization. We expected to 
see a distinct shift towards IgG1 in overall subclass composition, but there was no 
significant change from baseline until after the 3rd immunization, and subsequent 
immunizations thereafter. Third, though there was not a significant change in the mean 
mutation frequency of IgG2 from the 1st to 2nd immunization, three time points did 
differ from the baseline value (immunizations 2, 3 and 5, p<0.05). The relatively erratic 
path of the changes in IgG2 may indicate that this is due to the highly diverse and 
transient repertoire, and these are just measurements of repertoire noise. It should also be 
noted that while alum is the exogenous adjuvant, the vaccine is likely to be comprised of 
a potentially immunogenic mixture of bacterial proteins including cell wall components. 
  
248 
We then must temper any extrapolation as to the molecular source of isotype-specific 
elicitation as there are likely to be interaction effects. 
We would also like to acknowledge two unusual outcomes in this study. First, 
while five of six subjects exhibit consistent genetic patterns in our analyses, subject 4 is a 
noticeable outlier. We were particularly struck by the lack of a clear, naïve-derived 
response or contraction of interclonal diversity on repeated immunization. Regardless, 
this subject displays antibody levels within the expected AVA range, suggesting alternate 
pathways may be important in some people. An outstanding question in immunology is 
the impact of host factors on immunization efficacy. Subject four’s distinct timeline and 
occasionally conflicting results remain a tantalizing path of inquiry. Second, we 
recognized an unexpected contraction in the PB population after the fourth immunization 
(Figure 5.2). We confirmed that there was no protocol discrepancy, and that samples 
from this time point were processed at every step with other samples that did not show 
this phenotype. However, we determined that this immunization was from a different lot 
than the batch used for the primary series. While we cannot make conclusions about this 
result without a same lot comparison, we are intrigued by the possibility that different 
AVA lots could result in distinct immune responses.  
  
249 
Supplemental Material 
 
 
Figure S5.1. Variance of plasmablast proportion of B cells between subjects 
following AVA immunization. 
Blood samples were collected from six subjects prior to and one week following AVA 
vaccination and PBMC was isolated and processed for single cell sorting of plasmablasts 
as described in “Materials and Methods: Anthrax Vaccine Adsorbed.” The proportion of 
plasmablasts was calculated per 100,000 B cells. Individual subject values of plasmablast 
proportions from total B cells were log transformed, and the variance calculated, 
weighted by the proportion of cells per time point. Dates of immunization are represented 
by dashed, red vertical lines. 
  
  
250 
Week 0 1 5 27 53 79 
Subject 1 97 271 425 592 100 605 
Subject 2 64 80 302 371 65 41 
Subject 3 208 80 309 262 NA NA 
Subject 4 236 132 98 309 NA NA 
Subject 5 508 223 382 443 239 1588 
Subject 6 499 104 254 669 219 704 
Table S5.1. Total counts for Atreca, Inc. single-cell plasmablast FACS.  
Total counts for single cell sorted, sequenced plasmablasts with full length, natively 
paired IgVRG [V(D)J] obtained from Atreca, Inc. by subject. Samples represent blood 
drawn prior to primary immunization and one week following all immunizations as 
shown in Figure 5.1. 
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Figure S5.2. B cell subset usage within clones in HTS inclusive Atreca Ig-seq by 
subject. 
All IgVRG data from high throughput sequencing were combined with single PB sorted 
Atreca IgVRG and clones with at least one member from the Atreca dataset were 
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analyzed for clonal subset composition. All estimated mixed clones per subject were 
organized by week of first observation and clustered by the B cell subset(s) observed in 
that clone at each time point. Immunization time points are in red text. (B cell subsets: N, 
naïve; M, memory; P, plasmablast; N+M, naïve and memory; N+P, naïve and 
plasmablast; M+P, memory and plasmablast; N+M+P, naïve, memory and plasmablast.) 
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A) 
 
B) 
 
Figure S5.3. Cumulative light chain nucleotide substitution by week and subject. 
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Single cell sorted plasmablast IgVRG libraries from six subjects before and following 
AVA vaccination were analyzed as described in “Materials and Methods: Anthrax 
Vaccine Adsorbed.” The observed mutation frequency per clone was calculated as base 
pair mismatches compared to the A) IGκ and B) Igλ chain V and J gene segment usage in 
the Cloanalyst-inferred unmutated common ancestor. These values were combined and 
plotted as the cumulative proportion of all IgG+ plasmablast light chains by nucleotide 
substitution frequencies, separated by subject and week.  
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A) 
 
B) 
 
Figure S5.4. Distribution of mutation frequency in the earliest observed light chain 
members following AVA immunization. 
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Single cell sorted plasmablast IgVRG libraries from six subjects before and following 
AVA vaccination were analyzed as described in “Materials and Methods: Anthrax 
Vaccine Adsorbed.” Clones were sorted by the week of first observation, and only 
IgVRG A) kappa and B) lambda chains from this time point per clone were included. 
Each distribution represents the mutation frequency or mean mutation frequency for 
clones with >1 sequence, of the earliest observed plasmablast members of all clones by 
subject (rows, S1-6) and week (columns). 
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Subject Week Mean Median 
1 0 0.052 0.049 
2 0 0.042 0.040 
3 0 0.052 0.045 
4 0 0.051 0.046 
5 0 0.059 0.054 
6 0 0.061 0.055 
1 1 0.053 0.046 
2 1 0.048 0.037 
3 1 0.050 0.045 
4 1 0.048 0.047 
5 1 0.057 0.052 
6 1 0.059 0.052 
1 5 0.037 0.025 
2 5 0.029 0.014 
3 5 0.043 0.036 
4 5 0.051 0.047 
5 5 0.044 0.037 
6 5 0.051 0.045 
1 27 0.039 0.031 
2 27 0.041 0.035 
3 27 0.047 0.043 
4 27 0.038 0.030 
5 27 0.048 0.036 
6 27 0.055 0.040 
1 53 0.039 0.032 
2 53 0.041 0.036 
5 53 0.050 0.044 
6 53 0.057 0.050 
1 79 0.040 0.032 
2 79 0.040 0.038 
5 79 0.058 0.047 
6 79 0.058 0.045 
 
Table S5.2. Descriptive statistics of mutation frequencies of IGH at first clonal 
observation following AVA immunization. 
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Single cell sorted plasmablast IgVRG libraries from six subjects before and following 
AVA vaccination were analyzed as described in “Materials and Methods: Anthrax 
Vaccine Adsorbed.” Clones were sorted by the week of first observation, and only 
IgVRG heavy chains from the earliest observed time point per clone were included. The 
mean and median mutation frequencies of the IgVRG per subject-week were calculated. 
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Subject 1 0 1 5 27 53 
1 0.1184        
5 <2.2E-16 <2.2E-16      
27 2.38E-12 2.21E-12 < 2.2E-16    
53 3.21E-05 7.80E-04 1.29E-07 0.2598  
79 3.86E-11 2.73E-09 1.57E-10 0.02433 0.485 
      
Subject 2 0 1 5 27 53 
1 0.638 1       
5 6.98E-11 1.43E-13 1     
27 6.00E-03 4.79E-05 <2.2E-16 1   
53 0.737 0.674 6.91E-12 0.055 1 
79 0.743 0.348 2.88E-09 0.319 0.348 
      
Subject 3 0 1 5 27  
1 0.848 1      
5 6.60E-08 2.72E-05 1    
27 0.191 0.234 8.29E-12 1  
      
Subject 4 0 1 5 27  
1 0.794 1      
5 0.835 0.810 1    
27 9.25E-13 7.60E-08 2.81E-07 1  
      
Subject 5 0 1 5 27 53 
1 0.183 1       
5 <2.2E-16 7.90E-11 1     
27 4.45E-09 1.47E-05 0.068 1   
53 6.48E-04 0.022 2.91E-06 0.054 1 
79 4.17E-05 0.066 3.33E-16 6.78E-04 0.148 
      
Subject 6 0 1 5 27 53 
1 0.396 1       
5 4.15E-04 0.027 1     
27 9.49E-12 6.32E-04 6.14E-03 1   
53 0.093 0.771 1.07E-03 6.94E-06 1 
79 5.84E-06 0.099 1.32E-03 5.22E-04 0.033 
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Table S5.3. Pairwise Kolmogorov-Smirnov tests between all time points before and 
following AVA immunization..  
Two sample Kolmogorov-Smirnov nonparametric tests were performed in R to compare 
the distributions of observed IGH mutation frequencies at all time points. P-values are 
shown for each pairwise comparison by subject. Significant p values indicate that the null 
hypothesis (the observed mutation frequency distributions are from the same 
distribution/population) is rejected with an alpha of 0.05.  
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Figure S5.5. Plasmablast persistence and mutation frequencies reveal two classes of 
clones. 
Single cell sorted plasmablast IgVRG libraries from six subjects before and following 
AVA vaccination were analyzed as described in “Materials and Methods: Anthrax 
Vaccine Adsorbed.” IgVRG were assigned to groups by the earliest time point their 
assigned clone was observed (week 0, black; week 1, green; week 5, purple; week 27, 
orange; week 53, blue and week 79, fuchsia). The mean mutation frequency was 
calculated per week-earliest time point for all subjects and plotted. The area of each circle 
is proportional to the number of plasmablasts/IgVRG observed at that week-earliest time 
point. Vertical lines represent standard error of the mean between subjects. 
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A) 
 
B) 
 
Figure S5.6. Representative examples of surface plasmon resonance (SPR) 
sensorgrams measuring antigen-binding fragments. 
Recombinant antibodies were synthesized and measured using SPR as described in 
“Materials and Methods: Anthrax Vaccine Adsorbed.” A) A preMPB antibody with no 
significant binding (>100µM, c2808) and B) a naïve-derived antibody with significant 
PA binding (55nM affinity) that has reached steady state (c1558). 
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Figure S5.7. Rarefaction analysis of single cell sorted, plasmablast Ig-seq. 
The complete Atreca plasmablast dataset was randomly sampled at increasing 1/8 
fractions, up to the total number of sequenced IgVRGs, and the number of clones per 
fraction were calculated. We expect that a homogenous sample will sharply increase with 
a small proportion of sequences then plateau, whereas a completely heterogeneous 
sample will continually increase at a 1:1 sequence to clone ratio. A 1:1 line (red) is shown 
for comparison. 
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 CHAPTER SIX: CONCLUDING REMARKS  
Overview 
In this dissertation, we asked whether study of the genetic immunoglobulin 
repertoire could reveal clonal correlates of the vaccine-elicited response. We first 
examined the quantitative and qualitative consistency of high throughput 
immunoglobulin sequencing (Ig-seq), and identified areas of concern for Ig-seq and, 
potentially, for RNA-seq wet lab methods. We then performed standard and molecularly 
tagged immunoglobulin sequencing to examine the total repertoire, which revealed 
profound clonal diversity and transience, even following the elicitation of antigen-
specific antibodies. We then zoomed in on the primary effector cell of the antibody 
response, plasmablasts, and performed single cell sequencing of natively-paired 
immunoglobulin variable region gene (IgVRG) heavy and light chains. While this dataset 
confirmed the high diversity and transience of the repertoire, it isolated a distinctive 
correlate of recent naïve B cell differentiation following secondary immunization. These 
clones exhibited characteristics consistent with our expectations for an antigen-specific, 
vaccine-elicited response.  
Summary of Major Findings 
 In Chapter Three, we examined the effect of technical error on the output of 
immunoglobulin sequencing. The key findings are: 
 Current library preparation methods introduce significant variation in Ig-
seq output. These errors are present as nucleotide miscalls, insertions, 
deletions, variation in observed clones and disparate read count output. 
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 The primary drivers of this variation are from adaptor-specific PCR, 
necessary for Illumina-platform sequencing, as well as sequencing itself. 
 Total repertoire coverage of clones is not accomplished by standard 
sample collection and processing, with the least coverage realized in the 
naïve B cell population. This is improved by both biological and technical 
replicates. 
 Unique molecular identifiers can correct nucleotide and read count errors, 
but not clonal variation, and also limit immunoglobulin-specific capture 
and sequence output of Ig-seq. 
 Raw read/sequence counts from Ig-seq are affected by PCR over-
amplification, which may be resolved by UID tagging. We developed a 
model to estimate the number of unique input molecules (mRNA) per 
clone in Ig-seq. 
 In Chapter Four, we explored high throughput Ig-seq data following Anthrax 
Vaccine Adsorbed (AVA) immunization to determine if there were genetic or clonal 
correlates of vaccination. This chapter focused on total bulk sorted and sequenced B cell 
subsets from six volunteers. The key findings are: 
 Memory B cells and plasmablasts do not significantly increase following 
AVA immunization until the third vaccination, administered at six 
months. This measurement is highly variable between subjects. 
 There is no consistent change in observed IgVRG CDR3 length, clonal 
gene segment usage nor mutation frequency following immunization. 
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 The average clone proportion in the observed repertoire decreases one 
week following the first three AVA administrations, then increases 
following the 4th and 5th doses to approach pre-immune values.  
 The clonal repertoire is highly diverse and transient. Most clones are 
observed at only one time point and no clone consistently grows following 
vaccination. 
 A population of relatively persistent clones is first observed following 
secondary vaccination, but not following any other dose.  
 Persistent clones first observed following secondary immunization have 
fewer intraclonal nucleotide differences, and the locations of these 
mutations are less focused within the IgVRG.  
 In Chapter Five, we re-examined the AVA samples from Chapter Four using a 
more focused approach. Here, we performed single cell plasmablast sorting and IgVRG 
sequencing of these samples. The key findings are: 
 There is a population of relatively persistent plasmablast clones that exist 
prior to immunization. 
 The plasmablast clonal repertoire is highly diverse and transient. No single 
clone ever represents the majority of the population nor do relatively large 
clones increase or persist at comparable levels. 
 We cannot distinguish plasmablasts observed following primary AVA 
vaccination from those observed in the pre-immune samples. These 
populations do not expand, share similar mutation frequencies that do not 
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change over time, have similar levels of intraclonal diversity, use similar 
proportions of IgG isotypes, and do not bind anthrax Protective Antigen. 
 Plasmablasts observed following secondary immunization show a distinct 
shift to low mutation frequencies, suggesting many are recently derived 
from the naïve B cell pool. Antibodies from these clones bind PA with 
increasing affinity upon observed and inferred accumulation of mutations. 
 Clones first observed after secondary and all subsequent doses have lower 
overall mutation frequencies than pre-immune clones, and these values 
gradually rise following additional immunizations.  
 The proportion of IgG1+ plasmablasts, which are associated with alum-
elicited responses, increase following secondary, but not primary 
vaccination. 
Significance 
This dissertation has two conclusions which we consider to have broad 
significance. The first is the immunological question of why AVA does not elicit a fast or 
long term response. Despite having the same vaccine composition, the primary dose 
appears to have negligible effects in the periphery, while the second dose leads to 
observable naïve-derived plasmablasts. Though PA-specific antibodies are not 
consistently observed until after the second dose, it would be feasible that vaccine-
responsive B cells are in the periphery after the first dose, but secrete antibodies with 
poor affinity. Our results show that, in fact, vaccine-elicited B cells do not exist in the 
periphery after the first dose, or exist in very small amounts. Therefore, there should be a 
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focus on utilizing an adjuvant, exogenous or otherwise, that is able to not only activate 
antigen-specific naïve B cells, but to more efficiently move them from secondary 
lymphoid tissues into the periphery.  
Similarly, there is the question of why AVA antigen-specific memory requires so 
many boosts – two during the vaccination schedule, and then annually thereafter. AVA-
specific memory is existent, we observe clones with mutation patterns consistent with 
increasing affinity maturation in all immunizations after the second dose. However, this 
memory is not robust or selective – individual clones do not exhibit sustained 
proliferation. We then draw a connection between our observed clonal data and the 
kinetics of AVA immunization. Antigen-specific antibodies are slow to emerge, and 
antigen-specific memory does not survive more than a few years without boost. It is 
possible that no individual clone receives sufficient signaling to robustly proliferate and 
outcompete other clones to come to dominate the post-immunization repertoire or persist 
in survival niches. Furthermore, while PA is the immunodominant antigen, LF and EF are 
known to elicit weak responses; it is possible that additional antigens in the milieu elicit 
similarly weak responses that further inhibit robust PA-specific selection and memory, 
resulting in polyclonal but not necessarily protective clonal responses.  
 The second broad outcome of this dissertation is more theoretical in nature. How 
do we appropriately design and implement experiments to adequately address the 
scientific question posed; or, is more data always better? Particularly in the era of “big 
data,” when is it appropriate to use these large datasets, and what special limitations do 
they have? For instance, our analysis of UID-tagged Ig-seq revealed serious technical 
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errors in nucleotide composition and count values. Many researchers take sequencing 
data for granted, assuming that if you see it, it’s true. Similarly, data scientists often 
neglect to consider the potential limitations and pitfalls of biological sampling and wet 
lab work. A common but technically problematic approach to RNA-seq, shallow 
sampling and deep sequencing, is made all the more confounding in Ig-seq, where the 
heterogeneity of a single sample may approach totality, and technical errors look just like 
affinity maturation. 
 In our AVA analysis, high throughput sequencing only revealed tenuous markers 
of the vaccine response, and expected outcomes, such as increasing clone size and gene 
subset usage were not observed. While UID tagging provides excellent nucleotide 
controls for groups with >1 sequence, and certainly helps mitigate PCR over-
amplification, it does not address the unequal production of immunoglobulin mRNA 
between cell subsets and individual cells. Plasmablasts produce many more transcripts 
(and expressed immunoglobulin) than naïve or memory B cells, and may dominate Ig-seq 
data collection. Depending on the question being asked, this may not be important, but 
neglecting this as a potential explanation of observed variation would be a mistake. For 
analysis of our AVA dataset, the proportional representation of cellular, but not 
necessarily antibody-associated IgVRG turned out to be important. It was only at single 
cell, then clonal resolution that a common, clear signal of vaccine-responding B cells 
could be identified. 
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Future Directions 
 Our analysis of technical error introduced during Ig-seq collection and library 
preparation made explicit to us the importance of optimal experimental methods and 
design. While UID tags provide significant value to Ig-seq, the current levels of Ig-
specific capture are very low, and make the cost of next-generation sequencing far too 
high at the nucleotide level. It also lowers the per-sample throughput, which we have 
shown is extraordinarily diverse. Improvement of this method will be important for buy-
in and increased use in the field. 
As discussed previously, AVA has room for improvement in the time to and long 
term efficacy of the protective response it generates. Here, we illustrate that it does not 
elicit the desired class of recently differentiated, naïve-derived plasmablasts until two 
doses have been administered, and that the overall response is polyclonal and individual 
clones are not sustained on multiple immunizations. It is possible that different adjuvants 
or more deliberate antigen inclusion may lead to an earlier response with better sustained 
memory and re-activation upon additional antigen exposure. The potential to improve 
anthrax vaccination is clear. The reasons to do so are made obvious when we consider 
some of the emergency uses. AVA is approved for post-exposure prophylaxis, which may 
be particularly important in protecting veterinarians and ranchers in an outbreak scenario. 
The U.S. government also stockpiles AVA in the event of a biological weapon. In both 
cases, the quick elicitation of an antigen-specific response is essential. Unfortunately, 
there is not an ideal animal model available for anthrax vaccination studies. The primary 
animal models are mice and guinea pigs which have AVA response kinetics and 
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outcomes that are distinct from humans (Turnbull et al., 1986; Welkos and Friedlander, 
1988; McBride et al., 1998). Non-human primates appear to have disease pathology that 
is more similar to humans, and rabbit vaccination responses may also be more similar to 
human correlates (Fellows et al., 2001; Vasconcelos et al., 2003). However, animal 
models also appear to have distinct mechanisms of pathogenicity (Levy et al., 2012). 
Further work must be done to improve the animal model if it is required for novel vaccine 
formulations. 
AVA as a model of multiple dose vaccines is somewhat unique in the sheer 
number of primes and boosts required, and the observed delay in the peripheral response 
may be magnified. In light of this work, it would be valuable to know whether other 
multiple dose vaccines exhibit a similar lack of plasmablasts with a naïve-derived 
phenotype, and if this outcome stratifies by broader vaccine types. Similarly, 
experimental work to determine if the draining lymph node following primary AVA 
administration is comprised of antigen-specific - or precursors to antigen-specific – B 
cells. Unfortunately the primary animal model used in AVA studies is the mouse, which 
exhibits a robust, PA-specific response following primary inoculation, so improved 
animal models or human studies would be needed. 
A final, unusual note in this study was the observation of a persistent group of 
memory and plasmablast-comprised clones in the periphery. We expect that plasmablasts 
in the periphery are part of an active response against an antigen. We also expect that 
these antigens are diverse and constantly changing. Yet the same highly mutated clones 
persist at low levels in healthy adults. We performed preliminary study and analysis of 
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this population, included in this dissertation as an appendix, and look forward to future 
insights about the nature of this B cell population.  
Study Limitations 
During the course of the presented studies, we determined that our assumptions 
about peripheral vaccine responses were not necessarily met by this vaccination, limiting 
our ability to interpret the data. The rationale for not performing antigen selection of B 
cells during processing was multipart. We wanted to observe the total repertoire to 
identify B cells within lineages that have gained antigen affinity, but do not necessarily 
have strong enough affinity for pre-selection themselves. This may include earlier clonal 
precursors, or even branches of a clone that do not achieve antigen binding while others 
do. We also do not know all of the potential antigens in the vaccine itself, just that PA is 
the immunodominant antigen, followed by LF and EF. Other vaccine components have 
not been investigated for cognate antibody generation. Importantly, the presence of 
peripheral plasmablasts is strongly linked to recent immune responses, and we assume 
that the majority of observed plasmablasts one week following immunization are elicited 
by that immunization and may then be used to establish AVA-elicited clones.  
With this in mind, we did not perform antigen-specific selection prior to 
sequencing, and synthesized antibodies were selected entirely by genetic and kinetic 
characteristics. However, it is now clear to us that despite the limitations of not knowing 
all the AVA components, antigen selection with any known components may help clarify 
what, if any response, is being elicited throughout the immunization series. As it is, it is 
difficult to find a vaccine-derived signal in the high throughput data, though there is one 
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in the single cell sorted plasmablasts. This discrepancy also points to the potential of 
skewed sequencing counts by technical error to obfuscate signal, another consideration 
that should be made for future approaches. Future studies may include antigen selection, 
but should also continue to measure and sequence non-antigen binding B cells to 
determine if and how non-specific B cells and clones are involved in vaccine responses. 
 Another assumption that we made was that there would be a primary, peripheral 
response following the first vaccination. Instead we observed no significant increase in 
plasmablasts at one or two weeks following the first dose, suggesting that if there is a 
response, it is not able to exit secondary lymphoid tissues. Future studies of this 
vaccination, and potentially of others with similar outcomes, should consider including 
collection and analysis of lymph node-associated B cells.  
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APPENDIX 
A POPULATION OF STEADY STATE PLASMABLASTS IN HEALTHY 
INDIVIDUALS ENCODE AUTOREACTIVE IMMUNOGLOBULIN. 
Rationale 
 During the course of our work concerning single cell Ig-seq of plasmablasts 
(Chapter Five), we observed that highly affinity matured plasmablasts were the primary 
PB population one week following AVA immunization. We initially attributed this 
population to that of PBs being elicited by vaccination, which is a rational assumption 
given the kinetics of adaptive immunity. These PBs were somewhat unusual in that they 
were proportionally more dominated by very highly mutated IgVRG than expected. We 
investigated the potential antigens and functional outcome of these cells. 
Our primary concern was that a non-immunodominant component of AVA was 
eliciting these cells and delaying the more efficacious PA response. The potential for 
previously affinity-matured memory B cells to contribute to the response against related 
antigens by original antigenic sin has been described in many pathogen contexts 
(Halstead et al., 1983; Briney et al., 2012; Buricchi et al., 2013; Tan et al., 2014; 
Andrews et al., 2015a; Andrews et al., 2015b; Li et al., 2015). Anti-influenza memory B 
cells established on primary immunization or infection are elicited by exposure to 
influenza strains different from the original, and can contribute to protection or interfere 
with the establishment of an effective response against the novel strain. The conditions 
that lead to one outcome rather than the other are not understood.  
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7.1 Preexisting memory, but not naïve-derived antibodies bind human autoantigens. 
Given that no subject had known prior exposure to B. anthracis, as supported by 
ELISA, the high IgVRG mutation frequencies observed one week following primary 
immunization were uncharacteristic of the response expected in a naïve host. This was 
made all the more unusual when none of the diverse, synthesized mAbs from this 
population exhibited measurable PA binding. With the knowledge that 1) the B cells 
expressing these IgVRG have undergone substantial affinity maturations, 2) these B cells 
are present prior to immunization and 3) the extensive somatic mutations observed are a 
characteristic result of multiple antigen exposures, we asked if these antibodies had 
measurable binding to autoantigens. We tested a set of 18 antibodies (11 from preMPB 
and 7 from a naive-derived PB clone) against a protein microarray of >9,400 human 
antigens (ProtoArray®, ThermoFisher Scientific). Experimental antibodies were 
compared to a commercially available monoclonal antibody with known autoantigen 
affinities and one isotype control (Liu et al., 2015). 
Of the preMPBs, 11 of 11 antibodies exhibited autoreactivity against 29 
autoantigens (Table 7.1, Figure S7.1). Only 1 of 7 naive-derived antibodies exhibited 
autoreactivity against 2 autoantigens (Figure S7.2). Interestingly, the single autoreactive 
naïve-derived antibody was the unmutated clone founder of clone C1.1, which loses this 
autoreactive function through affinity maturation. While the autoantigen hits do have 
some overlap between unique clones, there is no cross-subject overlap (Table S7.1). 
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ID Subject Clone KD against PA  
Observed 
mut. freq. 
# auto- 
antigens 
s6192 1 1 >100mM 0.058 5 
s6010 1 1 >100mM 0.050 3 
s5572 1 2 >100mM 0.071 4 
s5811 1 2 >100mM 0.108 2 
s6047 1 3 >100mM 0.125 4 
s6189 1 4 >100mM 0.046 4 
c4011 3 5 >100mM 0.119 2 
c2755 5 6 >100mM 0.088 1 
c2808 5 7 >100mM 0.094 1 
c2836 5 8 >100mM 0.984 2 
c5099 6 9 >100mM 0.094 2 
c1635* 1 10 1500nM 0.000 2 
c1558 1 10 55nM 0.006 0 
i5 1 10 4nM NA 0 
c1153 1 10 0.84nM 0.031 0 
c1184 1 10 0.47nM 0.070 0 
i12 1 10 1.8nM NA 0 
c1168 1 10 1.5nM 0.028 0 
Table 7.1. Protein microarray assessment of autoantigen binding to candidate 
antibodies.  
PreMPBs, but not naïve-derived PBs exhibit autoreactive binding. Eighteen antibodies 
were selected from the IgG+ PB dataset based on the established characteristics of naïve- 
and preMPBs. Selected preMPBs represent four subjects and nine unique clones. 
Selected naïve-derived PBs are from a single clone, C1.1. PA affinity was determined if 
SPR-derived KD was above the limit of detection. Mutation frequency was calculated by 
Cloanalyst from the inferred unmutated common ancestor. Autoreactivity was tested by 
ProtoArray® assays.  
*Observed immunoglobulin is also the inferred unmutated common founder for its clone.  
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7.2 Autoantigens against observed antibodies are not genetically similar to anthrax 
vaccine components. 
AVA is comprised of the cell-free filtrate of an attenuated strain of B. anthracis. 
The precise components of this filtrate are not public knowledge, but analysis of a related 
vaccine, AVP, reveals additional bacterial proteins are present. It is then possible that 
preMPBs with autoreactive immunoglobulin may be part of a poorly elicited, cross-
reactive response against non-immunodominant AVA components. Using BLAST®, we 
compared amino acid sequences of the autoantigen hits to the three published 
immunogenic vaccine components, PA, lethal factor and edema factor, as well as seven 
additional B. anthracis proteins that have previously been identified in the related anthrax 
immunization, AVP, used in the UK (Table S7.2) (Turnbull, 1991b; Whiting et al., 2004; 
Taft and Weiss, 2008). The resulting values indicated that there is no significant 
similarity between the antigens likely introduced by immunization and autoantigens that 
are bound by preMPBs. 
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7.3 Serum does not contain detectable autoreactivity before or after AVA immunization. 
 PreMPBs are the dominant population before and after primary AVA 
immunization, and random sampling revealed a strong correlation to autoreactivity by 
protein microarray. However, immunoglobulin mRNA does not necessarily translate to a 
functional effect, either through non-translation or low amounts of antibody secretion. To 
determine whether immunoglobulin from the observed, autoreactive preMPBs has a 
functional role in serum, we performed HEp-2 anti-nuclear antigen (ANA) staining 
assays (MBL). ANA is a standard diagnostic screen for a number of autoimmune 
disorders (Mariz et al., 2011). Both the titer and indirect immunofluorescent pattern are 
useful readouts. No subject showed positive staining, either nuclear or cytoplasmic, even 
above the minimum clinical dilution before or after primary immunization (Figure 7.1). 
We further asked whether there was a consistent, qualitative change in cellular staining 
after first and second immunization. No significant differences were observed using 
optimum minimum and maximum values for visualization (Figure 7.2). Thus, while 
preMPBs observed before and after early AVA immunization can encode potentially 
autoreactive antibodies, these antibodies do not have a measurable clinical effect. 
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Figure 7.1. HEp-2 anti-nuclear antigen staining of serum before and after primary 
AVA immunization. 
HEp-2 anti-nuclear antigen assay is negative before and one week following primary 
AVA immunization even at subclinical dilutions. Assays were performed using 
manufacturer protocols on subject serum at an optimized dilution of 1:20. The minimum 
clinical dilution is 1:40. Micrographs are representative for results on the day of first 
immunization (day 0) and one week post-immunization (day 7). Manufacturer provided 
negative and positive control antibodies are included for reference. 
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Figure 7.2. Quantification of HEp-2 anti-nuclear antigen staining of plasma before 
and after primary AVA immunization. 
HEp-2 anti-nuclear antigen staining reveals no significant change in nuclear or 
cytoplasmic staining before and one week following primary AVA immunization. Serum 
from the day of (Day 0) and 1 week post-immunization (Day 7) from all 6 subjects was 
diluted 1:20, and subsequent micrographs were displayed for optimized signal to noise 
using maximum and minimum greyscale values from the raw image. Fluorescent signal 
was normalized by corrected total cell fluorescence (CTCF). 100% CTCF was set using 
the value of a positive pixel with near-maximum white value. Error bars represent 
standard error of the mean between subjects. There is no significant difference from 
before to after vaccination in either nuclear or cytoplasmic staining.  
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Discussion 
We were driven to investigate the functional nature of the preMPBs due to the 
highly mutated IgVRGs observed soon after immunization. While these cells do not 
appear to be a part of the vaccine-specific response, they represent a memory population 
that, to our knowledge, has not been described from a genetic perspective, and may have 
a special role in the immunoglobulin repertoire. All subjects were healthy, so we 
considered the possibility of repeated antigen exposure as a possible driver of extensive 
somatic hypermutation (Freund et al., 2014; Pappas et al., 2014; Liu et al., 2015; 
Williams et al., 2015). We tested 11 preMPBs and 8 naïve-derived PB synthesized mAbs 
against a panel of more than 9,400 human proteins and found that all preexisting-memory 
samples were autoreactive, and many were weakly polyreactive. We propose that, due to 
their population-level similarities, there is a persistent population of clones at steady state 
that retain autoreactive binding potential. This was in contrast to the naïve samples, 
where only 1 mAb from a founder B cell had autoantigen affinity, and this affinity was 
lost as the clone affinity matured. 
These results are consistent with an emerging body of work that is establishing a 
functional value to autoreactivity. The existence of autoreactive B cells in healthy adults 
is far from novel; autoreactivity in naïve B cells and memory B cells have both been 
observed, and autoreactive antibodies comprise up to 20% of all antibodies in humans 
(Lacroix-Desmazes et al., 1998; Wardemann et al., 2003; Tiller et al., 2007; Sabouri et 
al., 2014). Polyreactive antibodies are also a healthy component of the immunoglobulin 
repertoire, and are capable of binding many unrelated antigens with low affinity (Gunti 
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and Notkins, 2015). In this context, autoreactivity may then contribute to the ability of 
the repertoire to react to diverse antigens. However, we observed an autoreactive 
population of affinity matured B cells. The possible gain of autoreactive function in these 
highly mutated IgVRGs mirrors that seen in broadly neutralizing antibodies against HIV 
(Finton et al., 2013; Liu et al., 2015). 
It remains to be seen whether these preMPB populations are able to be 
productively stimulated, or if they circulate in an anergic state, unable to be activated 
except perhaps by repetitive, tolerance-breaking signals. If the former were true, the lack 
of signal from the HEp-2-ANA assays suggest they do not secrete antibodies at a high 
concentration. In the case of the latter, it would be surprising to learn that a potentially 
large proportion of plasmablasts at any given time are nonresponsive. As with all cells, 
preMPBs require resources to survive, which would lead to questions about their 
evolutionary advantage. 
It is important to note that AVA has been extensively studied for safety and no 
evidence for any association with autoimmune disease or, indeed, any other long-term 
adverse effects have, to our knowledge, been cited (Friedlander et al., 1999; Pittman et 
al., 2001; Pittman et al., 2002; Campbell et al., 2007). Our findings are entirely consistent 
with this assessment, particularly as two of our selected preMPBs with autoreactivity 
were from pre-immune samples. The autoreactive clones are present at very low 
concentrations in the PBMC and may secrete inconsequential amounts of autoantibody. 
Whether they have any effect at all is unknown, though our hope is that their further 
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study will contribute to our evolving understanding of natural, non-pathogenic 
autoreactive lymphocytes in healthy humans  
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Figure S7.1. Autoreactivity array for preexisting memory-derived plasmablasts.  
Eleven preexisting memory-derived PBs observed after primary AVA immunization 
were selected and tested for autoreactivity by ProtoArray® assays against >9,400 human 
antigens printed in native conformation in duplicate per assay, and fluorescent signal 
normalized using intra- and inter-assay controls. Positive antigen results were called if 
fluorescent signal was 500-fold greater than mAB control (151K, bottom right red dotted 
line). Non-autoreactive intra-assay controls are shown to the right of their respective 
array.  
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Figure S7.2. Autoreactivity array for naïve-derived plasmablasts. 
Seven naïve-derived PBs observed after second AVA immunization and one isotype 
control were selected and tested for autoreactivity by ProtoArray® assays against >9,400 
human antigens printed in native conformation in duplicate per assay, and fluorescent 
signal normalized using intra- and inter-assay controls. Positive antigen results were 
called if fluorescent signal was 500-fold greater than mAB control (151K, bottom right 
red dotted line).  Non-autoreactive intra-assay controls are shown to the right of their 
respective array. Isotype control is included in the bottom right panels. 
  
  
287 
Autoantigen hit 
NCBI 
Accession No 
No. binding  
Abs Subject 
No. unique 
clones 
GSTA3 BC020619.1 4 1 3 
RGS20 BC015614.1 4 1 3 
MYL5 NM 002477.1 3 1 3 
MYL9, mRNA NM 181526.1 3 1 3 
Ectoplacental cone mRNA BC036710.1 2 5 2 
ARV1 NM 022786.1 1 1 1 
CA9 NM 001216.1 1 1 1 
CCDC21 BC019902.1 1 1 1 
EPM2AIP1 NM 014805.2 1 1 1 
HES6 NM 018645.3 1 1 1 
MTUS1 BC033842.1 1 1 1 
Protein LOC 136242 NM 001008270.1 1 1 1 
ssDNA NA 1 1 1 
UGP2 BC002954.1 1 1 1 
USP5 BC005139.2 1 1 1 
STIP1 NM 006819.1 1 3 1 
CPEB4 BC036899.1 1 3 1 
NGLY1 NM 018297.2 1 5 1 
SLC9A3R1 NM 004252.1 1 5 1 
TBCKL BC068496.1 1 6 1 
TFCP2 NM 005653.2 1 6 1 
 
Table S7.1. Autoantigen hits against plasmablast IgVRG. 
List of autoantigens to which PBs displayed significant affinity. Twelve of 18 antibodies 
displayed affinity for 32 total autoantigens (21 unique). 
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BLASTP 2.3.0+ 
Database: AVA_components 
A) 
Subject Subject AN Bacillus anthracis strain 
EA1 CAA68063.1 Sterne-9131 
EF AAA79215.1 Sterne 
Eno AJH99280.1 V770-NP-1R 
Fba-2 AJH99375.1 V770-NP-1R 
GroL AJI01742.1 V770-NP-1R 
LF AJH97078.1 V770-NP-1R 
NDK AJH97520.1 V770-NP-1R 
PA AAF86457.1 V770-NP-1R 
PAG AJ413937.1 IT-Carb1-6241 
SAP AJI00926.1 V770-NP-1R 
 
B) 
Query Query AN Subject Percent ID Length Evalue 
CA9 NM_001216.1 SAP 30.769 26 3.5 
CCDC21 BC019902.1 EA1 31.429 35 0.95 
CCDC21 BC019902.1 Eno 24.752 101 0.056 
CCDC21 BC019902.1 GroL 25.714 70 1.5 
CCDC21 BC019902.1 LF 50 12 5.4 
CCDC21 BC019902.1 LF 18.919 74 8.2 
CPEB4 BC036899.1 EF 46.154 13 6.2 
Ectoplacental_cone BC036710.1 EF 29.63 27 7.8 
Ectoplacental_cone BC036710.1 GroL 36.364 33 2.7 
Ectoplacental_cone BC036710.1 SAP 31.373 51 4.7 
EPM2AIP1 NM_014805.2 EA1 24.419 86 0.89 
EPM2AIP1 NM_014805.2 EA1 25 24 7.7 
EPM2AIP1 NM_014805.2 Eno 38.889 18 3.7 
EPM2AIP1 NM_014805.2 Fba-2 30.769 26 5.2 
EPM2AIP1 NM_014805.2 LF 42.857 21 7 
EPM2AIP1 NM_014805.2 PA 26.316 38 4.8 
EPM2AIP1 NM_014805.2 PAG 26.316 38 4.5 
EPM2AIP1 NM_014805.2 SAP 26.136 88 0.53 
EPM2AIP1 NM_014805.2 SAP 18.421 38 6.5 
GSTA3 BC020619.1 EA1 27.273 55 1.1 
GSTA3 BC020619.1 EF 54.545 11 4.5 
GSTA3 BC020619.1 GroL 38.095 21 2.8 
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GSTA3 BC020619.1 GroL 41.176 17 7.5 
GSTA3 BC020619.1 LF 58.333 12 7.6 
GSTA3 BC020619.1 LF 26.316 38 8.2 
GSTA3 BC020619.1 SAP 24.324 111 1.3 
GSTA3 BC020619.1 SAP 27.869 61 3.7 
MTUS1 BC033842.1 EF 36.842 19 9.1 
MTUS1 BC033842.1 LF 37.5 16 0.46 
MYL5 NM_002477.1 EA1 66.667 9 5.2 
MYL5 NM_002477.1 EA1 37.5 24 7.3 
MYL5 NM_002477.1 EF 36 25 1.5 
MYL5 NM_002477.1 EF 43.75 16 1.8 
MYL5 NM_002477.1 EF 47.619 21 6.9 
MYL5 NM_002477.1 LF 36.842 19 3.6 
MYL5 NM_002477.1 LF 40.909 22 8.3 
MYL5 NM_002477.1 SAP 34.483 29 3.8 
MYL5 NM_002477.1 SAP 45.833 24 4.7 
MYL5 NM_002477.1 SAP 31.25 48 5.8 
MYL9_mRNA NM_181526.1 EA1 33.333 33 1.6 
MYL9_mRNA NM_181526.1 EA1 40 20 4.9 
MYL9_mRNA NM_181526.1 EF 55.556 9 8.7 
MYL9_mRNA NM_181526.1 GroL 25 32 7.1 
NGLY1 NM_018297.2 EF 42.308 26 9.7 
NGLY1 NM_018297.2 LF 50 16 5.1 
NGLY1 NM_018297.2 SAP 41.935 31 1.8 
Protein_LOC_136242 NM_001008270.1 LF 23.148 108 9 
Protein_LOC_136242 NM_001008270.1 PA 38.095 21 1.8 
Protein_LOC_136242 NM_001008270.1 PAG 38.095 21 1.8 
RGS20 BC015614.1 Fba-2 26.19 42 0.45 
RGS20 BC015614.1 GroL 31.579 38 1.1 
RGS20 BC015614.1 PA 23.333 60 1.2 
RGS20 BC015614.1 PA 22.222 144 1.2 
RGS20 BC015614.1 PAG 23.333 60 1.3 
RGS20 BC015614.1 PAG 22.222 144 1.4 
RGS20 BC015614.1 SAP 29.167 24 9 
RGS20_2 NM_003702.2 Fba-2 26.19 42 0.45 
RGS20_2 NM_003702.2 GroL 31.579 38 1.2 
RGS20_2 NM_003702.2 PA 22.222 144 1.2 
RGS20_2 NM_003702.2 PA 23.333 60 1.3 
RGS20_2 NM_003702.2 PAG 22.222 144 1.3 
RGS20_2 NM_003702.2 PAG 23.333 60 1.3 
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SLC9A3R1 NM_004252.1 EA1 17.857 28 8.5 
SLC9A3R1 NM_004252.1 EF 25 52 5.2 
SLC9A3R1 NM_004252.1 Eno 57.143 14 1.1 
SLC9A3R1 NM_004252.1 LF 42.105 19 3.6 
SLC9A3R1 NM_004252.1 LF 29.73 37 7.8 
SLC9A3R1 NM_004252.1 SAP 38.889 18 3.9 
SLC9A3R1 NM_004252.1 SAP 26.667 60 9.2 
STIP1 NM_006819.1 EA1 25.532 47 5.6 
STIP1 NM_006819.1 EF 29.897 97 5 
STIP1 NM_006819.1 LF 26.136 88 0.086 
STIP1 NM_006819.1 LF 28.846 52 0.24 
STIP1 NM_006819.1 LF 30.233 43 0.53 
STIP1 NM_006819.1 LF 25 56 2.3 
STIP1 NM_006819.1 PA 29.412 34 7 
STIP1 NM_006819.1 PAG 29.412 34 6.7 
TBCKL BC068496.1 EA1 32.143 28 2.2 
TBCKL BC068496.1 LF 39.13 23 4.7 
TBCKL BC068496.1 LF 28.571 21 5.4 
TBCKL BC068496.1 LF 28.947 76 6.1 
TFCP2 NM_005653.2 GroL 50 14 1.2 
TFCP2 NM_005653.2 LF 28.571 42 4.2 
TFCP2 NM_005653.2 SAP 21.302 169 0.24 
UGP2 BC002954.1 Fba-2 36.667 30 0.85 
UGP2 BC002954.1 PA 33.333 27 5.6 
UGP2 BC002954.1 PA 50 14 7.8 
UGP2 BC002954.1 PA 30.303 33 9.5 
UGP2 BC002954.1 PAG 33.333 27 5.6 
UGP2 BC002954.1 PAG 50 14 7.9 
UGP2 BC002954.1 PAG 30.303 33 9.6 
UGP2_2 NM_006759.3 Fba-2 36.667 30 0.84 
UGP2_2 NM_006759.3 PA 33.333 27 5.9 
UGP2_2 NM_006759.3 PA 50 14 7.9 
UGP2_2 NM_006759.3 PA 30.303 33 9.7 
UGP2_2 NM_006759.3 PAG 33.333 27 5.9 
UGP2_2 NM_006759.3 PAG 50 14 8.1 
UGP2_2 NM_006759.3 PAG 30.303 33 9.7 
USP5 BC005139.2 SAP 22.131 122 0.81 
 
Table S7.2. BLASTP comparison of AVA components to autoantigen hits. 
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BLASTP results between known Anthrax Vaccine Precipitated (AVP) components and 
autoantigens recognized by preexisting memory B cells. A) Reference database of B. 
anthracis proteins previously identified in AVP. Where possible, AVA strain bacteria 
(V770-NP-1R) is used. B) All autoantigens were queried against the AVP component 
database. BLASTP was run using default values, using a BLOSUM62 scoring matrix and 
an E value threshold of 10. 
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